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ABSTRACT 
The FDA approved pre-exposure prophylaxis (PrEP) with Truvada® in 2012 as 
the first drug to reduce the risk of HIV infection among uninfected individuals (FDA 
2012). There is a strong scientific base for its effectiveness among uninfected 
heterosexual individuals who engage in sexual intercourse with HIV-infected partners. 
Studies further reveal no significant differences by HIV-infection status in regard to 
childbearing motivations or future pregnancy motivations (Finocchario-Kessler 2012). 
Historically, serodiscordant couples comprised of an HIV-positive male and HIV-
negative female have faced challenges to accessible, affordable options for safe 
conception. Assisted reproductive technologies (ART) are often prohibitively expensive 
and also largely inaccessible to this population. The CDC suggests PrEP as another 
reproductive option for these couples to reduce the risk of sexual HIV acquisition during 
periconception and pregnancy.  
Truvada® for PrEP, however, is also costly and may provide only modest 
  
 vii
additional prevention benefits to serodiscordant couples in which the HIV-infected 
partner is already on anti-retroviral therapy with suppressed HIV viremia. cART for the 
infected partner is recommended regardless of conception plans due to proven health 
benefits for people living with HIV (PLHIV). However, there is also a prevention benefit 
to the non-infected partner when the HIV-positive partner is on cART, with a relative risk 
reduction of 96% (Cohen et al. 2011).  
While Truvada® for PrEP is potentially a more accessible option for these 
couples compared to assisted reproductive technology services, adoption of PrEP has 
been slow among providers. In addition to better understanding the impact of PrEP when 
the male partner is consistently on cART, it is also critical to understand the barriers to 
prescribing Truvada® for this indication. There is also insufficient information on the 
ability of HIV-serodiscordant couples to access other reproductive options outside of 
PrEP. Whether for the purpose of risk reduction or for supported fertility, serodiscordant 
couples should have access to the same spectrum of reproductive services as non-HIV 
affected couples.  
The overall research question this thesis addressed was: What are the access and 
cost implications for HIV serodiscordant couples seeking conception services in the 
United States? To address these issues, I used the following methods: (1) a cross-
sectional survey of infectious disease, internal medicine, and family medicine providers 
to determine prescribing behaviors and perceptions of PrEP utilization; results analyzed 
using multivariable regression modeling; (2) “secret shopper” methodology whereby a 
physician and “patient” carried out scripted phone calls to fertility clinics to gauge a more 
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realistic picture of access; results analyzed using McNemar tests to assess marginal 
homogeneity and chi square goodness of fit; and (3) cost effectiveness analysis using a 
Markov state-transition model to project long-term clinical outcomes, costs, and cost-
effectiveness of different HIV prevention strategies for serodiscordant couples seeking 
conception. 
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CHAPTER I: Literature Review and Theoretical Framework 
 
 
Patient and provider communication: Potential barriers to voicing fertility desires and 
engaging in preconception counseling  
 
Studies have shown that having HIV does not eliminate individual desires or 
intentions to have children (Chen et al. 2001, Finocchario-Kessler 2012). A study 
comprised of primarily African American youth aged 15–24, including both those who 
were HIV-infected and those who were not infected, revealed no significant differences 
by HIV-infection status in regard to childbearing motivations or future pregnancy wishes 
(Finocchario-Kessler 2012). Other studies among people living with HIV (PLHIV) in the 
United States have shown that 30% of HIV-infected women in Ohio, 55% of PLHIV in 
Louisiana, and 40% of PLHIV in the states of Georgia, North Carolina, and South 
Carolina had been pregnant since their HIV diagnosis (Nattabi et al. 2009, Craft et al. 
2007, Bedimo-Rung et al. 2005, Sowell et al. 2002). 
Communication differences between patients and physicians have historically 
been challenging for different populations. For instance, among African Americans, race 
and ethnicity have been barriers to patient and physician interactions, with African 
American patients rating their visits with physicians as less participatory compared to 
white patients (Cooper-Patrick 1999). Patients in race concordant relationships as 
opposed to race discordant pairs have also expressed significantly greater participatory 
provider interaction (Cooper-Patrick 1999). Similarly, barriers exist in HIV patient-
provider communication with discussions about fertility desires not included in routine 
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HIV prevention counseling (Heffron et al. 2016, Squires 2011, Finocchario-Kessler 2010, 
Mindry 2012, Coll et al. 2015).  
Squires et al. 2011 found ‘significant’ communication barriers between HIV-
infected women and their providers related to preconception and reproductive counseling 
(Squires et al. 2011). In a cross-sectional study of African American HIV-infected 
women, 67% reported having a general discussion about pregnancy and HIV with their 
primary care provider, while 31% reported having more personalized discussions with 
their providers about their plans to conceive. Of these latter discussions, 64% were 
patient-initiated (Squires 2011, Finocchario-Kessler 2010). Similarly, a study based in 
two Los Angeles County clinics found that 66% of PLHIV who reported a desire to have 
children had not discussed their motivations with their provider (Mindry 2012).  
More recently, a qualitative study in an urban center in southern Florida revealed 
that preconception counseling with PLHIV is not regularly conducted in clinical care, nor 
have patients initiated these discussions due to patient perceptions of stigma (Coll et al. 
2015). Another recent qualitative study found that HIV serodiscordant couples seeking 
conception experienced challenges in both physically accessing counseling and in finding 
knowledgeable providers for preconception counseling. Patients preferred using HIV 
specialists to address their reproductive desires as compared to providers in other 
specialties (Friedman et al. 2016). These studies present important opporunities for 
decision aids and provider trainings within this setting.   
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The Efficacy of Pre-Exposure Prophylaxis  
 
Recent studies have shown the efficacy of Truvada® for Pre-Exposure 
Prophylaxis (PrEP) in preventing HIV transmission among men who have sex with men 
(MSM), high-risk heterosexuals, and intravenous drug users (CDC/HHS 2014; Smith et 
al. 2013; Smith et al. 2012; CDC MMWR 2011). The Partners PrEP trial, for instance, 
demonstrated that daily tenofovir disoproxil fumarate (TDF) and emtricitabine/ tenofovir 
disoproxil fumarate (TDF-FTC, or Truvada) reduced the incidence of HIV-1 by 67% and 
75%, respectively with 97% medication adherence by returned pill count (Baeten et al. 
2012; Smith et al. 2012). However, tenofovir detection as compared to an undetectable 
level was associated with a relative risk reduction of 90% in contracting HIV with TDF-
FTC (Baeten et al. 2012). Meanwhile, the CDC’s TDF2 trial yielded a 62.2% efficacy in 
men and women with 84% medication adherence (Smith et al. 2012). Studies focused on 
PrEP for conception purposes have also shown positive outcomes. Studies of couples 
with an HIV-negative female partner and HIV-positive male partner have been successful 
in yielding 70–75% pregnancies with no HIV seroconversions or other adverse events 
(Vernazza et al. 2011; Whetham et al. 2014).   
Other studies such as the iPrEX trial that enrolled MSMs and transgender women 
and the Bangkok Tenofovir study among intravenous drug users (IDUs) also showed 
efficacy, albeit at lower levels. The iPrEX trial found a 44% HIV reduction in MSM who 
engage in risky sexual behavior with 89–95% medication adherence by returned pill 
count (Grant 2010). The authors noted that drug levels required to achieve protection 
could vary according to the type of sexual exposure, in this case, anal exposure (Grant et 
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al. 2010). Additionally, the Bangkok Tenofovir study reached a 48.9% reduction in HIV 
incidence with tenofovir detection and yielded a 70% reduction in the overall risk for 
infection. In this study, participants took their medication on an average of 83.8% of days 
(Smith et al. 2013). Other studies, however, such as the FEM-PrEP and the oral TDF 
component of the VOICE trial were discontinued due to futility issues, though 
suboptimal adherence may have precluded the opportunity to demonstrate protective 
efficacy (Smith et al. 2012). 
 
Provider willingness to prescribe PrEP   
 
Notwithstanding overall PrEP efficacy estimates reaching up to 90% with optimal 
adherence, there remains limited utilization of PrEP among providers (Karris 2014; Levin 
2014; White et al. 2012; Baeten et al. 2012; Thigpen et al. 2012; Grant et al. 2010). 
Previous literature has questioned whether evidence, even “strong” and “relevant” 
evidence, is enough to cement the adoption of an innovation (Ferlie et al. 2005). Ferlie et 
al. (2005) argue that both knowledge boundaries and social or identity boundaries 
“inhibit diffusion.” Williams and Gibson (1990) recognized that users’ interpretations of 
evidence impact outcomes.  
Among the estimated 1.2 million PLHIV in the United States, more than half have 
partners who are HIV-negative (CDC 2014 and Lampe et al. 2011). Historically, 
serodiscordant couples composed of an HIV-positive male and HIV-negative female have 
faced significant challenges to accessible, affordable options for safe conception. In 
addition to assisted reproductive technologies often being prohibitively expensive, these 
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services are also largely inaccessible to this population (Sauer 2006, ASRM 2015). The 
CDC suggests the use of PrEP during periconception and pregnancy by an uninfected 
partner as another option to reduce the risk of sexual HIV acquisition (CDC/HHS 2014). 
Limited studies to date have examined provider perceptions related to prescribing 
Truvada® for the indication of conception.  
 A recent study examined the evolution of knowledge and attitudes toward PrEP 
among primary care providers. The national survey found support for PrEP had increased 
since 2009 (Smith et al. 2016). Prior to FDA approval of PrEP in 2012, studies of 
physicians and other clinicians in the United States found that despite high awareness of 
PrEP, few actually prescribed it. In a cross-sectional survey of generalist and HIV 
specialist physicians in Massachusetts from 2010 to 2011, 96% of participants indicated 
that formal CDC guidelines would “have the greatest impact on their willingness to 
prescribe PrEP” (White et al. 2012). Within this study, only 4% (5/115) of physicians had 
prescribed PrEP.  
After FDA approval of PrEP in 2012, a study in 2013 found that support for PrEP 
was strong among infectious disease physicians but few physicians (51/573, 9%) had 
actually prescribed it (Karris et al. 2014). A more recent study following the release of 
the 2014 CDC Guidelines on PrEP suggests that the prescribing of PrEP among 
infectious disease providers may have increased (Krakower et al. 2016). This study, 
surveying the same network of Infectious Disease physicians (The Emerging Infectious 
Disease Network, EIN) as Karris et al. 2014, found that 32% (117/411) had experience 
prescribing PrEP. When providing care to HIV serodiscordant couples in particular, 75% 
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and 80% of providers, respectively, said they would recommend PrEP in situations in 
which the HIV-infected partner had suboptimal adherence. However, only one third of 
providers (33%) indicated that they would recommend PrEP when the HIV-infected 
partner had an undetectable viral load (Krakower et al. 2016).  
Gilead reports between January 1, 2012 and March 31, 2014 revealed limited 
provider uptake of PrEP with initiation led mostly by non-infectious disease physicians. 
Between these dates, clinicians within internal medicine prescribed 19% of the total 
prescriptions, while clinicians from family medicine and infectious disease followed at 
18% and 11%, respectively (Levin 2014). Among a national survey of primary care 
clinicians in the United States, however, only 4% of primary care physicians had 
experience prescribing PrEP in 2013 (60/1507) and 2014 (60/1508), which rose to 7% 
(105/1501) in 2015 (Smith et al. 2016). The slow uptake of PrEP could stem from 
provider attitudes and their hesitancy to incorporate this new method into already 
overburdened clinical practice settings (Landovitz 2015). 
For the indication of conception, 17% (24/140) of survey respondents at a one-
day course on HIV and antiretrovirals in New York City in 2013 had experience 
prescribing Truvada® for a woman in a serodiscordant couple. Of this population, 37% 
(53/141) had referred a serodiscordant couple for either intrauterine insemination (IUI, 
placing the sperm directly into the uterus) or in vitro fertilization (IVF) (Scherer 2014). 
Among primary care clinicians that prescribed PrEP in a 2015 national survey, 73% had 
prescribed PrEP for MSM, 22% for injection drug users, and 27% for uninfected women 
seeking conception with their HIV serodiscordant partners. Additionally, 45% had 
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prescribed PrEP for uninfected women in a serodiscordant relationship not attempting 
conception and 30% for uninfected men in this situation (Smith et al. 2016). Across the 
five survey years (2009–2015), clinician willingness to prescribe PrEP was highest for 
HIV-negative partners in a serodiscordant couple (79%), followed by MSM (66%), 
intravenous drug use (63%), and HIV serodiscordant couples seeking conception (61%) 
(Smith et al. 2016).  
Similar to earlier studies, a newer survey of providers at three HIV-related 
medical conferences in New York, San Diego, and Los Angeles found knowledge to play 
an important role in provider experience in prescribing PrEP (Blumenthal et al. 2015; 
Tripathi et al. 2012). The most common concerns about PrEP included drug toxicities, 
drug resistance, and patient adherence and follow-up (Blumenthal 2015).  
The influence of knowledge on PrEP prescribing behavior and engagement among 
patients 
 
From a female patient’s perspective, one study reveals knowledge gaps and 
concerns about taking PrEP.  Auerbach et al. 2015 conducted a qualitative study of 
confirmed HIV-negative black/African American women (who are disproportionately at 
risk for HIV) in multiple sites in the United States. The focus groups in six U.S. cities—
New York, Dallas, Atlanta, Newark, Chicago, and New Orleans—revealed limited 
knowledge of PrEP, with only 10% of participants indicated ever hearing about it (N=144 
total). The women who did know about PrEP were unaware of its use in women. 
Participants raised concerns about cost, side effects, stigma, mistrust in the medical 
institution, chaotic lifestyle/housing, and “newness of drug” (Auerbach et al. 2015).  
8 
 
 
 
Integration of PrEP within a fertility setting  
 
Further integration of PrEP within a fertility context is necessary to realize its 
benefits for HIV serodiscordant couples seeking conception. Provider uptake of PrEP is a 
critical step for its effective implementation and to ensure appropriate access to care. 
From the perspective of patient uptake, a strong correlation exists between detectable 
blood levels of PrEP with prophylactic effect, highlighting the need for maximal 
adherence to the medication (Baeten et al. 2012). Thus, effectively delivering PrEP to 
serodiscordant couples desiring conception will involve extensive reproductive and 
sexual health counseling, adherence monitoring, and coordination of care. A study that 
examined physician adherence to the 2014 CDC/HHS PrEP clinical practice guidelines 
found provider divergence from clinical practice guidelines. Clinicians varied in their 
approaches to using PrEP in serodiscordant couples, while also differing from the 
guidelines in confirming HIV risk, HIV testing, and STI screening. The physicians 
interviewed also preferred more frequent follow-up visits overall (Mullins et al. 2015). 
Further work is required to integrate PrEP into existing general health services and 
engage providers to implement PrEP within a fertility setting (Thomson et al. 2016). 
More information on provider perceptions of PrEP within this context is critical for 
successful implementation.   
Assisted reproductive technology: A prevention option for serodiscordant couples 
seeking conception  
 
Quality of care encompasses both patient information and choice. Consequently, 
serodiscordant couples should have the option of assisted reproduction either for the 
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purpose of risk reduction or for supported fertility if they experience reproductive 
challenges. Evidence suggests similar fertility motivations of PLHIV in the United States 
compared to the general U.S. population. Trends in assisted reproduction for non-HIV 
infected couples have continued to rise from 107,587 cycles in 2001 to 190,773 ART 
cycles performed at 467 reporting clinics in 2013. These latter cycles resulted in 54,323 
live births and 67,996 live born infants (CDC 2013). Despite a growing trend in utilizing 
ART services among the general population, it remains primarily a privately funded 
service with clear barriers to access among less advantaged patients (Jain et al. 2005, 
ASRM 2008, 2010). The barriers become more apparent for HIV serodiscordant couples 
where there are fewer facilities offering these services to this population (Sauer 2006, 
ASRM 2008, 2010, 2015). In general, HIV has disproportionately impacted individuals 
with historically lower socioeconomic status and of racial minority, which can negatively 
impact their utilization of health services, including ART (Rubin et al. 2010). 
Evidence reveals an acceptance and demand for ART services among this 
population. The Center for Women's Reproductive Care (CWRC) at Columbia University 
conducted a survey between April 1999 and January 2001 of 50 serodiscordant couples—
where the woman was HIV-negative and the man HIV-positive—seeking in vitro 
fertilization with intracytoplasmic sperm injection (IVF-ICSI, an in vitro procedure 
where a single sperm is injected directly into an egg) to reduce risk of HIV transmission 
to the uninfected female partner. The majority of both women and men (66%) said they 
would use IVF-ICSI to conceive a second child if the method resulted in a healthy first 
child, while 40% of couples stated they would have unprotected intercourse to achieve 
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pregnancy if there were no other alternatives (Moragianni 2014, Klein 2003). Similarly, 
between 2006 and 2011, the National Perinatal HIV Hotline and Clinicians Network 
experienced an increase in the number of calls inquiring about safe conception. Over 80% 
of calls involved questions about couples where the male is HIV-positive and the female 
is HIV-negative. Sixty-three percent of these calls inquired about access/referrals to 
fertility clinics offering assisted reproduction and 34% about alternatives to assisted 
reproduction, such as PrEP (Cohan 2013).  
Other studies have shown, however, that demand may be dependent on household 
income. Newmeyer et al. 2011 found that HIV-serodiscordant couples seeking such 
services had household incomes above $45,000 per year. More recently, an evaluation of 
preconception counseling for serodiscordant couples in the U.S. found that patients’ 
perceptions of ART might correlate with personal finances. Patients with higher incomes 
expressed greater familiarity with ART services than those with lower incomes 
(Friedman et al. 2016).  
The American Society for Reproductive Medicine (ASRM) and the American 
College of Obstetricians and Gynecologists (ACOG) support fertility services for PLHIV 
(ASRM 2002, 2010, 2015; ACOG 2001), yet only an estimated 3% of ART practices 
registered with the Society of Assisted Reproductive Technologies (SART) report 
offering services to HIV-positive individuals (Sauer 2006, ASRM 2010, 2015). This 
figure is anecdotally presented in the literature, however. Sauer in 2006 notes, “As best as 
I can ascertain, to date there are still fewer than 10 centers that admit to actively treating 
men with HIV, which represents less than 3% of the practices registered with the Society 
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for Assisted Reproductive Technology” (Sauer 2006). Due to the lack of data on the 
availability of services for this patient population, ASRM recently cited this figure in 
2015. Reasons given for low provision of such services include transmission and cross-
contamination concerns during laboratory prep, lack of expertise, and high costs for 
maintaining separate laboratory space. There have been no reported cases to date, 
however, of occupational transmission to personnel or contamination in the clinic setting 
(ASRM 2008, 2010, 2015). While ASRM reports indicate a low percentage of ART 
practices providing services to this population, no studies to date have rigorously 
examined the number of clinics providing services and the barriers in accessing assisted 
reproductive services among this population.  
Medical providers in Europe and the United States have spent the last 20 years 
demonstrating both the safety and effectiveness of reproductive technologies for HIV-
positive individuals seeking to conceive with their partners. Technologies such as sperm 
washing (or donated sperm) coupled with intrauterine insemination (IUI), in vitro 
fertilization (IVF), and intracytoplasmic sperm injection (ICSI) have proven effective for 
this population (Bujan et al. 2004, Gilling-Smith et al. 2000, Marina et al. 1998, Pena et 
al. 2003, Loutradis et al. 2001, Weigel et al. 2001, Sauer et al. 2002, Ohl et al. 2003, 
Garrido et al. 2004, Nicopoullos et al. 2004, Mencaglia et al. 2005, Savasi et al. 2007). 
Europe’s Center for Reproductive Assisted Techniques (CREAThE), for example, 
conducted a multicenter retrospective study at eight centers on the safety of sperm 
washing in HIV serodiscordant couples where the male is positive. A series of 3,390 
treatment cycles including 2,840 IUI cycles from eight different centers yielded no 
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seroconversions (Bujan et al. 2007). Meanwhile, the CWRC at Columbia University has 
provided fertility therapy for over 15 years. At this center, 259 serodiscordant couples 
where the male partner is HIV-positive safely pursued one or more IVF-ICSI treatment 
cycles (Sullivan-Pyke et al. 2013).  
Furthermore, in economic simulation studies, the risk of HIV transmission has 
shown to be the lowest with SW-IUI compared to PrEP and treatment as prevention 
(Mabileau et al. 2015). Due to one case of seroconversion in 1989, where sperm washing 
was employed at lower standards without density gradient procedures, the CDC 
recommended against SW-IUI (CDC 1990). Whereas SW-IUI has become routine for 
HIV serodiscordant couples in Europe, fertility clinics in the U.S. preferentially provide 
IVF or IVF-ICSI for HIV serodiscordant couples, which has proven more costly for 
couples (Semprini et al. 2013, Sauer et al. 2009). Assessing limitations in accessing 
fertility services among this population is a step towards improving patient choice for 
safe conception and ensuring patient preferences are realized. Providers also play a 
critical role in ensuring that couples exercise their rights in accessing the information, 
education, and means to such services (Aday and Andersen 1974). 
 
The cost effectiveness of Truvada® for PrEP compared to alternative methods for 
conception 
 
While Truvada® for PrEP is potentially a more accessible option for 
serodiscordant couples composed of an HIV-positive male and HIV-negative female, 
Truvada is costly for payers, and it may provide only modest additional prevention 
benefit to serodiscordant couples in which the HIV-infected partner is already on 
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continuous anti-retroviral therapy with suppressed HIV viremia (Gray et al. 2001, 
Semprini et al. 2007, Semprini et al. 2013, Hoffman et al. 2015, Mabileau et al. 2015, 
Ciaranello and Matthews 2015). Cost effectiveness analysis is a useful tool for 
determining the largest health gains with limited allocated funds (Muennig 2008).  
Cost effectiveness studies have been conducted on PrEP for MSM in the United 
States and on use of PrEP for both men and women in South Africa with varying 
parameters (Juusola et al. 2012, Paltiel et al. 2009, Desai et al. 2008, Walensky et al. 
2012, Pretorius et al. 2010). The studies on PrEP for women in South Africa assumed 
reduced costs of PrEP and varied in context compared to the HIV situation in the U.S. 
One study also solely focused on the PrEP microbicide gel (Walensky et al. 2012, and 
Pretorius et al. 2010). Cost effectiveness studies for the MSM population in the U.S. vary 
in their conclusions due to slightly different parameters such as duration that MSM 
remain on the medication (Juusola et al. 2012, Paltiel et al. 2009, Desai et al. 2008). 
However, the studies reach a similar conclusion in that PrEP is only cost-effective for the 
highest-risk subgroup of MSM, which in one study was an estimated 20% of the overall 
MSM population (Juusola et al. 2012).  
Three recently published studies, however, focus exclusively on PrEP within a 
conception framework. These studies simulated the additional benefit of PrEP versus that 
of cART alone or medically assisted procreation with IUI and suggest unfavorable cost 
effectiveness ratios and minimal additional benefit of PrEP with an already suppressed 
viral load (Hoffman et al. 2015, Mabileau et al. 2015, Ciaranello and Matthews 2015, and 
Letchumanan et al. 2015). All three studies suggest that intercourse limited to timed/peak 
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ovulation is the dominant conception strategy for this population (Hoffman et al. 2015, 
Mabileau et al. 2015, Letchumanan et al. 2015). While cART non-targeted intercourse 
yielded higher HIV transmission rates and lowest with assisted reproduction, cART with 
targeted intercourse represented better value for money overall (Mabileau et al. 2015, 
Letchumanan et al. 2015).  
Hoffman et al.’s 2015 analysis likewise shows minimal added benefit of PrEP 
when the HIV-infected male partner is adherent to ART and other transmission risks are 
optimized such as limited sex to ovulation and screening/treatment of STIs. This 
simulation model focuses on two outcomes: (1) “Successful outcome” whereby the 
female remained HIV-uninfected and conceived a child; and (2) “unsuccessful outcome” 
whereby the female became HIV-infected and did not conceive a child. When the male’s 
viral load was suppressed and the couple limits condomless sex to the window of 
ovulation, the average probability of the successful outcome was 29.1%; increasing to 
29.2% with PrEP (Hoffman et al. 2015).  
While these recent studies significantly contribute to the literature on PrEP for 
conception, they fail to address important parameters and contextual components of 
conception for serodiscordant couples including: 
• Examining the cost effectiveness of PrEP compared to the full range of 
reproductive strategies (i.e. IVF) for HIV serodiscordant couples within a U.S. 
context. 
• Considering the timing of HIV testing and other varying approaches to 
monitoring PrEP, which can influence the outcome including the costs and 
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effectiveness of the interventions being examined.  
• Taking heterogeneous approaches to computing the mother and child’s QALYs 
saved by including the baby in the incremental cost effectiveness ratio (ICER) 
calculations. Previous literature either did not incorporate utilities in their 
analysis, thereby equating the mother and child’s lives, (Mabileau et al. 2015) or 
grounded their utilities on an underrepresented survey of 8 participants 
(Letchumanan et al. 2015).  
• Considering the potential impact of HIV and/or cART on male fertility 
• Integrating the probability of females becoming infected with HIV but “unaware” 
of their status (delayed awareness) and those becoming “aware” after a true 
positive test.  
• Integrating “aware” versus “unaware” in utero HIV transmission probabilities to 
the baby.  
• Incorporating supported pharmacokinetics data (PK) data on PrEP for women. 
Mabileau et al. 2015 included a PrEP strategy limited to fertile days (2 to 5 days 
accordingly) but equated the efficacy of PrEP when limited and used 
continuously.  
The European landscape drastically varies from the U.S. landscape in that experts 
in France recommend sperm wash with IUI for conception in HIV serodiscordant couples 
but also consider “treatment as prevention” with intercourse limited to fertile days as an 
alternative method for these couples (Mabileau et al. 2015). In the U.S., the CDC has 
historically recommended against IUI techniques for this population and does not 
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recognize “treatment as prevention” as a stand-alone option (CDC 2014, CDC 1990).  
Both Mabileau et al. 2015 and Letchumanan et al. 2015 also did not consider in 
vitro fertilization in their cost effectiveness analyses, which is an important method to 
consider for couples when IUI fails. While IVF would increase medical costs, the method 
would also increase effectiveness since the probability of having a child could increase 
while simultaneously lessening ones exposure to HIV. Hoffman et al.’s 2015 simulation 
model is not a cost effectiveness study. Rather, their model estimates the average annual 
probability of a woman remaining HIV-negative and conceiving a child with her HIV-
positive partner through natural conception (cART with PrEP versus cART suppression 
only). Their model did not consider other reproductive options for these couples.  
Current cost effectiveness analyses and mathematical simulation studies have not 
considered the probability, cost, or utility parameters for both mothers and babies when 
the negative partner became infected with HIV but “unaware” of her status and became 
“aware” only after a true positive test. Such parameters are critical for the analysis since 
“aware/unaware” can have important implications for both costs and effectiveness of an 
intervention (Mabileau et al. 2015, Letchumanan et al. 2015, Hoffman et al. 2015). 
Another important limitation of current analyses is their computation of the mother and 
child’s life years saved. Mabileau et al. 2015, for instance, aggregated life expectancies 
for both the mother and the baby, which equates their value by omitting a QoL 
component. Letchumanan et al. 2015 incorporated a QoL scale based on an 
underrepresented survey of eight participants. It is also unclear how they integrated the 
baby into their model. Hoffman et al. 2015 encompassed a probabilistic model and did 
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not simulate the child’s life years.  
 Further limitations of the current CEA/simulation literature on risk reductive 
options for conception include assumptions based on normal female and male fertility. 
Low sperm count and motility are predictors in HIV-positive men and could thus lower 
the chances of pregnancy for the modeled interventions (Bujan et al. 2007, Nicopoullos et 
al. 2004, and Mascarenhas et al. 2012). Hoffman et al. 2015 also made the assumption 
that HIV-infected men underwent a semen analysis prior to attempts to conceive. Semen 
analysis is optional though not required (HHS/CDC 2014 guidelines). Based on a PrEP 
demonstration study at four sites in Boston, Baltimore, Chicago, and Philadelphia, a 
recommended semen analysis is burdensome for patients. Fertility experts at Boston 
University Medical Center (BUMC) have also questioned its baseline value, as when 
semen analyses are used in circumstances other than an active infertility investigation, the 
predicted value of such tests is unclear (BUMC personal communication 2015).  
 Lastly, Mabileau et al. 2015 included a PrEP strategy limited to fertile days (2 to 
5 days accordingly) but equated the efficacy of PrEP when limited and used 
continuously. Their study did not incorporate supported PK data on PrEP for women. 
While two to three doses per week has proved effective 75% to 90% effective in men, a 
higher threshold is required for women at approximately six to seven doses per week to 
achieve 85% protective effect from HIV in the lower female genital tract tissue (Cottrell 
et al. 2016).  
My study will thus fill an important gap in the literature by predicting the cost 
effectiveness from an American payer perspective and modeling key parameters that 
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these studies did not consider.  
 
Summary 
 
Overall, my research brings substantial innovation toward better understanding 
provider attitudes and perceptions about PrEP, while identifying barriers to accessing 
other fertility services for couples in which one partner is HIV-positive. It also further 
expands the cost effectiveness literature on PrEP compared to other fertility options in the 
United States. There remains limited uptake of PrEP prescribing among providers in 
general and thus it is critical to understand the barriers in prescribing Truvada® for this 
specific indication to advance the integration of this method into clinical care. Assessing 
limitations to accessing fertility services among this population is also a step towards 
improving patient choice and ensuring patient preferences are realized. Additionally, 
while Truvada® for PrEP is an important option for these couples, it may provide only 
modest additional prevention benefits and thus it is important to compare this method to 
other reproductive options for these couples.   
 
Theoretical context and framework 
 
To better understand the complexity of decision making and individual access to 
reproductive services for HIV serodiscordant couples, I developed a conceptual 
framework based on the Cabana and Andersen models (Cabana et al. 1999, Andersen 
1995). The model is illustrated in Figure 1 below.  
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Figure 1: Hybrid model based on the Cabana and Andersen models indicating 
potential barriers in accessing assisted reproductive services for serodiscordant 
couples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Health system and provider influences to implementation 
 
This component of the conceptual model is adapted from Cabana’s model on 
barriers to physician adherence to practice guidelines in relation to behavior change 
(Cabana et al. 1999). Cabana linked barriers to physician adherence to sequences of 
behavior change through knowledge, attitudes, and behaviors. The model incorporates 
“different behavioral constructs,” which are important components to understanding and 
improving physician adherence to practice guidelines. In the context of my research, 
provider experience and attitudes were assumed drivers of provider behavior and 
therefore, one’s access and engagement in health services. Limited clinical experience 
working with at-risk populations, clinical uncertainty, values/predisposing characteristics, 
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and patient behavior could impact physician behavior in incorporating PrEP and other 
innovations into their practice.  
Other barriers that might influence physician behavior include perceived liability 
and environmental factors such as lack of time, resources, and organizational constraints. 
Likewise, as Cabana et al. found, external barriers could also “affect a physician’s ability 
to execute recommendations,” and in this case, a physician’s willingness to adopt a new 
practice (Cabana et al. 1999). In addition, the organizational and external environment 
such as provider “champions” and “boundary spanners” could influence one’s source of 
behavior and one’s role in delivering PrEP for conception. Champions might also help to 
spread knowledge and foster a shared understanding of values in an innovation, which 
could reduce social barriers within and across departments (Ferlie et al. 2005). Shared 
social values inside an organization could further be important determinants of adoption.   
 
Social contextual factors 
 
The Andersen model suggested that predisposing characteristics (such as age, 
race, and social standing) and enabling factors (such as availability of health personnel 
and facilities) drove utilization of health services. Andersen noted that ‘both community 
and personal enabling resources must be present for use to take place’ (Andersen 1995). 
Individuals must also have sufficient resources and knowledge/awareness to use health 
services. For example, despite a growing trend in utilizing assisted reproductive fertility 
services among the general population, it remains primarily a privately funded service 
with clear barriers to access among less advantaged patients. The barriers become more 
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apparent for HIV serodiscordant couples where there are fewer facilities offering these 
services to this population. 
Andersen further explained that one’s perceived need and perception of risk must 
also be considered before an individual seeks services. For HIV serodiscordant couples, 
individual need is realized within the patient’s social and cultural environment, 
perception of risk of acquiring the virus, and one’s knowledge of the different services 
available to them. The “evaluated component of need,” is also important within this 
context, as professional judgment influences one’s perception of need. However, like 
Andersen described, this professional judgment also has a social component and varies 
“according to the training and competency of the professional expert doing the 
assessment” (Andersen 1995). Providers have their own biases, experience, and attitudes 
that could also largely influence one’s perceived need and perception of risk.   
 
Societal costs  
 
Finally, societal costs were added to these two important constructs in the model 
to emphasize the underlining importance that incremental costs and benefits play in 
patient access and engagement in health services. The balance between incremental costs 
and benefits are an important contributor in determining how to “maximize the quality 
and quantity of life in a particular society that is constrained by a particular budget” 
(Muennig 2008). Such priority setting could influence both provider behavior and 
“enabling resources” available to ensure patient engagement in health services. 
Therefore, by evaluating the overall cost and effectiveness of a given strategy, we can 
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influence decision making and priority setting to ensure that populations have access to 
beneficial services.  
 
Research papers 
 
My thesis research is unique in taking an integrative perspective in examining 
both patient access and societal cost implications for HIV serodiscordant couples seeking 
conception services. This research brings substantial innovation toward better 
understanding provider attitudes and perceptions towards PrEP for conception, 
highlighting access issues to other fertility services for HIV serodiscordant couples, and 
in deducing the cost effectiveness of the full array of risk reducing conception options for 
these couples in the United States. As part of the Boston University Health Services 
Research doctoral dissertation model, I developed three papers integrating the interrelated 
components of physician behavior, patient choice, and cost to improve health outcomes 
for HIV serodiscordant couples seeking reproductive services. 
My first paper examines the perceptions and experiences of providers in the U.S. 
in regard to prescribing PrEP and their attitudes towards other reproductive options for 
serodiscordant couples. The second paper aims to better understand access to assisted 
reproductive services for serodiscordant couples where the male is HIV-positive and the 
woman is HIV-negative. Finally, the third paper projects the long-term outcomes and cost 
effectiveness of Truvada® for conception compared to alternative reproductive methods. 
My three studies provide a complementary and integrative picture of this important issue.  
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The provider piece complements the other proposed studies by examining this 
topic through the eyes of a prescriber. The paper on assessing access to ART options for 
serodiscordant couples ties the other papers together by more closely examining why 
other fertility options apart from PrEP are not equitable for this population. Finally, the 
cost effectiveness paper complements the other perspectives by capturing the underlining 
importance that incremental costs and benefits play in patient access and engagement in 
health services. This paper fills an important gap in the literature by predicting the cost 
effectiveness from an American payer perspective and modeling key parameters that 
other studies did not consider. All three perspectives are critical to better understand 
patient engagement in health services. 
The following section details each paper’s research question, hypotheses, specific 
aim(s), data source(s), and methodology.   
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CHAPTER II: Provider Perceptions of Pre-Exposure 
Prophylaxis (PrEP) for Conception 
 
 
BACKGROUND 
 
 With approximately 50,000 new annual HIV infections and half a million women 
in the United States at significant risk of HIV infection, PrEP has become a critical HIV 
prevention strategy (Krakower 2016, Prejean et al. 2011, Seidman and Weber 2016, 
Smith et al. 2015). While the implementation of PrEP for conception purposes is still 
being examined in clinical settings across the world, physicians have an important role to 
play in determining its use for women at risk for exposure in this setting (BUMC 2016; 
Baeten et al. 2012). Despite its significant potential for thwarting the spread of HIV, 
providers in the United States have been slow to prescribe it (Krakower et al. 2016, 
Karris et al. 2014, Levin 2014, Scherer 2014, White et al. 2012, Tripathi et al. 2012). This 
barrier could stem from provider attitudes and hesitancies to incorporate this new method 
into already overburdened clinical practice settings (Landovitz 2015).  
The CDC recognizes the use of PrEP as “an additional tool to reduce the risk of 
sexual HIV acquisition” during pregnancy (CDC/HHS 2014). While data on in utero 
exposure of PrEP is incomplete, PrEP use in periconception has not been shown to 
increase the risk of pregnancy loss, birth defects, per-term birth, or other congenital 
abnormalities (Heffron et al. 2016, Mugo et al. 2014). Limited studies to date have 
examined provider perceptions related to prescribing Truvada® for the indication of 
conception. Further research is needed to understand provider attitudes and perceptions 
toward integrating PrEP into existing health services for different indications including 
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that of conception. The benefits of PrEP will only be fully realized if providers across 
disciplines are on board with its use.  
The goal of this study was to evaluate the perceptions and experiences of clinical 
prescribers in the U.S. related to prescribing PrEP for conception, and to assess their 
attitudes towards other reproductive options for serodiscordant couples. The research also 
brings innovation towards better understanding provider experiences and attitudes toward 
PrEP for different indications compared to that of conception. This research enhances our 
knowledge on practice patterns for PrEP and whether any variations exist between 
providers from different disciplines (infectious disease, internal medicine, and family 
medicine).  
Figure 2 below denotes the conceptual domains from my overall dissertation 
conceptual framework that were addressed in this study. As noted in Chapter I above, this 
component of the conceptual model was adapted from Cabana’s model on barriers to 
physician adherence to practice guidelines in relation to behavior change (Cabana et al. 
1999). Cabana linked barriers to physician adherence to sequences of behavior change 
through knowledge, attitudes, and behaviors. The model incorporates “different 
behavioral constructs,” which are important components to understanding and improving 
physician adherence to practice guidelines. In the context of my research, provider 
experience and attitudes were assumed drivers of provider behavior and therefore, one’s 
access and engagement in health services. Limited clinical experience working with at-
risk populations, clinical uncertainty, values/predisposing characteristics, and patient 
behavior could impact physician behavior in incorporating PrEP and other innovations 
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into their practice.  
 
Figure 2: Conceptual domains addressed in Study 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Questions  
 
Do providers differ by specialty in: (1) their experience and perceptions around 
prescribing indications and general prescribing of PrEP including for serodiscordant 
couples desiring conception, and (2) their attitudes towards other reproductive options, 
such as assistred reproductive technology (ART) services for serodiscordant couples?    
 
Specific Aims 
 
The aims of this study were to evaluate the perceptions and experiences of 
providers in the U.S. in regard to prescribing PrEP and examine their attitudes toward 
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other reproductive options for serodiscordant couples. The study also sought to better 
understand prescribing patterns for serodiscordant couples seeking conception services 
compared to other at-risk populations for HIV such as for MSM and IDUs.   
 
Hypotheses  
 
(1)  H0: Providers will not differ between categories (infectious disease, internal 
medicine, family medicine) in regard to experience prescribing PrEP 
 
H1: Providers will differ between categories (infectious disease, internal medicine, 
family medicine) in regard to experience prescribing PrEP.  
 
(2) H0: There will not be an association of provider willingness to prescribe PrEP 
across the different indications for PrEP, with provider willingness being the same 
across the different prescribing indications for PrEP.  
 
H1: There will be an association of provider willingness to prescribe PrEP among 
the different indications for PrEP, with providers feeling more hesitant to 
prescribe PrEP for conception than for MSM’s and IDU’s.  
 
(3)  H0: The proportion of respondents who will answer either “strongly agree” or 
“agree” is less than or equal to 50% to the statement, “If cost and access were not 
barriers, I would refer all of my HIV-infected patients in serodiscordant 
relationships who wish to conceive for assisted reproductive technologies” 
(Scherer 2014).  
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H1: The majority of respondents (> 50%) will answer either “strongly agree” or 
“agree” to this statement.   
 
Key outcomes and variables for this paper are outlined in Tables 2.0 and 2.1 below: 
 
Outcomes and key variables  
 
Table 2.0: Chapter II, Outcomes and variables  
Hypothesis #1 Associated variables 
H0: Providers will not differ 
between categories (infectious 
disease, internal medicine, family 
medicine) in regard to experience 
prescribing PrEP 
 
H1: Providers will differ between 
categories (infectious disease, 
internal medicine, and family 
medicine) in regard to experience 
prescribing PrEP 
Dependent variable (outcome):  
Experience prescribing PrEP (Have you prescribed PrEP? 
Y/N) 
 
Independent variable of interest:  
Provider specialty area (infectious disease, internal 
medicine, and family medicine)  
 
Control variables:  
Age, gender, ethnic/racial groups, course attended, 
qualification/licensure length of practice.  
 
Analysis:  
Chi square test and logistic regression  
Logit (Experience) = β0+ β1 Provider specialty + control 
variables 
Hypothesis #2 Associated variables 
H0: There will not be an 
association of provider willingness 
to prescribe PrEP across the 
different indications for PrEP, 
with provider willingness being 
the same across the different 
prescribing indications for PrEP.  
 
H1: There will be an association of 
provider willingness to prescribe 
PrEP among the different 
indications for PrEP, with 
providers feeling more hesitant to 
prescribe PrEP for conception 
than for MSM’s and IDU’s.  
Dependent variable (outcome):  
Provider response indicating PrEP as the ‘first best step’ to 
vignette question #15  
 
15.A 30-year old female who is HIV-negative with an 
unremarkable PMH is hoping to conceive with her HIV-
positive partner.  The (+) partner is on cART with an 
undetectable HIV viral load. What do you recommend as a 
first step?   
 
Independent variable of interest:  
Physician responses to questions #14 and #16 and their 
interaction. 
 
14.A 30-year-old male who is HIV-negative and has sex 
with men with an unremarkable PMH is sexually active 
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with his HIV-positive husband. The (+) partner is on cART 
but having challenges reaching an undetectable HIV viral 
load. What do you recommend as a first step?   
 
16.A 30-year old male who is HIV-negative with a history 
of injection drug use reports sharing needles with injection 
partners of unknown sero-status. What do you recommend 
as a first step?   
 
Control variables: 
Age, gender, ethnic/racial group, course attended, 
qualification/licensure, length of practice, specialty area, 
and experience prescribing PrEP. 
 
Analysis:  
Chi square test and logistic regression  
Logit (Conception) = β0+ β1 Druguser + β2 MSM+ β3 
Druguser&MSM + control variables 
Hypothesis #3 Associated variables 
H0: The respondents that will 
answer either “strongly agree” or 
“agree” is less than or equal to 
50% to the statement, “If cost and 
access were not barriers, I would 
refer all of my HIV-infected 
patients in serodiscordant 
relationships who wish to conceive 
for assisted reproductive 
technologies.” 
 
H1: The majority of respondents 
(> 50%) will answer either 
“strongly agree” or  “agree” to 
this statement.   
Dependent variable (outcome):  
Collapsed ordinal responses (strongly agree/agree) to 
question #12 (preference to refer HIV-infected patients in 
serodiscordant relationships who wish to conceive for 
ART services).  
 
12.If cost and access were not barriers, I would refer all of 
my HIV-infected patients in sero-discordant relationships 
who wish to conceive for assisted reproductive 
technologies.  
 
Please state whether you “strongly agree,” “agree,” are 
“neutral,” “disagree,” or “strongly disagree” with the 
following: 
 
 
Control variables: 
Age, gender, ethnic/racial group, course attended, 
squalification/licensure, length of practice, specialty area, 
and experience prescribing PrEP. and provider specialty 
area (infectious disease, internal medicine, and family 
medicine)  
 
Analysis:  
One sample binomial test; P(x;p,n)=(n/x)(p)x(1−p)(n−x) 
Chi Square Goodness of Fit test; X2=∑(Observed-
expected)2/expected  
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Table 2.1: Chapter II, Control variables 
Variable Question on survey 
Course attended All surveys were separated by course attended  
(SF, NYC, LA, DC, and Chicago) 
Age Age: _________________________ 
 
Gender Gender:  Male       Female  Other: 
____________________ 
 
Ethnic/racial group Which ethnic and racial group(s) do you identify with? 
 Hispanic/Latino  
 White    
 American Indian or Alaska Native 
 Black or African American   
 Native Hawaiian or other Pacific Islander  
 Asian  
 Other 
Qualification/licensure  Please state your qualification/licensure:  
 MD/DO             
 Physician Assistant (PA)  
  Nurse Practitioner (NP)     
  
Length practicing independently How long have you been practicing independently?  
 In training   11–20 years  5–10 years 
 <5 years  21+ years  
Specialty area What is your specialty area? 
 Infectious diseases  Internal medicine 
 Family medicine   Other 
Experience prescribing PrEP Have you prescribed PrEP? 
 Yes  
 No 
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METHODOLOGY 
 
 
Study Design 
 
The study design was a cross-sectional survey of infectious disease (ID), internal 
medicine (IM), family medicine (FM), and other providers that could independently 
prescribe medications. The study examined perceptions and behaviors of PrEP use and 
other options for at risk indications.   
 
Study Population  
 
Continuing Medical Education (CME) courses are educational platforms for 
medical providers to stay abreast the new and developing areas in their fields. Many 
states require a certain number of CME education credits per year for providers to 
maintain their medical licenses. In collaboration with the International Antiviral Society 
(IAS-USA) from March to May 2015, a paper-based survey was distributed to 954 
participants at the CME advanced-level HIV course in five locations across the U.S.: San 
Francisco, CA, New York, NY, Los Angeles, CA, Washington, D.C., and Chicago, IL. 
The course aimed to improve the management of HIV and provide updates in HIV 
pathogenesis, antiretrovirals, and other selected issues in HIV disease management. 
According to IAS-USA, the courses were designed for “HIV specialists actively involved 
in HIV disease management” (IAS-USA HIV CME course description 2015). No 
incentives were provided for survey completion.  
 For the purposes of this study, only providers that could independently prescribe 
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were included in the sample; of the 954 participants, 652 were independent prescribers. 
The sample comprised of physicians (MDs or DOs), Nurse Practitioners (NPs) and 
Physician Assistants (PAs). Pharmacists were excluded from the study sample due to 
their minimal role in providing direct care and in prescribing PrEP for this population. I 
categorized providers by their specialty and subspecialty training. Provider 
specialties/subspecialties included: Infectious disease, internal medicine, family 
medicine, and “other,” which was comprised of obstetrics/gynecology, pediatrics, and 
other specialties noted in Table 2.7 below. A total of 14 respondents marked “other” only 
and wrote in “HIV” to the question, “What is your specialty area?” Based on clinical 
advice from committee members, I classified these respondents as “internal medicine.” 
Since they did not check “infectious disease,” they would most likely be internal 
medicine providers who did not complete an ID fellowship.  
 
Survey  
 
 A 17-item survey assessed practices, attitudes, and openness regarding the 
provision of PrEP and other reproductive options for serodiscordant couples seeking 
conception. Since no validated survey instrument exists for this topic, I used published 
questions, data, and clinical opinion to develop the survey instrument (White et al. 2012, 
Scherer et al. 2014, Mullins et al. 2015, and Abdool Karim, Gray and Martinson 2012). 
Domains surveyed included prescriber characteristics such as age, gender, race/ethnicity, 
state of practice, qualification/licensure, length of practicing independently, and specialty 
area. The key content area domains included experience prescribing PrEP (have you 
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prescribed PrEP?); the primary population to which they have prescribed; how often in 
the course of routine care do respondents typically ask their patients their partners’ HIV 
sero-status (generally, HIV-positive males, and HIV-positive females); and level of 
agreement with two statements: (1) “if cost and access were not barriers, I would refer all 
of my HIV-infected patient in serodiscordant relationships who wish to conceive for 
assisted reproductive technologies” (Scherer et al. 2014); and (2) “I am comfortable 
counseling my HIV-infected patients on safe options for conception/pregnancy.”  
Conditional scenarios were also developed to examine provider preference 
between PrEP for conception versus for other indications. The fields included case 
vignettes followed by specific clinical options where respondents were asked to choose 
one option as the best first step in cases that involved (1) A 30-year-old male who is 
HIV-negative and has sex with men with an unremarkable PMH is sexually active with 
his HIV-positive husband; (2) A 30-year old female who is HIV-negative with an 
unremarkable PMH is hoping to conceive with her HIV-positive partner; and (3) A 30-
year old male who is HIV-negative with a history of injection drug use reports sharing 
needles with injection partners of unknown sero-status (Abdool Karim, Gray and 
Martinson 2012) (survey instrument available in Appendix Document 1). The last 
question was open-ended and inquired, “what barriers, if any, do you foresee or have 
encountered in implementing PrEP for conception purposes?”  
 Consistent with my hypotheses, analyses were restricted to specific domains 
including the provision of PrEP across provider specialties, willingness to prescribe PrEP 
across different indications, and preference in regard to referring serodiscordant couples 
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for other reproductive options such as assisted reproductive technologies. 
 
Statistical Analyses  
 
 I used a level of significance α = 0.05 for all statistical tests, and set β at 0.20 (or a 
power of 0.80) to avoid Type II error, which I used when assessing sample size. I used 
SAS® 9.4 for statistical analysis. I calculated descriptive statistics including means and 
standard deviations (SDs) for continuous variables and counts with proportions for 
categorical variables. I performed unadjusted bivariate analyses comparing the physician 
groups using cross-tabulations with chi-square (χ2) and chi-square goodness of fit tests for 
the likert scale ordinal variable. I performed multivariable logistic regression analysis for 
nominal and collapsed ordinal outcomes, which were interpreted using probabilities and 
odds ratios from logistic models. Control variables included age, gender, ethnicity/race, 
CME course location, qualification/licensure, number of years practicing independently, 
and specialty area. I adjusted for covariates that altered the association between physician 
groups and outcome by more than 10% when compared to unadjusted results. In addition, 
I examined effect modification (interaction) between physician group and salient 
covariates such as age, gender, and preferences prescribing for other indications versus 
that for conception.  
 
Power Analyses  
 
The first alternative hypothesis 1(a) states that providers will differ between 
categories (infectious disease, internal medicine, and family medicine) in regard to 
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experience prescribing PrEP. To test this hypothesis, I used a chi square test for bivariate 
analyses and logistic regression for multivariable analysis. I modeled the dependence of 
the binary yes/no response to “experience” with provider specialty as the independent 
variable of interest. Control variables included age, gender, race/ethnicity, CME course, 
and length practicing. To power this hypothesis, I used chi square goodness of fit based 
on Levin’s 2014 data on the proportion of clinicians within internal medicine, family 
medicine, and infectious disease that prescribed PrEP between January 1, 2012 and 
March 31, 2014. Based on these proportional differences, I had a medium to strong effect 
(0.53) to detect a significant difference. In other words (and as the graph below indicates) 
if the true effect proved as low as 0.15, we would still have had adequate power to detect 
a small effect size between provider categories.  
 
Figure 2.1: Hypothesis #1 power analysis 
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The second alternative hypothesis states that there is an association of provider 
willingness to prescribe PrEP among the different indications for PrEP, with providers 
feeling more hesitant to prescribe PrEP for conception than for MSM’s and IDU’s. I 
categorized responses for each case vignette into a binary variable, “considered PrEP” or 
“did not consider PrEP” in their response. To test my hypothesis, I used a chi square test 
for bivariate analyses and logistic regression for multivariable analysis. Within the 
regression model, I tested the interaction between providers who would “consider PrEP” 
for MSMs and IDUs when “conception” was the outcome variable. Control variables 
included provider specialty, age, gender, race/ethnicity, CME course, and length 
practicing. To power this hypothesis, I used a chi square test of independence estimating 
provider response to the vignettes. This test yielded power to detect an effect size as 
small as .14. 
The third alternative hypothesis states that the majority of respondents (> 50%) 
answered either “strongly agree” or  “agree” to the statement, “If cost and access were 
not barriers, I would refer all of my HIV-infected patients in serodiscordant relationships 
who wish to conceive for assisted reproductive technologies.” To test this hypothesis, I 
used a chi square goodness of fit test for bivariate analyses and logistic regression for 
multivariable analysis. I modeled the dependence of the collapsed ordinal response 
(strongly agree/agree) across all prescribers. Control variables included provider 
specialty, age, gender, race/ethnicity, CME course, and length practicing. To power this 
hypothesis, I used a one-sample proportion difference from a constant proportion of 50%, 
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binomial test. Based on this test, I had significant power at 80% to detect a small effect 
size of .05   
Missing data  
 
I excluded respondents with missing outcome variables for each hypothesis, 
which is shown in Tables 2.2 to 2.5 below. For hypothesis #1, four observations were 
excluded, which represented less than 1% of the total sample. For hypothesis #1, the 
excluded individuals comprised of four females (two MDs and two NPs). Two females 
identified themselves as white, one as black/African American, and one Hispanic/Latina. 
Their mean age was 55.8. Three practitioners were from the DC CME course, while one 
was from the L.A. course.  
 
Table 2.2: Hypothesis #1, Excluded individuals (4 observations) based on missing outcome 
data 
Course Gender Qualification Specialty Age Race/ethnicity 
Length 
practicing 
4 Female NP ID 66 White 21+ yrs 
4 Female MD “Other” 39 
Black/African 
American 
Missing 
4 Female MD ID 61 White Missing 
3 Female NP FM 57 Hispanic/Latina 11–20 yrs 
Excluded 
group (%) 
100% 
Female 
50% MDs, 
50% NPs  
(CI+/-49) 
50% ID 
(CI+/-49), 
25% FM 
(CI+/-42.43), 
25% other 
(CI+/-42.43)  
Avg. 
age =56  
50% white 
(CI+/-49), 25% 
AA (CI+/-
42.43), 25% 
Hispanic (CI+/-
42.43) 
50% 11–20 
years’ (CI+/-49), 
50% 21+ years’ 
experience   
(CI+/-49) 
Remaining 
sample (%) 
56% 
Female 
70% MDs, 
21% NPs, 8% 
PAs  
38% ID, 
26% IM, 
27% FM, 9% 
other 
Avg. 
age =49 
58% white, 
10% AA, 8% 
Hispanic 
7% in training, 
17% <5 years’, 
16% 5–10 years’, 
25% 11–20 
years’, 34% 21+ 
years’ experience 
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For hypothesis #2, 17 observations were excluded: 11 observations with missing 
outcome data for Vignette #2, and six observations with missing responses to Vignette #1 
and/or Vignette #3 (observation #9 is missing both Vignettes), which were important 
predictor variables to Vignette #2. The excluded observations represented 3% of the total 
sample and included nine females (two MDs, six NPs, and one PA) and eight males 
(seven MDs and one NP). Four females identified as white, two as black/African 
American, two as Latina/Hispanic, and one as Asian. Seven males identified as white and 
one identified as Hispanic/Latino. Mean age was 46 years old (female: 44; male: 62); 
though two observations had missing age values. Three practitioners were from the DC 
CME course, five from SF, five from NYC, two from Chicago, and two from LA. 
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Table 2.3: Hypothesis #2, Excluded individuals (11 observations) based on missing outcome 
data Vignette #2 
Course Gender Qualification Specialty Age Race/ethnicity Length 
practicing 
4 Female NP ID 38 Black/African 
American 
5–10 yrs 
4 Female NP FM 33 White 5–10 yrs 
2 Male NP Other 57 White <5 years 
2 Male MD FM 63 White 21+ yrs 
2 Male MD IM 71 White Missing 
1 Female MD ID 43 Hispanic/Latina 11–20 yrs 
1 Male MD IM 50 White 11–20 yrs 
1 Female NP FM 51 Hispanic/Latina 5–10 yrs 
5 Female MD ID 31 Asian In training 
5 Male MD ID Missing White 21+ yrs 
3 Male MD IM 47 White 11–20 yrs 
Table 2.4: Hypothesis #2, Excluded individuals (6 observations) based on missing outcome data 
Vignettes #1 & #3 
Course Gender Qualification Specialty Age Race/ethnicity Length 
practicing 
4 Female NP FM 54 White 21+ yrs 
2 Female PA FM 45 White 11–20 yrs 
2 Male MD IM 83 White 21+ yrs 
1 Female NP IM 56 Black/African 
American 
5–10 yrs 
1 Female NP Other Missing White <5 yrs 
3 Male MD ID 61 Hispanic/Latino 21+ yrs 
 
Excluded 
group (%) 
53% 
Female 
(CI+/-
23.73) 
53% MDs 
(CI+/-23.73), 
41% NPs 
(CI+/-23.38), 
6 PA (CI+/-
11.29) 
29% ID, 
29% IM, 
29% FM 
(CI+/-
21.57), 12% 
other (CI+/-
15.45) 
Avg. 
age=46 
65% white (CI+/-
22.67), 12% AA 
(CI+/-15.45), 
18% Hispanic 
(CI+/-18.26) 
6% in training 
(CI+/-11.64), 
12% <5 years 
(CI+/-15.92), 
25% 5–10 years, 
25% 11–20 years 
(CI+/-21.22), and 
31% 21+ years’ 
experience (CI+/-
22.66) 
Remaining 
sample 
(%) 
57% 
Female 
70% MDs, 
21% NPs, 9% 
PAs 
38% ID, 
26% IM, 
27% FM, 
9% other 
Avg. 
age=49 
58% white, 10% 
AA, 8% Hispanic 
7% in training, 
17% <5 years, 
16% 5–10 years, 
25% 11–20 
years, and 34% 
21+ years’ 
experience 
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For hypothesis #3, 12 observations were excluded, which represented 2% of the 
total sample. The excluded individuals included 10 females (six MDs, three NPs, and one 
PA) and two males (two MDs). Four females identify as white, three as black/African 
American, two as Latina/Hispanic, and one as Asian. The two males identify as white. 
Mean age is 48.8 years old (female: 45.9; male: 63.5). Four practitioners were from the 
D.C. CME course, one from S.F., five from NYC, one from Chicago, and one from L.A.  
Table 2.5: Hypothesis #3, Excluded individuals (12 observations) based on missing outcome 
data 
Course Gender Qualification Specialty Age Race/ethnicity Length 
practicing 
 
4 
Female MD Other 39 Black/African 
American 
Missing 
4 Female MD ID 61 White Missing 
4 Female NP Other 40 Black/African 
American 
5–10 yrs 
4 Female MD Other 37 Asian 5–10 yrs 
2 Male MD IM 71 White Missing 
1 Female PA IM 39 Black/African 
American 
< 5 years 
1 Female MD FM 39 White < 5 years 
1 Female MD FM 59 White < 5 years 
1 Female MD ID 43 Hispanic/Latina 11–20 yrs 
1 Female NP FM 51 Hispanic/Latina 5–10 yrs 
5 Female NP FM 51 White 21+ yrs 
3 Male MD FM 56 White 21+ yrs 
Excluded 
group (%) 
83% 
Female 
(CI+/-
21.25) 
67% MDs 
(CI+/-26.6), 
25% NPs 
(CI+/-24.5), 
8% PAs (CI+/-
15.35) 
17% ID (CI+/-
21.25), 0% IM, 
42% FM 
(CI+/-27.93), 
25% other 
(CI+/-24.5) 
Avg. 
age 
=49 
50% white 
(CI+/-28.29), 
25% AA (CI+/-
24.5), 17% 
Hispanic (CI+/-
21.25), 8% 
Asian (CI+/-
15.35), 
0% in training, 
33% <5 years, 
33% 5–10 years 
(CI+/-30.72), 
11% 11–20 years 
(CI+/-20.44), and 
22% 21+ years’ 
experience (CI+/-
27.06) 
Remaining 
sample (%) 
56% 
Female 
70% MDs, 
22% NPs, 9% 
PAs 
39% ID, 26% 
IM, 27% FM, 
8% other 
Avg. 
age 
=49 
58% white, 
10% AA, 8% 
Hispanic, 19% 
Asian 
8% in training, 
17% <5 years, 
16% 5–10 years, 
26% 11–20 years, 
and 35% 21+ 
years’ experience 
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Since the number of missing values was slight and represented less than 3% of the 
total sample (see Table 2.6 below), I adjusted the logistic regression models without 
imputing the missing control values. Furthermore, I used backward selection to select the 
most useful predictors for the model out of the larger group.  
 
Table 2.6: Overview of missing control variables for each hypothesis  
N=519 
Hypothesis #1 
N=515 
Missing control variables 
Age: Missing 21 responses 
Gender: Missing 5 responses 
Ethnicity/race: Missing 11 responses 
Length practicing: Missing 5 responses 
Hypothesis #2 
N=502 
Missing control variables 
Age: Missing 19 responses 
Gender: Missing 5 responses 
Ethnicity/race: Missing 11 responses 
Length practicing: Missing 6 responses 
Hypothesis #3 
N=507 
Missing control variables 
Age: Missing 21 responses 
Gender: Missing 5 responses 
Ethnicity/race: Missing 11 responses 
Length practicing: Missing 4 responses 
 
 
 
RESULTS 
 
Survey Respondents  
 
 Of the 954 participants across the five CME courses, 728 responded (response 
rate, 76%). However, of the 652 independent prescribers (MD/DOs, NPs, and PAs) 519 
prescribers responded to the survey with a response rate of 79.6%. Of the final sample of 
519, 362 (70%) were physicians, 45 (9%) PAs, and 112 (21%) NPs. The response rate for 
physicians was 76.5%, 81.8% for PAs, and 90.3% for NPs. 38% of participants attended 
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the NYC CME course, while 21% attended the Chicago course, 15% the San Francisco 
course, 14% the L.A. course, and 12% attended the course in D.C. Respondents’ average 
age was 49 (std +/- 12.05) with the majority female (57% female, 43% male, 0.2% 
transgender), and white (58% white, 18% Asian, 10% African American, 8% Hispanic, 
and 5% other). Corresponding with age, 34% of respondents had practiced independently 
for 21 or more years, while 25% had practiced for 11–20 years, 16% for 5–10 years, 17% 
less than 5 years, and 7% were still in training. 38% of the sample specialized in ID, 27% 
in FM, 26% in IM, and 9% in other specialties including obstetrics and gynecology 
(OBGYN) and pediatrics. Table 2.7 depicts the descriptive characteristics of the study 
sample. 
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Table 2.7: Descriptive statistics; Provider characteristics  
*Not excluding missing data for key outcome variables 
N=519 
Characteristic N (Mean + SD) or (%) 
CME Course 519 100% 
• New York City (NYC) 200 38.54% 
• San Francisco, CA (SF) 77 14.84% 
• Los Angeles, CA (LA) 71 13.68% 
• District of Columbia (DC) 63 12.14% 
• Chicago, Illinois  108 20.81% 
Age 498 (Missing= 21) (49.2 +/- 12.05) 
Gender 514 (Missing= 5)  
• Males 221 43.00% 
• Females 292 56.81% 
• Transgender 1 0.19% 
Ethnicity/race 508 (Missing= 11)  
• Hispanic/Latino 42 8.27% 
• White 293 57.68% 
• Black or African American 52 10.24% 
• Asian 94 18.50% 
• Native Hawaiian or other Pacific 
Islander 
1 0.20% 
• Mixed race (chose 2 or more 
categories 
17 3.35% 
• Other 9 1.77% 
Qualification 519 (Missing= 0)  
• MD/DO 362 69.75% 
• PA 45 8.67% 
• NP 112 21.58% 
Length practicing  512 (Missing= 7)  
• In training 38 7.42% 
• <5 years 86 16.80% 
• 5–10 years 82 16.02% 
• 11–20 years 130 25.39% 
• 21+ years 176 34.38% 
Specialty  516 (Missing= 3)  
• Infectious disease 197 38.18% 
• Internal medicine 133 25.78% 
• Family medicine 141 27.33% 
• Other 
45 
(18=other responses; 
18=”pediatrics”; 
9=OBGYN) 
8.72% 
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PrEP prescribing patterns  
 
Of the 519 total prescribers in our sample (four of those did not answer the 
question on experience prescribing PrEP), 54% (276/515) had experience prescribing 
PrEP, with internal medicine providers having the highest proportion (62%) with 
prescribing experience (Table 2.7). The first alternative hypothesis 1(a) states that 
providers will differ between categories (infectious disease, internal medicine, and family 
medicine) in regard to experience prescribing PrEP. Before controlling for salient control 
variables, Table 1.2 presents the unadjusted logistic regression results, which revealed no 
significant proportional differences between provider specialty areas and their overall 
experience prescribing PrEP. After adjusting for relevant control variables, however, 
those who identified as internal medicine providers only were 1.6 times as likely as those 
who identified themselves as infectious disease providers to have experience prescribing 
PrEP, albeit borderline significance (p=.0524). When keeping everything constant, 
prescribing decreased by 0.0433 with every one-unit increase in age. In other words, 
younger prescribers were more likely to have had experience prescribing PrEP compared 
to older providers (p=0.0014). Those still in training, however, were 0.298 times as likely 
compared to those with 20 or more years’ experience to have experience prescribing 
PrEP (p=0.0214). Additionally, females were 0.574 times as likely compared to males to 
have had experience prescribing PrEP (p=0.0044) (See table 2.10 below).  
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Table 2.8: Chi Square frequencies (Hypothesis #1) 
Provider specialty * Prescribed PrEP (Y/N) 
N=515  
Have you prescribed PrEP? 
Specialty Experience 
prescribing PrEP 
TOTAL 
Infectious 
Disease 
103 (53%) 195 
Internal 
Medicine 
82 (62%) 133 
Family Medicine 70 (50%) 140 
Other 21 (45%) 47 
Total 276 (100%) 515 
Chi Square: DF=3; Value = 5.7494; Prob= 0.1245 
 
 
Table 2.9 Logistic Regression [Unadjusted Analysis] (Hypothesis #1) 
Global null hypothesis: BETA=0; likelihood ratio Chi-Square= 5.7857; Pr>ChiSq= 0.1225 
Parameter Estimate Standard Error Wald Chi-Square Pr > ChiSq 
Intercept 0.113 0.143 0.620 0.431 
Internal Medicine 0.362 0.229 2.501 0.114 
Family Medicine -0.113 0.222 0.259 0.61 
Other -0.327 0.327 0.999 0.317 
Infectious Disease (Reference) 
 
 
Table 2.10: Logistic Regression [Adjusted Analysis] (Hypothesis #1) 
N=494 (21 observations were deleted due to missing values for the explanatory variables) 
Global null hypothesis: BETA=0; likelihood ratio Chi-Square= 25.5150; Pr>ChiSq= 0.0025 
Parameter Estimate 
Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq 
Odds 
ratio 
95% CI 
Intercept 3.006 0.849 12.521 <.001   
Internal 
Medicine 
0.475 0.245 3.761 0.052 1.609 0.995–2.601 
Family 
Medicine 
-0.183 0.234 0.610 0.435 0.833 0.526–1.318 
Other -0.283 0.340 0.690 0.406 0.754 0.387–1.468 
Reference: Infectious Disease   
Age -0.043 0.013 10.255 0.001 0.958 0.933–0.983 
Female -0.556 0.195 8.101 0.004 0.574 0.391–0.841 
In training -1.211 0.526 5.296 0.021 0.298 0.106–0.836 
11–20 years’ 
experience 
-0.440 0.279 2.488 0.115 0.644 0.373–1.113 
5–10 years’ 
experience 
-0.624 0.369 2.870 0.090 0.536 0.260–1.103 
< 5 years’ 
experience 
-0.730 0.413 3.126 0.077 0.482 0.214–1.082 
Reference: 20+ years’ experience   
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Provider willingness to consider PrEP for different indications 
 
The second alternative hypothesis states that there will be an association of 
provider willingness to prescribe PrEP among the different indications for PrEP, with 
providers feeling more hesitant to prescribe PrEP for conception than for MSM’s and 
IDUs. As shown in Table 2.11 below, the chi square frequencies reveal a significant 
association between those considering PrEP as the “first best step” for conception and 
IDUs but an insignificant association between those willing to consider PrEP for 
conception and MSMs  (See Appendix Document 1 for other “steps” offered as options 
for this survey question and Appendix Document 2 for the chi square test between MSM 
and IDU).  
 
 
Table 2.11: Chi Square frequencies (Hypothesis #2) 
N=502 
Conception 
(307/502 = 61%) 
MSM (449/502 = 89%) 
Selected PrEP option Did NOT select PrEP  Total 
Selected PrEP option 273 34 307 
Did NOT select PrEP 176 19 195 
Total 449  53 502 
• Of those that selected PrEP for MSM (449/502=89%), 273/449 (61%) 
would also consider PrEP for conception purposes 
• Of those that did not select PrEP for MSM (53/502=11%), 34/53 (64%) 
selected PrEP for conception 
Chi Square: DF=1; Value = 0.2238; Prob = 0.6361 
Conception 
(307/502 = 61%) 
IDU (178/502 = 35%) 
Selected PrEP option Did NOT select PrEP Total 
Selected PrEP option 128 179 307 
Did NOT select PrEP 50 145 195 
Total 178 324 502 
• Of those that selected PrEP for IDU (178/502=35%), 128/178 (72%) 
would also consider PrEP for conception purposes 
• Of those that did not select PrEP for IDU (324/502= 65%), 179/324 (55%) 
selected PrEP for conception 
Chi Square: DF=1; Value = 13.4280; Prob= 0.0002 
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In the unadjusted logistic regression models (Tables 2.12 and 2.13) providers who 
viewed PrEP as the “first best step” for MSMs were less likely to have also considered 
PrEP as the “first best step” for conception purposes, albeit not significantly less likely. 
On the other hand, providers who viewed PrEP as the “first best step” for IDUs were 2.1 
times as likely to have also considered PrEP as the “first best step” for conception, and 
vice versa (See Appendix Document 2 for IDU as outcome variable). As Table 2.13 
illustrates, I performed a test for interaction between MSM and IDUs and its effect on the 
outcome variable, conception. This interaction was not significant and thus I refit the 
model excluding the interaction terms. After adjusting for control variables, the model 
did not change when “conception” was the outcome variable (see Table 2.14 below). 
 
Table 2.12:  Logistic Regression [Unadjusted Analysis] (Hypothesis #2) 
Outcome = Conception  
N=502 
Parameter Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq Odds 
ratio 
95% CI 
Intercept 0.505 0.289 3.066 0.080   
MSM -0.343 0.309 1.238 0.266 0.709 0.388–1.299 
IDU 0.767 0.204 14.182 <.001 2.154 1.445–3.211 
Conception Outcome 
 
 
Table 2.13: Logistic Regression [Unadjusted Analysis] (Hypothesis #2) 
Outcome = Conception; Interaction model  
N=502 
Parameter Estimate Standard Error Wald Chi-Square Pr > ChiSq 
Intercept 0.477 0.300 2.526 0.112 
MSM -0.310 0.323 0.922 0.337 
IDU 1.132 1.136 0.994 0.319 
MSM*IDU -0.378 1.155 0.107 0.743 
Conception Outcome  
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Table 2.14: Logistic Regression [ADJUSTED Analysis]  
Outcome = Conception   
N=502 
Global null hypothesis: BETA=0; likelihood ratio Chi-Square= 17.0278; Pr>ChiSq=0.0044 
Parameter Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq Odds 
ratio 
95% CI 
Intercept 0.371 0.312 1.415 0.234   
MSM -0.288 0.312 0.853 0.356 0.750 0.406 – 1.382 
IDU 0.736 0.206 12.787 <0.001 2.088 1.395 – 3.127 
Internal 
Medicine 
0.115 0.238 0.235 0.628 1.122 0.704 – 1.790 
Family 
Medicine 
0.292 0.238 1.507 0.220 1.339 0.840 – 2.135 
Other specialty -0.120 0.346 0.121 0.727 0.886 0.450 – 1.746 
Reference: Infectious Disease 
Conception Outcome 
 
 
 
Provider preference to refer serodiscordant couples to assisted reproductive technologies  
 
The third alternative hypothesis states that the majority of respondents (> 50%) 
will answer either “strongly agree” or  “agree” to the statement, “If cost and access were 
not barriers, I would refer all of my HIV-infected patients in serodiscordant relationships 
who wish to conceive for assisted reproductive technologies.” As shown in Tables 2.15 to 
2.17 below, I rejected the null hypothesis and agreed with the alternative hypothesis that 
the majority of respondents (>50%) answered either “strongly agree” or “agree” to this 
statement. The one sample binomial test presented in Table 2.15 reveals that those who 
answered “strongly agree” or “agree” to this statement significantly deviated from the 
hypothesized value of 50% (p<.0001). The goodness of fit tests reveals statistically 
significant deviations from the test proportions presented. The first test proportion 
represented in Table 2.16 presents a significant deviation from the literature. Scherer et 
al. (2014) presented this question at a one-day provider conference in NYC on HIV and 
cART. Compared to this publication, my study revealed higher responses among those 
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who selected “strongly agree/agree” to this statement, and significantly lower proportions 
of those who selected “strongly disagree/agree” and “neutral.” These results were also 
not random (Table 2.17); otherwise, we would expect at .20, .40, .40 distribution.  
After conducting goodness of fit tests comparing study results to prior literature and 
weighted proportions across answers, I conducted a logistic regression test to determine 
an association between those that selected “strongly agree/agree” and specialty area. I 
found no statistically significant association between specialty area and those who 
responded to this question. After adjusting for control variables, there was no difference 
between the unadjusted and adjusted models.  
 
 
 
 
 
 
 
 
 
Table 2.16: Chi Square Goodness of fit frequencies compared to literature (Hypothesis #3) 
N=507 
Chisq testp= (0.28, 0.48, 0.24)  Neutral; Strongly agree/agree; Strongly disagree/disagree  
  Response Frequency Percent Test percent  
(Scherer et al. 2014) 
Neutral 99 19.5% 28% 
Strongly agree/agree 349 68.8% 48% 
Strongly disagree/disagree 59 11.64% 24% 
Chi Square= 91.1456; Pr > ChiSq = <0.0001 
 
 
 
 
 
 
  
Table 2.15: Binomial test; (Hypothesis #3) 
N= 507  
Offers services? (Provided a definite “yes” response) 
 N % 95% CI 
Strongly Agree/Agree 349 (68.8%) 0.6460–
0.7285 Neutral/disagree 158 (31.2%) 
Test of H0: Proportion=0.5; Two-sided Pr>|Z| <.0001 
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Table 2.17: Chi Square Goodness of fit frequencies compared to random selection 
(Hypothesis #3) 
N=507 
Chisq test= (0.20, 0.40, 0.40)  Neutral; Strongly agree/agree; Strongly disagree/disagree 
Response Frequency Percent Test percent  
Neutral 99 19.5% 20% 
Strongly agree/agree 349 68.8% 40% 
Strongly 
disagree/disagree 
59 11.64% 40% 
Chi Square= 207.4181; Pr > ChiSq = <0.0001 
 
 
DISCUSSION 
 
PrEP has transformed the role of HIV prevention. It is the first prevention tool 
that provides HIV-negative individuals with the agency to use the tool to protect 
themselves from transmission. Prescribers across multiple specialties have an important 
role to play in integrating PrEP within their practices. Despite strong evidence regarding 
the efficacy of PrEP, providers have been slow to adopt it. Of the prescribers in our 
sample, 54% had experience prescribing PrEP. My finding that over half had experience 
prescribing PrEP represents the highest proportion in the literature to date (Smith et al. 
2016, Karris et al. 2014, Krakower et al. 2016).  
A study of infectious disease physicians conducted in 2014, for instance, found 
that while 59% of providers had counseled HIV-infected patients about PrEP, only 32% 
had prescribed the medication (Krakower et al. 2016). This study’s finding may be 
related to changes in PrEP knowledge and attitudes over time. Since the FDA approval of 
PrEP in 2012, trends in the literature suggest that providers have increasingly prescribed 
PrEP over time (White et al. 2012, Levin 2014, Karris et al. 2014, Scherer et al. 2014, 
Krakower et al. 2016).  
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In my study, internal medicine providers were 1.6 times more likely than 
infectious disease providers to have had experience prescribing PrEP. This finding 
corresponds to other literature indicating that prescriptions by non-infectious disease 
providers make up the largest proportion of Truvada® prescriptions in the United States 
(Levin 2014). Among a national survey of primary care clinicians in the United States, 
however, only 7% of primary care physicians had experience prescribing PrEP in 2015 
(Smith et al. 2016). Course attendees with IM backgrounds, however, are likely to be far 
different in their experiences with PrEP as compared to other PCPs. My results further 
indicate that younger prescribers were more likely to have had experience prescribing 
PrEP compared to older providers; however, those still in training were less likely to have 
had experience prescribing PrEP compared to those with 20 or more years’ experience. 
Additionally, females were less likely compared to males to have had experience 
prescribing PrEP. These results suggest the need for further research and could be useful 
for hypothesis generating.  
My results additionally show that providers who would consider PrEP as the “first 
best step” for MSM were less likely, albeit not significantly less likely, to also consider 
PrEP as the “first best step” for conception purposes. These results confirm my 
hypothesis that prescribers might be more hesitant to consider PrEP as a “first best step” 
within a conception framework compared to the more familiar indication of MSM. While 
the association between “conception” and “MSM” indications were not statistically 
significant, the beta coefficient comparing MSM to conception is negative and yet trends 
in the opposite direction for IDUs, which is clinically relevant to note. Future studies 
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should further examine provider acceptabiliy of PrEP across populations and factors that 
might lead providers to feel more comfortable or more willing to prescribe to certain 
populations compared to others. 
 When examining provider attitudes toward other reproductive options for 
serodiscordant couples who wish to conceive, if cost and access were not barriers, 70% 
said they would refer couples to assisted reproductive technologies. These responses were 
not random (Table 2.20) and significantly deviated from previous literature (Scherer et al. 
2014). While more safety data exist for HIV serodiscordant couples using ART for 
pregnancy, there remain concerns about offering TDF/FTC to healthy women during pre-
conception or during pregnancy and possible adverse effects on the fetus (Thomson et al. 
2016, Heffron et al. 2016). Therefore, it is reasonable for clinicians to refer couples to 
ART if cost and access were not barriers. While some states and insurance companies 
cover infertility treatment, serodiscordant couples experience extra barriers in accessing 
such services. Infertility might not be diagnosed for such couples, particularly if they are 
seeking ART for prevention only, and facilities might not be equipped with the expertise 
nor laboratory space to treat HIV-infected samples (ASRM 2008, 2010, 2015). It is thus 
critical to continue upholding the rights of these couples to ensure they have equal 
options for care.  
This study has limitations. The study represented a convenience sample of 
providers from a CME advanced-level HIV course in five locations across the U.S.: San 
Francisco, CA, New York, NY, Los Angeles, CA, Washington, D.C., and Chicago, IL. 
Therefore, these providers were likely interested in HIV and/or worked directly with 
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HIV-infected and affected persons. Thus, their opinions and experiences might not be 
generalizable to all providers within the specialty areas represented. However, similar 
studies sampling networks of infectious disease providers reveal lower prescribing rates 
of PrEP (Krakower 2016, Karris et al. 2016).  
Providers could also overestimate their true beliefs based on what they believe is 
more socially or medically acceptable. However, the survey was anonymous and 
therefore social desirability bias was likely mitigated. Furthermore, missing responses to 
the outcome variable of interest and corresponding control variables could have biased 
the results. After careful review of the missing outcome variables, however, no visible 
pattern existed in regard to the characteristics of respondents that omitted such variables 
and comprised of less than 3% of the total sample. Therefore, I do not expect these 
exclusions to bias the results. There were also few missing control variables. 
Furthermore, since PrEP for conception purposes should be examined within OBGYN, 
further research is needed to specifically examine the use of PrEP within this specialty 
area. Due to the HIV focus of the CME course, there were few OBGYN providers 
present.  
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CHAPTER III: Assessing Access to Assisted Reproductive 
Services for HIV-Positive Individuals 
 
 
BACKGROUND 
 
 Approximately 75% of new HIV infections in the United States are in individuals 
of reproductive age (15–44 years old) (CDC 2014). Studies show no significant 
differences by HIV-infection status in regard to childbearing motivations or future 
pregnancy desires (Finocchario-Kessler 2012). Sperm washing techniques have been 
effective in preventing HIV transmission and in assisting pregnancy for HIV 
serodiscordant couples (Zafer et al. 2015, ASRM 2015, Barnes et al. 2014). Given the 
fertility desires of people living with HIV (PLHIV) in the United States, evidence reveals 
an acceptance of and demand for Assisted Reproductive Technology (ART) services 
among this population (Moragianni 2014; Cohan 2013; Klein 2003).  
The American Society for Reproductive Medicine (ASRM) recently published a 
revised committee opinion on HIV and infertility treatment where they found “no ethical 
reason[s] to withhold fertility services at clinics with the necessary resources to provide 
care to HIV-infected individuals” (ASRM 2015). Reports indicate, however, a low 
percentage of ART practices providing services to HIV-positive individuals (ASRM 
2015, Sauer 2006). Low access has been attributable to personnel transmission concerns, 
cross-contamination, lack of expertise among clinicians in handling such specimens, and 
the high cost of separate laboratory facilities as recommended by ASRM (ASRM 2015, 
ASRM 2013). ASRM strongly encourages providers to “reduce these barriers to care in 
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order to make infertility treatment available to HIV-infected individuals” (ASRM 2015). 
Despite reports of low access, no studies to date have rigorously examined this issue. 
The goal of this study was to better understand access and barriers to fertility 
services for HIV-positive individuals from both the provider and patient perspectives. 
With the availability of Pre-Exposure Prophylaxis (PrEP), the reproductive landscape has 
changed and priorities have shifted for serodiscordant couples seeking conception. 
Patient information and choice are critical components to achieving quality of care. Thus, 
serodiscordant couples should have the option of assisted reproduction either for the 
purpose of risk reduction or for supported fertility.  
Figure 3 below denotes the conceptual domains from my overall framework 
addressed in this study. According to the Andersen model, predisposing characteristics 
(such as age, race, and social standing) and enabling factors (such as availability of health 
personnel and facilities) drive utilization of health services. Andersen noted that “both 
community and personal enabling resources must be present for use to take place” 
(Andersenhe 1995). Individuals must also have sufficient resources and 
knowledge/awareness to use health services. For example, despite a growing trend in 
utilizing ART services among the general population, it remains primarily a privately 
funded service with clear barriers to access among less advantaged patients (Jain et al. 
2005, ASRM 2008, 2010). The barriers become more apparent for HIV serodiscordant 
couples where there are fewer facilities offering these services to this population (Sauer 
2006, ASRM 2008, 2010, 2015). In general, HIV has disproportionately impacted 
56 
 
 
 
individuals with historically lower socioeconomic status and of racial minority, which 
can negatively impact their utilization of health services (Rubin et al. 2010).  
Figure 3: Conceptual domains addressed in Study 2 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research questions  
 
Do serodiscordant couples, where the woman is HIV-negative and the man is 
HIV-positive, currently have access to the same spectrum of reproductive services as 
couples in which neither partner has HIV? Does access differ between patient-initiated 
versus provider initiated calls?  
 
(a) From a patient’s perspective, what proportion of fertility clinics offer fertility 
services to serodiscordant couples?  
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(b) Are clinics’ responses to patients about services the same as the responses to  
providers seeking a referral?  
(c) Will patient and physician callers elicit different rates of referral from clinics 
that do not offer fertility services for these couples? 
 
Specific Aim 
 
The specific aim of this study was to better understand access to fertility services 
for HIV positive couples. 
 
Hypotheses 
 
(1)  H0: Greater than or equal to 50% of clinics sampled will offer services to HIV-
positive individuals or agree to schedule an appointment with the patient caller. 
 
H1: Less than 50% of clinics sampled will offer services to HIV-positive 
individuals or agree to schedule an appointment with the patient caller. 
 
(2) H0: Across all clinics and by state, patient callers will elicit similar rates of 
availability from clinics as physician callers  
 
H1: Across all clinics and by state, patient callers will elicit different rates of 
availability from clinics as physician callers.  
 
(3) H0: Across clinics that do not offer fertility services to these couples, patient 
callers will elicit the same rates of referrals from clinics as to physician callers.  
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H1: Across clinics that do not offer fertility services to these couples, patient 
callers will elicit different rates of referrals from clinics as to physician callers.  
  
I examined the following dichotomous (yes/no) primary outcomes: 
• Whether clinics sampled offered services to HIV-positive individuals or agreed 
to schedule an appointment with the patient caller 
• Whether across all clinics and by state, patient callers elicited similar rates of 
availability from clinics as physician callers  
• Whether clinics that did not offer fertility services to these couples elicited 
different rates of referrals from clinics as physician callers.  
 
Secondary outcomes included: 
• Type of fertility services offered, including sperm washing with banking, IUI, 
IVF, and/or ICSI.  
• Whether clinics agreed to see couples if the reason for seeking services is for 
prevention of an infection in the female partner, for fertility only, or both.  
• If clinics provided services for this population, whether they also would provide 
their patients with PrEP.  
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Outcomes and key variables  
 
Table 3.0: Chapter III, Outcomes and variables  
Hypothesis #1 Associated variables 
H0: Greater than or equal to 50% of 
clinics sampled will offer services to 
HIVpositive individuals or agree to 
schedule an appointment with the 
patient caller. 
 
H1: Less than 50% of clinics sampled 
will offer services to HIV-positive 
individuals or agree to schedule an 
appointment with the patient caller. 
Dependent variable (outcome):  
Offer services to “patient caller (Y/N); If yes, agree to 
schedule appointment with patient caller (Y/N) 
 
 
Analysis:  
Proportions for the unknown population parameters 
with corresponding confidence intervals. 
Hypothesis #2 Associated variables 
H0: Across all clinics and by state, 
patient callers will elicit similar rates 
of availability from clinics as 
physician callers  
 
H1: Across all clinics and by state, 
patient callers will elicit different 
rates of availability from clinics as 
physician callers.  
Dependent variable (outcome):  
Offer services to patient caller (Y/N); Agrees to offer 
services to physician caller (Y/N) 
 
 
Analysis:  
McNemar’s test for marginal homogeneity; χ 2 = (b-c)2 
/(b+c) 
Hypothesis #3 Associated variables 
H0: Across clinics that do not offer 
fertility services to these couples, 
patient callers will elicit the same 
rates of referrals from clinics as to 
physician callers.  
 
H1: Across clinics that do not offer 
fertility services to these couples, 
patient callers will elicit different 
rates of referrals from clinics as to 
physician callers.  
Dependent variable (outcome):  
“Patient caller”: [If said no to services], do you know 
of other clinics in the area that you could refer me to? / 
“Physician caller”: [If services not offered to these 
couples], can you refer me to someone who does? 
 
Analysis:  
McNemar’s test for marginal homogeneity; χ 2 = (b-c)2 
/(b+c) 
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METHODOLOGY  
 
Study Design  
 
 The study used a “secret shopper” methodology whereby a “patient” and 
physician conducted standardized, scripted phone calls to a sample of fertility clinics 
registered through the Society for Assisted Reproductive Technology (SART). As 
Rhodes (2011) explained in NEJM, major advantages of an “audit study” lie in the “‘high 
level of confidence in the results and its ability to detect more subtle forms of 
discrimination such as ‘opportunity-diminishing’ as well as ‘opportunity-denying’ 
behavior’” (Rhodes 2011). This research method has been used since the 1970s in 
healthcare and in other fields to elicit a more accurate picture of reality. Social 
desirability bias can often hide an accurate view of a situation, and therefore such 
audit/secret shopper techniques “are a powerful tool for understanding the experiences of 
patients as they seek needed health care” (Rhodes 2011). In such studies, society benefits 
from understanding important capacity issues and potential inequities in the delivery of 
healthcare. As Rhodes 2011 further explained, “audit studies are not intended to entrap 
individual providers or reveal their identities” (Rhodes 2011).  
 
Study Population  
 
SART is the primary platform for ART organizations and professionals in the 
United States. Over 90% of ART clinics in the United States are registered with SART. 
SART is an organization that sets standards for clinics to meet for quality and safety 
(SART 2016). The CDC reported a total of 460 reporting ART clinics in the United 
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States during 2014 (CDC 2016).  
From January to March 2016, a patient and physician inquiring on behalf of 
his/her patient population conducted scripted phone calls to a sample of 140 fertility 
clinics registered through SART. The sampling frame included fertility clinics in 15 
states with the highest HIV prevalence rates per 100,000 people among males of all 
race/ethnicities, age groups, and the transmission categories of heterosexual contact, 
injection drug use and all other transmissions excluding MSM contact (see Appendix 
Document 3, CDC NCHHSTP 2015). In selecting my sample,  I excluded the MSM 
transmission category due to its lack of relevance to the study question (HIV-positive 
male and HIV-negative female couples desiring conception).  
 
Study procedures  
 
 Each clinic received call(s) from a physician caller (male or female) and a female 
patient caller. Physician and patient calls were separated by at least three weeks and the 
order in which they called each clinic was random. When calling clinics, callers blocked 
the number that they were calling from. In situations in which a blocked call was not 
accepted by a clinic (four clinics total), callers used personal cell phones to call the 
clinics. Additionally, there were several situations in which clinics requested to call back 
the patient or physician callers. Either personal cell phones or google telephone numbers 
were used in these cases. Since it is reasonable for cell phone users to keep their numbers 
from different places of residence, it is not unrealistic for a patient or professional to have 
a cell phone number from another state (Smith 2015). To avoid potential biases around 
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this issue in addition to voice/accent-related biases, both physician and patient callers 
introduced themselves as someone who recently moved to the state (or as a new 
gynecologist in the area). Call scripts were piloted in 10 clinics in states with the next 
highest HIV prevalence rates in the nation (following the 15 states included in the study 
sample), Virginia and Illinois. There were 12 and 19 clinics in each pilot state, 
respectively. Within these states, I randomly selected 10 clinics (five each for the 
physician and patient caller) to pilot.  
 
• Physician callers 
 
To control for gender differences, both a female and male physician caller called 
clinics inquiring about services. There were three physician callers total: (1) Male 
OBGYN first year resident physician; (2) Female OBGYN third year resident physician; 
and (3) Female fourth year medical student. The OBGYN residents were randomly 
allocated 70 clinics each (140 total) to call within the 15 states. The female medical 
student made further call attempts to 26 clinics that were deemed unreachable by the 
resident physician callers. This latter caller posed as a colleague of “Dr. Brown’s” who 
had previously called and left messages with clinic personnel. Physician callers aimed to 
mimic a real practice situation in which they sought to speak with a clinician in the 
fertility clinic. However, if such personnel were unavailable, they either left a message or 
spoke with an alternative person in the clinic. 
Each physician caller posed as a new OBGYN in the “area” looking to obtain care 
for one of his/her new clinic patients. The physician caller described the patient for whom 
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he/she was looking for services as a 30-year-old (Gravida 1, Para 0) HIV negative 
woman with no medical issues who is married to an HIV positive man. They are trying to 
conceive but want to do so safely and minimize their risk of transmission to the female 
partner. Neither has a diagnosis of infertility.  
 
• Patient caller  
 
The female patient caller posed as an HIV-negative female whose partner was 
HIV-positive. Based on general consensus from the dissertation committee, a female 
caller (as opposed to also needing a male caller) was deemed sufficient due to the higher 
likelihood of females inquiring about fertility services in this proposed situation. The 
patient posed as an HIV-negative 30-year-old who just moved to the area and was trying 
to get pregnant with her HIV-positive husband. She seeks to have a child but wants to do 
so safely and minimize her risk of HIV. Neither the patient nor her husband had a 
diagnosis of infertility. The patient’s goal was to inquire about access to assisted 
reproductive fertility services based on this situation. The patient caller called all 140 
clinics in the sample. 
 
 
Call scripts 
 
 An eight-item call script inquired about the general availability of services for this 
patient population, sperm wash and/or specimen transfer capabilities, and whether clinics 
that do not offer such services for this patient population could refer the couple to another 
facility that offered the services (in accordance with the ASRM 2015 guidelines). The 
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development of both the physician and patient call scripts was a collaborative effort 
among health services researchers, OBGYN physicians, and infectious disease 
physicians.  
For the physician call script, the key content area domains included assigned 
clinic number and state, person at the clinic who he/she spoke with, whether the clinic 
offered services to HIV serodiscordant couples, whether the clinic had previously taken 
care of HIV serodiscordant couples, and the services they offer for these couples (sperm 
washing with banking, IUI, IVF, and/or ICSI). The script also included a question 
inquiring about whether the clinic would see couples if the reason for seeking services 
was for prevention of an infection in the female partner only, for infertility purposes only, 
or both. If the clinic answered this question as “to prevent infection” or “both,” the 
physician inquired whether they give patients PrEP. If services were not offered to 
serodiscordant couples where the female partner is HIV-negative, the physicians asked 
whether they could refer them to someone who does.  
 For the patient call script, the key content area domains also included assigned 
clinic number and state, person at the clinic spoken with, and whether the clinic offered 
services to HIV serodiscordant couples. I added a follow-up question querying whether 
the caller could use her husband’s sperm to conceive. I added this question after the first 
few calls when a clinic answered “yes” to this question but noted that they could offer 
donor sperm, only. The call script also asked clinic personnel whether they could offer 
services for prevention purposes or for infertility only, whether the patient could make an 
appointment with a doctor, and reason(s) for not offering services (if applicable), and – if 
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so - if they could refer to another clinic that could offer services. All data were recorded 
in Google Forms and transported into Excel, and analyzed using SAS® 9.4.  
 Consistent with my hypotheses above, analyses were restricted to specific issues 
including the availability of services from the patient’s perspective, availability of 
services between patient and physician callers, and referral patterns between patient and 
physician callers.  
 
Statistical Analyses   
 
Based on the dichotomous outcomes detailed above, I calculated proportions for 
the unknown population parameters with corresponding confidence intervals. The first 
alternative hypothesis states that less than 50% of clinics sampled within the selected 
HIV prevalent criterion will offer services to HIV-positive individuals or agree to 
schedule an appointment with the patient caller. I chose a 50% threshold because there 
was no data available to determine a more precise threshold for our study population, and 
50% of clinics were just as likely to offer services compared to not. It could be 
reasonable to expect the number to be lower than this 50% threshold based on the “3%” 
figure reported in the literature. However, this study targeted specific states within a more 
narrowly defined population of HIV prevalence and thus the figure could represent an 
upper confidence interval of clinics offering services. The 50% level also provides a more 
conservative limit to ensure sufficient power to detect a difference.  
To achieve 80% power at a two-sided alpha of 0.05 for exact one-sample test of 
proportions, we needed a total sample size of 90 clinics to detect an effect size of 0.15, or 
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a minimum 15% difference between clinics that offered services or agreed to schedule an 
appointment with the patient caller compared to those that did not. In other words, this 
one sample test assesses whether the proportion equaled 50% or deviated from value.  
The true proportion needed to be greater than 65% or less than 35% to reject the null with 
80% power and alpha of .05. Since the sample comprised of 140 clinics across 15 states, 
however, we were able to detect an effect size of 0.12, or a minimum of 12% difference 
between clinics (true proportion greater than 62% or less than 38%).  
 Conversely, if I powered this outcome based on the width of a confidence interval 
as scholars have suggested (Bland 2009, Trafimow and Marks 2015), I used the 
following equation for a one-sample proportion: 
Based on this equation, the margin of error equaled .08, which means the width of the 
confidence interval would be no greater than .16. Therefore, the sample size was 
sufficient to yield a narrow confidence interval in the fertility clinic responses.   
The second alternative hypothesis states that across all clinics and by state, patient 
callers will elicit similar rates of availability from clinics as physician callers. To test this 
hypothesis, I used the McNemar test for marginal homogeneity to test discordance 
between physician and patient responses. To power this hypothesis, I used a test of 
difference in two proportions of two dependent groups (McNemar). Based on this test, I 
had 80% power with a sample of 140 clinics to detect a minimum of 30% proportional 
difference between patient and provider responses.  
The third alternative hypothesis states that across clinics that do not offer fertility 
services to these couples, patient callers will elicit different rates of referrals from clinics 
n = p(1− p)
Z
m






2
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as to physician callers. To test this hypothesis, I used McNemar’s test of marginal 
homogeneity since the patient and physician callers phone the same clinics. Since there 
was no literature on the number of clinics that might not offer services to this population, 
I outlined three power scenarios below. Notwithstanding these scenarios, however, it was 
challenging to predict the discordance between pairs.  
 
• Scenario 1   
 
40% of clinics would offer fertility services to this population. Therefore, a total 
of 84 clinics out of the 140 clinics sampled were predicted to not offer fertility services to 
HIV serodiscordant couples where the male is HIV-positive and the female is HIV-
negative. I assumed that physicians were referred elsewhere 50% of the time, or 42 out of 
the 84 times. The below table assumes a 54% discordance between pairs (37-11=26; 
37+11=48; 26/48=54% discordance). Therefore, with a sample size of 84, I would have 
81% power at a two-sided alpha of 0.05 to detect an odds ratio of 2.6 (and 54% 
discordance) between physician and patient callers in regard to clinics referring to 
another clinic.  
 
Table 3.1: Power projections; Hypothesis 3, Scenario 1 
 Patient caller 
referred 
Patient caller not 
referred 
Total 
Physician referred 5 
(~10%) 
37 42 
Physician not referred 11 
 (~1/4) 
31 
(~3/4) 
42 
Total 16 68 84 
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Figure 3.1: Hypothesis #3 power analysis, Scenario 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Scenario 2  
  
30% of clinics would offer fertility services to this population. Therefore, a total 
of 98 clinics out of the 140 clinics sampled were predicted to not offer fertility services to 
HIV serodiscordant couples where the male is HIV-positive and the female is HIV-
negative. I assumed that physician’s were referred elsewhere 60% of the time, or 59 out 
of the 98 times. In this scenario, similar proportions to scenario one remained but varied 
in the percentage of clinics that would not offer fertility services in addition to the 
number of physician’s referred. The below table reveals a 68% discordance between pairs 
(53-10=43; 53+10=63; 43/63= 68 % discordance). Therefore, with a sample size of 98, I 
would have 84% power at a two-sided alpha of 0.05 to detect an odds ratio of 2.1 and 
68% discordance between physician and patient callers in regard to clinics referring to an 
outside clinic. 
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Table 3.2: Power projections; Hypothesis 3, Scenario 2 
 Patient caller 
referred 
Patient caller not 
referred 
Total 
Physician referred 6 
(~10%) 
53 59 
Physician not referred 10 
 (~1/4) 
29 
(~3/4) 
39 
Total 16 82 98 
 
Figure 3.2: Hypothesis #3 power analysis, Scenario 2 
 
 
 
 
 
 
 
 
• Scenario 3 
 
30% of clinics would offer fertility services to this population. Therefore, a total 
of 98 clinics out of the 140 clinics sampled were projected to not offer fertility services to 
HIV serodiscordant couples where the male is HIV-positive and the female is HIV-
negative. I assumed that physician’s were referred elsewhere 70% of the time, or 69 out 
of the 98 times. In this scenario, I varied the proportions of clinics referring to both the 
physician and patient. The below table reveals a 40% discordance between pairs (21-
9=12; 21+9=30; 12/30= 40% discordance). Therefore, with a sample size of 98, I would 
70 
 
 
 
have 80% power at a two-sided alpha of 0.05 to detect an odds ratio of 2.6 (40% 
discordance) between physician and patient callers in regard to clinics referring to 
another clinic. Despite the sample size increasing, the number of discordant pairs varied.  
 
Table 3.3: Power projections; Hypothesis 3, Scenario 3 
 Patient caller 
referred 
Patient caller not 
referred 
Total 
Physician referred 48 
(~70%) 
21 69 
Physician not referred 9 20 
(~70%) 
29 
Total 57 41 98 
 
Figure 3.3: Hypothesis #3 power analysis, Scenario 3 
 
 
 
 
 
 
 
 
 
Missing data 
 
 I excluded clinics that did not respond to the physician and/or patient callers after 
at least three calls. The physician callers could not reach 13 clinics (~10% of the total 
sample), yielding a sample of 127/140 clinics. The patient caller could not reach two 
clinics, yielding a total sample of 138/140 (see Table 3.4 below).  
71 
 
 
 
 
 
RESULTS 
 
Clinic Respondents  
 
 Of the 140 sampled ART clinics across 15 states, the patient caller reached 138 
clinics with two clinics unresponsive after multiple attempts (response rate, 99%). The 
physician callers reached a total of 127 clinics with 13 clinics unresponsive after multiple 
attempts (response rate, 90.7%). Tables 3.5 and 3.6 describe the number of clinics 
reached per state by patient and physician callers and the clinic personnel that the patient 
and physician communicated with. As per the nature of calls, the patient caller spoke 
primarily to receptionists or coordinators, 57% of whom placed the caller on hold to 
inquire with a clinician and 24% were able to answer the patient’s questions without 
consulting with other personnel. A smaller proportion of calls were directed to 
“unknown” personnel within the clinic, 7.9% to a nurse or physician, and 1.4% to lab 
personnel. The physician callers, on the other hand, spoke mainly with registered nurses 
Table 3.4: Hypotheses #1–#3, unreachable clinics  
Clinic State Caller 
42 New York Physician 
57 Connecticut  Physician 
132 Georgia Physician 
117 Pennsylvania Physician 
31 Florida Physician 
60 North Carolina *Physician + Patient callers 
65 North Carolina *Physician + Patient callers 
75 New York Physician 
98 New Jersey Physician 
99 New Jersey Physician 
129 Georgia Physician 
135 South Carolina Physician 
140 Rhode Island Physician 
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(RNs) (42%) followed by receptionists or clinic coordinators (29%), physicians (24%), 
Nurse Practitioners (NPs)/Physician Assistants (PAs) (4%), and lab personnel (0.8%).  
 
Table 3.5: Clinics reached by patient and physician callers 
State # Total 
clinics 
# Clinics reached by 
patient caller  
(N=138, 2 missing) 
# Clinics reached by 
physician caller 
(N=127, 13 missing) 
Connecticut 7 7 6 
Delaware 2 2 2 
District of 
Columbia 
2 2 2 
Florida 19 19 18 
Georgia 7 7 5 
Louisiana 5 5 5 
Maryland  6 6 6 
Massachusetts 8 8 8 
Mississippi 2 2 2 
New Jersey 16 16 14 
New York 32 32 30 
North Carolina 12 10 10 
Pennsylvania 16 16 15 
Rhode Island 1 1 0 
South Carolina 5 5 4 
 
 
 
Table 3.6: Person at clinic reached by patient and physician callers 
State # Total clinics Person reached by patient 
caller  
(N=138, 2 missing) 
Person reached by 
physician caller 
(N=127, 13 missing) 
Connecticut 7 
5= Receptionist or 
Patient/Clinic Coordinator 
2=Lab 
2=Receptionist or 
Patient/Clinic Coordinator 
2=RN 
2=Physician 
Delaware 2 
1= Receptionist or 
Patient/Clinic Coordinator 
1=Unsure; transferred or left 
VM and did not specify 
2=RN  
District of 
Columbia 
2 
2= Receptionist or 
Patient/Clinic Coordinator 
2=RN 
Florida 19 
15= Receptionist or 
Patient/Clinic Coordinator 
3=Clinician 
3= Receptionist or 
Patient/Clinic Coordinator 
10=RN 
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1= Unsure; transferred or left 
VM and did not specify  
5=Physician 
Georgia 7 
5= Receptionist or 
Patient/Clinic Coordinator  
2= Unsure; transferred or left 
VM and did not specify 
1=RN 
3=Physician 
1=NP/PA 
Louisiana 5 
5= Receptionist or 
Patient/Clinic Coordinator 
1= Receptionist or 
Patient/Clinic Coordinator 
2=RN 
2=Physician 
Maryland  6 
6= Receptionist or 
Patient/Clinic Coordinator 
2= Receptionist or 
Patient/Clinic Coordinator 
3=RN 
1=Physician 
Massachusetts 8 
5= Receptionist or 
Patient/Clinic Coordinator  
3= Clinician 
3= Receptionist or 
Patient/Clinic Coordinator 
5=RN 
Mississippi 2 
2= Receptionist or 
Patient/Clinic Coordinator  
1=RN 
1=Physician 
New Jersey 16 
10= Receptionist or 
Patient/Clinic Coordinator  
3= Clinician 
3= Unsure; transferred or left 
VM and did not specify 
4= Receptionist or 
Patient/Clinic Coordinator 
5=RN 
4=Physician 
1=NP/PA 
New York 32 
29= Receptionist or 
Patient/Clinic Coordinator 
2=Clinician 
1= Unsure; transferred or left 
VM and did not specify 
14= Receptionist or 
Patient/Clinic Coordinator 
9=RN 
7=Physician 
North 
Carolina 
12 
7= Receptionist or 
Patient/Clinic Coordinator  
3= Unsure; transferred or left 
VM and did not specify 
5= Receptionist or 
Patient/Clinic Coordinator 
4=RN 
1=Physician 
Pennsylvania 16 16= Receptionist or 
Patient/Clinic Coordinator 
3= Receptionist or 
Patient/Clinic Coordinator 
6=RN 
3=Physician 
3=NP/PA 
Rhode Island 1 1= Receptionist or 
Patient/Clinic Coordinator 
Missed 
South 
Carolina 
5 3= Receptionist or 
Patient/Clinic Coordinator  
2= Unsure; transferred or left 
VM and did not specify  
2=RN 
1=Physician 
1=Lab 
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Access to ART services  
 
 Of the 138 clinics reached by the patient caller, 41% of clinics (57/138) said they 
could offer services using sperm from an HIV-positive male. On the other hand, 40% 
(55/138) did not offer services, while 19% (26/138) were unsure. Some clinics said they 
would offer services for this situation but with donor sperm only (2/75; 3%), or were not 
sure if they could use HIV-positive sperm (18/75; 24%). Thus, the follow-up question, 
“would we be able to use my husband’s sperm?” was an important addition to the call 
script. All clinics agreed to schedule an appointment with the patient caller, even clinics 
that did not offer services for these couples.  
The first alternative hypothesis (1) states that less than 50% of clinics sampled 
within the selected HIV prevalence criterion will offer services to HIV-positive 
individuals or agree to schedule an appointment with the patient caller. Based on the 
results (and as shown in Table 3.7 below), I rejected the null hypothesis with 41% of 
clinics agreeing to offer services to the patient caller. Additionally, a one sample 
binomial test verified whether the proportion of clinics that offered services significantly 
differed from the hypothesized value of 50%. As shown in Table 3.8 below, the 
proportion of clinics that offered services to the patient caller significantly deviated from 
the hypothesized value of 50% (p=.0498).  
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Table 3.7: Access to fertility services; patient caller (Hypothesis #1) 
N= 138 
Characteristic N 
(proportion + 
SD) or (%) 
Offers fertility services for this situation? (HIV+ male; HIV- 
female) 
138  
• No 53 38% 
• Yes 75 54% 
• Not sure 10 7.2% 
If yes to services, would we be able to use my husband’s sperm? 75  
• No 2 2.6% 
• Yes 57 76% 
• Not sure 16 21% 
*New breakdown of services when accounting for clinics that 
were unsure or denied sperm usage: 
  
• No 55 40% 
• Yes 57 41% 
• Not sure 26 19% 
If yes to services, can I make an appointment with a doctor? 75  
• No 0  
• Yes 75 100% 
 
 
Table 3.8: Binomial test; Access to fertility services; patient caller  (Hypothesis 
#1) 
N= 138  
Offers services? (Provided a definite ‘yes’ response) 
 
N % 95% CI 
No/Not sure 81 (59%) 0.500–0.670 
Yes 51 (41%) 
Test of H0: Proportion=0.5; Two-sided Pr>|Z| = 0.0411 
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Table 3.9: Access to fertility services (using HIV+ sperm) by state 
(Hypothesis #1) 
N= 138 
Characteristic N 
 (%) within 
each state 
Clinics that offer services (using HIV+ 
sperm) per state – the rest “no” or “not 
sure” 
57  
• Connecticut 3/7 43% 
• Delaware 2/2 100% 
• DC 1/2 50% 
• Florida 8/19 42% 
• Georgia 3/7 43% 
• Louisiana 1/5 20% 
• Maryland 2/6 33% 
• Massachusetts 5/8 63% 
• Mississippi 0/2 0% 
• New Jersey 6/16 38% 
• New York 12/32 38% 
• North Carolina 2/10 20% 
• Pennsylvania 9/16 56% 
• Rhode Island 0/1 0% 
• South Carolina 3/5 60% 
TOTAL 57/138 41% 
 
Availability and Access Differences between Patient and Physician Callers 
 
The second alternative hypothesis states that across all clinics and by state, patient 
callers will elicit similar rates of availability from clinics as physician callers. To test this 
hypothesis, I used the McNemar test for marginal homogeneity to test discordance 
between physician and patient responses. Across the 127 clinics that both the physician 
and patient callers could reach, physician and patient callers elicited different rates of 
availability of ART services for this population (63% and 40%, respectively, P <.0001, 
Table 3.10). Among physician calls, 80 (63%) resulted in the caller being told that the 
clinic could offer ART services for couples where the male partner is HIV-positive and 
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female partner is HIV-negative. In contrast, patients received a positive “yes” response in 
only 51 (40%) of calls. Since we compared two sets of callers to the same clinic, no 
additional adjustments to the model were made. McNemar’s test statistic suggests a 
statistically significant difference in the proportions of clinic responses (yes versus no/not 
sure) between patient and physician callers (See Table 3.10 below). Figure 3.4 further 
illustrates this finding by shading the regions of agreement (0, 0=both responded “no” to 
offering services and 1,1= both responded “yes” to offering services). 
 
Table 3.10: Availability and Access Differences between Patient and Physician Callers 
N=127 (Matched calls between patient and physician callers) 
Do you offer services 
for this situation? 
Patient Caller, n (%) Physician Caller, n (%) McNemar Test, P-
value 
• Yes 51 (40%) 80 (63%) 
<.0001 
• No/Not sure 76 (60%) 47 (37%) 
McNemar’s test statistic (S): 20.5122; Pr>S <.0001; 95% CI (0.2452 – 0.5263); 
Kappa=0.3857 
 
 
Figure 3.4: Agreement of patient and physician callers 
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Referrals to other providers/clinics   
 
 In this study, if a clinic indicated that it could not provide services to a couple in 
this situation, both the physician and patient callers queried about a referral to another 
clinic that could provide the care. Since inquiries differed between the physician and 
patient callers due to variances in clinic responses (as shown in Table 3.10 above), the 
patient results are presented to examine access from a potential patient’s perspective. Of 
the 138 clinics reached from the patient sample, 55 clinics provided a definitive response 
in denying services to these couples. The patient did not inquire about a referral in the 26 
“unsure” responses since clinics recommended the patient see a physician prior to making 
a firm decision. 
Of the 55 clinics that could not offer services, 28 clinics (51%) referred the 
patient to at least one outside clinic that they were certain could offer the couple services, 
whereas 10 clinics (18%) referred to other clinic(s) but were unsure whether they offered 
such services, and 17 clinics (31%) could not refer to another facility. Of the 38 clinics 
that referred to other clinics, 21 clinics (55%) referred within the same state. However, 17 
of these clinics (45%) referred to a facility or physician in another state (see Table 3.11 
below), often Columbia University in New York or the Bedford Institute in 
Massachusetts.  
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Table 3.11: Patient caller referral responses  
N=138 
Characteristic N  (%) 
N=54 who said No to being able to use husband’s sperm; referral    
• No, could not refer  17 31% 
• Yes, referred to other clinic(s) but unsure if they offer such 
services 
10 18% 
• Yes, referred to other clinic(s) that DO offer such services (level of 
certainty)  
28 51% 
Out of the 38 clinics that could refer,    
• Referred within state  21 55% 
• Out of state 17 45% 
 
 
The third alternative hypothesis states that across clinics that do not offer fertility 
services to these couples, patient callers will elicit different rates of referrals from clinics 
than physician callers. To test this hypothesis, I used McNemar’s test of marginal 
homogeneity since the patient and physician callers phone the same clinics. However, 
since it was challenging to predict discordance between pairs, I could only analyze a total 
of 38 ‘concordant’ pairs where both the physician and patient had matched “No” 
responses. For clinics that denied services or were unsure, there were not enough 
concordant pairs to determine statistical differences in rates of referral to clinics between 
patient and physician callers. The McNemar’s test statistic was thus not significant, 
which could be due to a Type II error.    
 
Physician Inquiry about the Availability of and Access to services  
 
 Given the professional nature of the physician calls, physician callers asked for 
greater detail regarding types of services offered, whether clinics offered services for 
infertility only or for both prevention and infertility, and whether they incorporated PrEP 
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into their care. Of the 80 clinics that responded “yes” to offering services for couples, 59 
clinics (74%) offered sperm wash with banking, 65 clinics (81%) offered IUI, 77 clinics 
(96%) offered IVF, and 75 clinics (94%) offered ICSI. Clinics that could not provide 
sperm wash with banking but could provide the spectrum of other services discussed 
washing and banking the sperm at an outside facility. Moreover, 67% of these clinics said 
they would provide services to these couples for both prevention and infertility purposes; 
however, 33% of clinics said they would treat these couples for infertility purposes only. 
Of the 51 clinics that indicated that they would provide services for both prevention and 
infertility purposes, 10 clinics (19%) offered PrEP, 20 clinics (39%) did not offer PrEP, 
and 21 clinics (41%) were unsure whether they offered PrEP (Table 3.12 below). 
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Table 3.12: Physician caller responses; secondary outcomes 
N= 127 
Characteristic N  (%) 
   
Offers fertility services   
• No 42 33% 
• Yes 80 63% 
• Not sure 5 4% 
Type of fertility services offered (Across all States 
sampled)  
80  
Sperm wash with banking   
• No  21 26% 
• Yes 59 74% 
IUI   
• No 15 19% 
• Yes 65 81% 
IVF   
• No 3 3.8% 
• Yes 77 96% 
ICSI   
• No 5 6.2% 
• Yes 75 94% 
If yes to services, do you still see couples if the reason for seeking services is for prevention 
of an infection in the female partner, for infertility, or both? 
N=76 (Missing=4 responses to this question) 
• Infertility only 25 33% 
• Both (prevention + infertility) 51 67% 
If yes to “Both prevention + infertility”, do you give them PrEP? 
N=51 (those who answered “both” to the above question) 
• No 20 39% 
• Yes 10 19% 
• Not sure 21 41% 
 
DISCUSSION 
 
 This study suggests that fertility services for HIV serodiscordant couples are more 
available than represented in the literature; however, there was heterogeneity in responses 
with answers dependent on the person calling. The results also indicate that clinics were 
frequently not in compliance with ASRM’s guidelines regarding referring patients to 
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other facilities. As per ASRM’s 2015 Committee Opinion on HIV and infertility 
treatment, clinics without “sufficient resources” to offer appropriate care should refer to 
providers/clinics equipped to manage such patients (ASRM 2015). Of the clinics that did 
not offer services, about half referred to clinics that they were certain offered such 
services; however, these were frequently not in the same state as the reporting clinic. 
 ASRM and ACOG support fertility services for HIV-positive individuals (ASRM 
2002, 2010, 2015; ACOG 2001). Yet, recent literature indicates that only 3% of fertility 
clinics registered with SART report offering services to HIV-positive individuals (ASRM 
2015). While this study selected clinics only in the 15 states with the highest HIV 
prevalence rates per 100,000 men (excluding MSM contact), these results indicate much 
better access than is believed (40% of clinics offering services compared to only 3%). 
Sauer et al. 2006 first reported this figure in 2006 when there was an estimated 300 
fertility clinics in the United States, meaning that at that time, an estimated 9 clinics 
nationwide offered services for these couples. If we use ASRM’s number of today’s 460 
reporting clinics and assume the percentage of clinics that offer services for HIV-positive 
persons has remained the same (since ASRM reported the same figure in 2015) the 
expected number of clinics offering these services would be around 14. New data from 
this study presents a more optimistic picture of access. However, provider callers elicited 
higher rates of availability compare to the patient caller, which could suggest underlying 
stigma towards PLHIV having children.  
 Furthermore, of the clinics that offered services to the physician callers in this 
study, most clinics had the capacity to offer multiple services.  Most offered IVF and 
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ICSI with a lower – but still very high –  proportion offering IUI. In addition,  sperm 
wash with banking was common, which indicated clinics using outside facilities to wash 
and bank sperm. As reported in the literature, reasons given for low access to services 
among this population include transmission and cross-contamination concerns, lack of 
expertise, and high costs for maintaining separate laboratory space, the latter in which is 
recommended by ASRM (ASRM 2008, 2010, 2015). It is thus encouraging that clinics 
are finding ways to wash and bank sperm offsite to enable access to services for these 
couples.  
 Additionally, almost two-thirds of clinics overall conveyed being able to offer 
fertility services for this population (when a physician called). A third of these clinics 
would treat couples for infertility purposes only. Also, of the 51 clinics that would 
provide services for both prevention and infertility purposes, 10 clinics (19%) offered 
PrEP, 20 clinics (39%) did not offer PrEP, and 21 clinics (41%) were unsure whether 
they offered PrEP. The integration of PrEP into an ART framework for these couples is a 
new area of research that should be further pursued in more detail. PrEP could be a way 
to scale up conception interventions that do not require specialized fertility clinics, which 
could possibly improve access 
Evidence regarding fertility desires of PLHIV in the United States indicates that 
there is an acceptance of and demand for ART services among this population 
(Moragianni 2014; Cohan 2013; Klein 2003). Serodiscordant couples should have access 
to ART either for the purpose of risk reduction or supported fertility. Importantly, this 
study presents a more optimistic picture of access compared to recently cited literature 
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(ASRM 2015). However, the perception that only 3% of clinics in the United States offer 
fertility services for these couples could have important implications on care received and 
being delivered. Physicians might refer couples to ART services less often because they 
do not believe that such services are available. They also might counsel patients less on 
the spectrum of options available due to this perceived notion of access. This study, 
which presents a different picture, has the potential to expand the availability of services 
and ensure a more uniform experience for couples when seeking care. Future research 
should also examine the barriers in providing services and issues related to cost and 
insurance coverage.  
 This study has limitations. First, there was only one Caucasian female patient 
caller. Accent and assumed demographic characteristics of the caller could bias the 
results towards the null. Patient and physician calls were also separated by at least three 
weeks to prevent bias. In addition, this study was based on telephone calls to clinics and 
thus does not necessarily reflect in-person interactions; however, a telephone call would 
likely be the mode of initial contact by any patient or provider and may most replicate 
reality. Notwithstanding these limitations, this study addresses important issues 
surrounding access to ART services for HIV serodiscordant couples where the male is 
HIV-positive. This study provides evidence that risk reductive services are more 
available than the literature cites; however, there was heterogeneity in responses with 
answers dependent on the person calling. Physician-initiated calls yielded a higher rate of 
access for these couples, which suggests a potential need for provider advocacy for 
patients in these situations. Furthermore, while the results revealed a more positive 
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environment for these couples seeking access compared to the 3% figure cited in the 
literature, not all clinics are adhering to ASRM’s 2015 guidelines of referring patients to 
another facility that might offer a broad range of ART services.  
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CHAPTER IV: The Cost Effectiveness of Pre-Exposure Prophylax 
for HIV Prevention for Conception 
 
BACKGROUND 
 
 In July 2012, the U.S. Food and Drug Administration approved Truvada® as a 
preventive medication for uninfected individuals who are at high risk for infection (FDA 
2012). The CDC acknowledges PrEP as an HIV risk reduction option during 
periconception and pregnancy (CDC/HHS 2014). With the availability of PrEP, the 
reproductive landscape has changed and priorities have shifted for serodiscordant couples 
seeking conception. Truvada®, however, is costly, and may provide only modest 
additional prevention benefits to serodiscordant couples in which the HIV-infected 
partner is already on continuous anti-retroviral therapy with suppressed HIV viremia 
(Gray et al. 2001, Semprini et al. 2007, Semprini et al. 2013, Hoffman et al. 2015, 
Mabileau et al. 2015, Ciaranello and Matthews 2015, Letchumanan et al. 2015).  
“Treatment as prevention” could potentially be a more viable option for these 
couples, yet it is not a recommended stand-alone strategy in the U.S. (CDC 2015; Gray et 
al. 2001, Semprini et al. 2007, Semprini et al. 2013, Hoffman et al. 2015, Mabileau et al. 
2015, Ciaranello and Matthews 2015, Letchumanan et al. 2015). Sperm washing 
techniques have also been effective in preventing HIV transmission and in assisting 
pregnancy for HIV serodiscordant couples (Zafer et al. 2015; ASRM 2015; Barnes et al. 
2014). The CDC considers IUI or IVF for this population if donor sperm is 
‘unacceptable’ (CDC 2015). Accessibility of assisted reproductive options becomes more 
apparent for this population, however, due to few facilities offering specialized services 
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(Sauer 2006, ASRM 2008, 2010, 2015).  
The goal of this study was to project the long-term outcomes and cost 
effectiveness of Truvada® for conception compared to alternative reproductive methods. 
The study focused on couples comprised of an HIV-positive male and HIV-negative 
female. This paper complements the previous two studies by capturing the underlining 
importance that incremental costs and benefits play in patient access and engagement in 
health services. The concept of quality and quantity maximization is critical when 
operating in a society with limited resources. Recently published studies that have 
simulated the additional benefit of PrEP versus that of cART alone or medically assisted 
procreation with IUI suggested unfavorable cost effectiveness ratios and minimal 
additional benefit of PrEP with an already suppressed viral load (Hoffman et al. 2015, 
Mabileau et al. 2015, Ciaranello and Matthews 2015, and Letchumanan et al. 2015). As 
detailed above, while these studies significantly contribute to the literature on PrEP for 
conception, they failed to address important parameters and contextual components of 
conception for serodiscordant couples including: 
• Examining the cost effectiveness of PrEP compared to the full range of 
reproductive strategies (i.e. IVF) for HIV serodiscordant couples within a U.S. 
context. 
• Considering the timing of HIV testing and other varying approaches to 
monitoring PrEP, which can influence the outcome including the costs and 
effectiveness of the interventions being examined.  
• Taking heterogeneous approaches to computing the mother and child’s QALYs 
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saved by including the baby in the incremental cost effectiveness ratio (ICER) 
calculations. Previous literature either did not incorporate utilities in their 
analysis, thereby equating the mother and child’s lives, (Mabileau et al. 2015) or 
grounded their utilities on an underrepresented survey of 8 participants 
(Letchumanan et al. 2015).  
• Considering the potential impact of HIV and/or cART on male fertility 
• Integrating the probability of females becoming infected with HIV but “unaware” 
of their status (delayed awareness) and those becoming “aware” after a true 
positive test.  
• Integrating “aware” versus “unaware” in utero HIV transmission probabilities to 
the baby.  
• Incorporating supported pharmacokinetics data (PK) data on PrEP for women. 
Mabileau et al. 2015 includes a PrEP strategy limited to fertile days (2 to 5 days 
accordingly) but equates the efficacy of PrEP when limited and used 
continuously.  
My paper sought to address these import gaps in the literature. Figure 4 below 
details the conceptual domains from my overall framework addressed in this study. As 
noted in the overall study conceptual framework,  societal costs were added to the 
constructs from the Andersen and Cabana models to emphasize the underlining 
importance that incremental costs and benefits play in patient access to and engagement 
in health services. From a payer’s perspective, it is pertinent to determine how to 
maximize the quality and quantity of life per dollar spent (Muennig 2008). By evaluating 
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the overall cost and effectiveness of a given strategy, one can influence decision making 
and priority setting to ensure that populations have access to beneficial services.  
Figure 4: Conceptual domains addressed in Study 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Question  
 
What are the clinical outcomes (for mother and baby), costs, and cost-
effectiveness of each of the following strategies for preventing HIV infection among 
serodiscordant couples seeking to conceive: 
(1) cART suppression alone with intercourse not limited to ovulation; 
(2) cART suppression alone with intercourse limited to ovulation; 
(3) cART suppression + Truvada® for PrEP without limiting intercourse to 
ovulation 
(4) cART suppression + Truvada® for PrEP with intercourse limited to ovulation; 
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(5) cART + IUI;  
(6) cART + in vitro fertilization 
 
Specific Aim 
 
The aim of this study was to project the long-term clinical outcomes, costs and 
cost effectiveness of Truvada® for conception compared to alternative risk reductive 
methods for conception.  
 
Hypotheses   
 
(1) Truvada® for conception will increase costs but have negligible impact on 
clinical outcomes and quality-adjusted life expectancy compared to alternate 
methods. 
(2) The ICER of PrEP compared to cART suppression and timing for ovulation will 
be > $100,000/QALY, the commonly used WTP threshold for CEA  (Neuman et 
al. 2014). 
 
METHODOLOGY   
 
Analytic overview  
 
I constructed a Markov cohort simulation of HIV serodiscordant couples with an 
HIV-negative woman and an HIV-positive male seeking to conceive. The model assumed 
a monthly time cycle, lifetime horizon, and a payer perspective on costs. All economic 
evaluation outcomes were reported using a 3% annual discount rate. Treatment strategies 
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considered are outlined above and in Table 4.0 below. Outcomes included cumulative 
risks of HIV transmission to the HIV-negative partner, HIV-infected mothers, proportion 
of HIV-infected babies, maternal life-expectancy, infant life-expectancy, quality-adjusted 
life expectancy (maternal and infant), discounted lifetime medical costs, and incremental 
cost-effectiveness ratios. I constructed the model and performed analyses in TreeAge Pro 
2015 software (TreeAge Software). 
 
Table 4.0: Risk reductive strategies considered in cost-effectiveness analysis of HIV 
serodiscordant couples seeking conception 
Strategy Specific elements within each strategy 
cART suppression alone  (a) Intercourse NOT limited to ovulation 
(b) Intercourse limited to ovulation 
cART suppression + Truvada® for PrEP 
• PrEP everyday up to pregnancy 
(CDC/HHS 2014) 
(a) Intercourse NOT limited to ovulation 
(b) Intercourse limited to ovulation 
cART + IUI Max of 3 cycles before transitioning to IVF 
cART + IVF Max of 6 cycles before transitioning out of 
state 
 
Model structure  
 
It remains uncertain the extent to which assisted reproductive technology (ART) 
services are available for serodiscordant couples seeking conception (ASRM 2015, Sauer 
et al. 2006). This analysis, however, considered the most optimal first choice options for 
couples notwithstanding barriers to access. IVF was also included in the model to fill an 
important gap in the literature (Mabileau et al. 2015, Letchumanan et al. 2015). While 
IVF would increase medical costs, the method would also increase effectiveness since the 
probability of having a child would increase while simultaneously lessening ones 
exposure to HIV. 
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All women in the model started as not pregnant and without HIV. Depending on 
the conception strategy being simulated, the monthly sequence of events differed as 
follows: 
 
• cART alone with or without sex limited to ovulation & PrEP with or without sex 
limited to ovulation 
 
The cART alone and PrEP options were structurally the same with the only difference in 
the additive effect of PrEP. For those that did not immediately start IUI or IVF (as the 
couple’s first choice option), women underwent attempts to naturally conceive for a 
period of 12 months and thereafter transitioned to a post 12-month fertility workup. At 
this post 12-month period, women first underwent IUI for a maximum of three cycles and 
then transitioned to IVF for at a maximum of six cycles. In the strategies involving cART 
alone and cART with PrEP, women underwent HIV testing every three months 
(CDC/HHS 2014). 
  
• Sperm wash with IUI or IVF 
 
For women that either first started IUI or transitioned to IUI post 12 months, couples 
underwent a maximum number of three cycles prior to transitioning to IVF (Lampe et al. 
2011; Kuhoung 2016). For women that either first started IVF or transitioned to IVF post 
IUI, couples underwent a maximum number of six cycles prior to ending conception 
attempts. For those that either first started IUI or IVF or transitioned to ART post 12 
months, couples underwent HIV/STI panel testing once a year while they undertook 
fertility treatment. Therefore, if a woman seroconverted during ART treatment, they 
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transitioned to an “unaware” health state and were not aware of their status until they 
were tested during pregnancy. However, if a woman became aware of her HIV-positive 
status during pregnancy, had a spontaneous abortion, but chose to keep trying, then she 
circled back to the fertility work-up “aware” health state. 
The risk of HIV transmission in every month was as a function of the HIV 
prevention strategy being employed (i.e. the risk of transmission varied depending on 
strategy). The cumulative risk of HIV increased with each conception attempt and 
women could become pregnant at any time. HIV infection led to higher costs and 
decreased life expectancy. There was risk of transmission to an unborn child if the 
mother became infected and not on cART. In the model, mothers could not take cART 
unless they were identified as having HIV (“aware” versus “unaware” health states). If 
there were delays in testing, then there could also be delays in starting cART and higher 
probability of transmission to the child. During pregnancy, women deemed at high risk 
for HIV infection are encouraged to be tested “as early as possible” and then a second 
time during the third trimester (CDC/NIH 2016). Therefore, the model incorporated HIV 
testing during pregnancy across all strategies during the first and third trimesters.  
If the HIV serodiscordant couple became HIV concordant and they continued to 
seek conception, the model assumed that a physician counseled the couple on both the 
mother’s use of cART and on the risks of MTCT. Thereafter, the couple would undergo 
condomless timed intercourse during ovulation, only. If conception did not occur, the 
couple would be referred to a fertility clinic after their attempt at 12 months. 
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After choosing a preventive conception method, women either continued in the initial 
state of “not pregnant, HIV-negative,” or transitioned to the following health states:  
• Pregnant –, HIV – (starting health state)  
• Pregnant +, HIV –  
• Pregnant +, HIV +  
• Pregnant –, HIV + 
These states are presented in the Markov bubble diagram below:  
 
Figure 4.2: Markov Bubble Diagram of Health States 
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Adding the child into the model 
 
 To isolate the protective effect of each method, I subtracted off QALM’s and 
added costs for HIV-positive babies, only. I chose this method to ensure that outcomes 
were driven by HIV protection as opposed to pregnancy outcomes.  For costs of HIV-
infected children, I used the total undiscounted lifetime costs saved for HIV-infected 
individuals in HIV care and calculated the costs per year associated with HIV 
(Schackman et al. 2015). I then calculated the present value for both female and male 
HIV-positive individuals and entered the following equation into the model as 
transitional discounted costs when a baby became infected with HIV: 
• (((p_femaleborn*(discount(C_PVbabyHIV_female; disc_rate; _stage) + 
p_maleborn*(discount(C_PVbabyHIV_male; disc_rate; _stage)))))) 
 
For QALMs, I calculated the present value of QALMs for both female and male HIV and 
non-HIV cohorts and took the difference between HIV and non-HIV individuals. I 
inputted the following equation into the model as a transitional discounted reward when a 
baby became infected with HIV: 
• - (((p_femaleborn*(discount(Female_PV_diff; disc_rate; _stage) + 
p_maleborn*(discount(Male_PV_diff; disc_rate; _stage)))))) 
 
Data Source(s) 
 
I used published literature on clinical trials, meta-analyses, and observational 
cohort studies to inform base-case parameters across the different strategies. I collected 
biologic parameters on both pregnancy outcomes and HIV transmission risks during 
conception attempts. I incorporated the latest literature on per act HIV transmission risks 
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for the different preventive strategies incorporated in the model (Mabileau et al. 2015, 
Barnes et al. 2014, Zafer et al. 2015, Wu et al. 2015, Cohen et al. 2011, Baeten et al. 
2012, Semprini et al. 2013, Lasry et al. 2014, Patel et al. 2014, Barnes et al. 2014, 
Hoffman et al. 2015). Since HIV testing was integrated into the model twice during 
pregnancy, the model assumed that women were aware of their HIV status before the 
birth of their child. Therefore, the model considered the risks involved for in utero 
exposure to HIV only and not intrapartum exposure (Magder et al. 2005). For pregnancy 
outcomes, I parameterized success rates of pregnancy based on age and prevention 
method, including the probability of spontaneous abortion (Dunson et al. 2004, Bujan et 
al. 2007, Barnes et al. 2014, Zafer et al. 2015).  
I integrated cost component data from Micromedex Red Book 2016® wholesale 
price index, which accounts for preferential pricing through Medicaid and private 
insurance. I used the American Medical Association (AMA) 2016 Clinical Diagnostic 
Laboratory Fee Schedule for Medicare CPT procedures, and claims data for non-
Medicare CPT codes through MarketScan® database for privately insured Americans.  
Gross cost computations were based on current medical practice and CDC guidelines. 
ICERs were computed based on QALYs for the effectiveness measure.  
 
Input parameters: Biologic  
 
 Model input parameters are presented in Tables 4.1 below. Based on current 
literature on serodiscordant couples seeking conception, women in the model started 
trying to conceive at age 33 (Semprini et al. 2013, Vitorino et al. 2011). Due to a skewed 
97 
 
 
 
distribution of Black/African American men and women living with HIV in the United 
States, life expectancies were weighted to reflect black female and male standard 
mortality ratios (SMRs) in the US population (CDC NCHHSTP 2015, National Vital 
Statistics 2015, Geronimus et al. 2011). For those in the model that contracted HIV 
during attempts to conceive or during pregnancy (if continued to engage in sexual 
intercourse), their life expectancy was additionally weighted to reflect HAART-treated 
HIV-infected patients within a 24-week period. The model incorporated an age-adjusted 
SMR for women with CD4 count of 600 x 106 cells/L after 24-weeks on cART (van 
Sighem et al. 2005, National Vital Statistics 2015, Geronimus et al. 2011).  
The analysis assumed that having suppressed HIV RNA in the male partner was 
prerequisite to any clinical decision-making about PrEP for conception (CDC/HHS 
2014). I therefore modeled the male partner being on cART. For HIV transmission 
parameters, I used data from the HPTN 052 study, which reflects a plasma viral load of 
less than 400 copies per milliliter for 89% of the participants. Participants had a median 
CD4 of 442 cells per cubic millimeter at enrollment to 603 cells per cubic millimeter at 
12 months (Cohen et al. 2011). Recent studies show that 78% to 87% of individuals 
receiving cART have an undetectable viral load (Gardner et al. 2011, Gill et al. 2010, Das 
et al. 2010). Therefore, HPTN 052 presents a more accurate representation of male cART 
use and a variation in adherence levels.  
 
Model assumptions specific to each risk reductive strategy for conception included the 
following:   
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• cART suppression alone; (a) Intercourse NOT limited to ovulation: In this 
strategy, I used HPTN 052’s monthly transmission probability of  HIV infection between 
HIV-positive males and their HIV-negative partners. I used the “early therapy” 
parameters as opposed to “delayed therapy” since my model assumed that the male 
partner was on cART during attempts to conceive. In the early therapy group in HPTN 
052, 49% of participants reported having one to two sexual encounters in the past week 
ranging from zero (28%) to three or more times (24%) (Cohen et al. 2011). Within this 
group, 4% reported unprotected sex in the past week. In the early-therapy group, 
antiretroviral therapy was initiated for the male partner at study enrollment (with a CD4 
requirement between 350 and 550 cells per cubic millimeter) (Cohen et al. 2011).  
• cART suppression alone; (b) Intercourse LIMITED to ovulation: In this 
strategy, I assumed three sex acts during the peak fertility period at one to two days 
before ovulation (Liao et al. 2015). Based on Cohen's 2011 parameters, I calculated the 
transmission rate per sexual encounter, which yielded 137,255.3 total sexual encounters 
in the early therapy group. The rate of transmissions for the year was 1/137,255.3 total 
sexual encounters, and I multiplied this figure by three and converted into a probability 
accordingly.  
• cART suppression + Truvada® for PrEP; (a) Intercourse NOT limited to 
ovulation: In this strategy, women started PrEP one month prior to a conception attempt 
and continued on PrEP everyday up to pregnancy (CDC/HHS 2014). To determine the 
additive effect of PrEP when the male partner was on cART, I used the hazard ratio of 
TDF-FTC versus placebo, which was 0.34 (0.16 – 0.72) (Baeten et al. 2012). I therefore 
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multiplied this figure by the HPTN 052’s monthly probability of infection (Baeten et al. 
2012; Cohen et al. 2011). If targeting fertile days only, I multiplied the hazard ratio of 
0.34 by the monthly probability of transmission when sexual intercourse was limited to 
ovulation. The model assumed PrEP would be discontinued 28 days after the last sexual 
exposure (CDC/HHS 2014).  
• cART suppression + Truvada® for PrEP; (b) Intercourse LIMITED to 
ovulation: In this strategy, I assumed three sex acts during the peak fertility period at one 
to two days before ovulation (Liao et al. 2015). I took the additive effect of PrEP (hazard 
ratio of 0.34) and multiplied this figure by the Cohen et al. 2011 rate of transmissions for 
three sexual encounters.  
• cART + IUI: For women that either first started IUI or transitioned to IUI post 12 
months, couples underwent a maximum number of three cycles prior to transitioning to 
IVF (Lampe et al. 2011; Kuhoung 2016). Due to the rarity of a seroconversion using this 
method, I used the one-month rate of 0.000001 (Mabileau et al. 2015) assuming that this 
figure corresponds to approximately 40 million spermatozoa per IUI cycle (Wu 2015). 
The monthly conversion corresponds to a probability of 0.0000009. 
• cART + IVF: For women that either first started IVF or transitioned to IVF post 
IUI, couples underwent a maximum number of six cycles prior to ending conception 
attempts. Due to the rarity of a seroconversion using this method, I used the one-month 
rate of 0.000001 (Mabileau et al. 2015) and weighted it to correspond to .4 million 
(400,000) spermatozoa per IVF cycle (Wu 2015). The monthly conversion returned a 
probability of 0.000000009 per cycle.  
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For mother-to-child in utero transmission probabilities, I used data from a 
prospective cohort study evaluating factors associated with perinatal HIV-1 transmission 
in the United States (Magder et al. 2005). For the “unaware”/not on cART scenario, I 
used the proportion with presumed in utero transmission from 1990 to 1992. During these 
years, patients were either on no therapy or on monotherapy. For the “aware”/on cART 
scenario, I used the proportion of subjects with presumed in utero transmission during the 
HAART era, 1999 to 2001 (Magder et al. 2005).  
For pregnancy outcomes, I used the natural pregnancy monthly probability of 
0.2246088 (the average probability between 30–34 and 35–39 year olds) (Dunson et al. 
2004). I took the average figure between the two time segments since the IUI and IVF 
pregnancy probabilities were reported between the ages of 29–40. Unlike IUI and IVF 
parameters, however, the probability for natural conception did not take into 
consideration the potential impacts of HIV and/or antiretroviral therapy on male sperm 
parameters (Frapsauce et al. 2015, van Leeuwen et al. 2008, Bujan et al. 2007, 
Nicopoullos et al. 2004, and Mascarenhas et al. 2012). Therefore, the probability of 
natural conception could be lower than what we assumed in the model for interventions 
incorporating natural conception (Frapsauce et al. 2015, van Leeuwen et al. 2008, Bujan 
et al. 2007, Nicopoullos et al. 2004, and Mascarenhas et al. 2012). As the results indicate 
in the sensitivity analysis (Table 4.4 below), however, lowering the monthly probability 
of conception for these strategies did not impact the results.  
For IUI for HIV-positive men (ages 29–40), the monthly pregnancy probability 
per cycle used was 0.1563351 (Barnes et al. 2014; Zafer et al. 2015). For IVF for HIV 
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positive men (ages 29–40), the pregnancy probability per cycle used was 0.2591817 
(Barnes et al. 2014; Zafer et al. 2015). The average spontaneous abortion (SAB) monthly 
probability for natural conception used was 0.038781833 between the ages of 30–39, 
while the model incorporated 0.0305244 for IUI (29–38) and 0.03478074867 for IVF 
(ages 30–40) (Zafer et al. 2015, Andersen et al. 2000). Additionally, the model accounted 
for IUI and IVF cancellations per cycle, 0.0951625 and 0.1512579 probabilities, 
respectively. Appreciating that not all couples would seek to continue conception 
attempts after 12 months of trying, the model assumed a probability of .44 of couples that 
continued post 12 months and therefore, transitioned to IUI (Mercer 1997).  
 
Input parameters: Costs  
 
 For each strategy, the model assumed that couples underwent baseline STI testing 
(HIV, hepatitis B, hepatitis C, Gonorrhoeae, Chlamydia trachomatis, and Syphilis). 
Additionally, I assumed that a semen analysis would be carried out in addition to other 
female fertility tests as necessary. Since such costs would be the same across all 
strategies, I did not include them in the analysis. Costs for new office/outpatient visits 
and established office/outpatient visits were derived from the Medicare Physician Fee 
Schedule (MPFS 2016). For new office visits, I calculated a weighted cost of 80% level 
four visit (CPT code: 99204, 45 minutes) and 20% level three visit (CPT code: 99203, 30 
minutes), which yielded a cost of $154.67. For established office visits, I also calculated a 
weighted cost of 80% level four visit (CPT code: 99214, 25 minutes), and 20% level 
three visit (CPT code: 99213, 15 minutes), which yielded a cost of $101.18. All strategies 
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also incorporate hCG tests (qualitative, $10.24; quantitative, $20.51) at certain time 
points.  
 Costs related to cART alone and cART plus PrEP were derived from the AMA 
2016 Clinical Diagnostic Laboratory Fee Schedule, the literature (Liao et al. 2015, 
Micromedex Red Book 2016®). These strategies assumed clinical monitoring, which 
include urinary LH testing ($15 to $24 per month), HIV testing every three months 
($32.80, 4th generation), and STI screening for both male and female partners every 6 
months (Neisseria Gonorrhoeae: $47.80; Chlamydia trachomatis: $47.80; Syphilis 
Antibody Cascading Reflex: $18.03). I also assumed male viral load testing every three 
months ($115.92). For a “true positive” HIV test, I considered costs for another HIV 
Antigen & Antibody, 4th generation screen ($32.80), HIV antibody differentiation, HIV-
1 ($12.11), HIV antibody differentiation, HIV-2 ($18.41), CD4/T-Helper Cell Profile, 
Lymphocyte Subset Panel 4 ($64.01), and a quantitative PCR ($115.92). For a “false 
positive” HIV test, I accounted for extra clinic/physician visits and included another HIV 
Antigen & Antibody, 4th generation screen ($32.80), HIV antibody differentiation, HIV-
1 ($12.11), HIV antibody differentiation, HIV-2 ($18.41), and a DNA/RNA; HIV 1 
amplified probe ($47.80). For PrEP costs, I included the monthly cost of PrEP (AWP pkg 
price: $1759.73) with a 23% Medicare reduction, which totaled $1,354.99/month 
(Micromedex Red Book 2016®). I also included creatinine clearance costs for PrEP 
monitoring at months three and nine ($12.88).  
 Costs related to insemination strategies were derived from the AMA 2016 
Clinical Diagnostic Laboratory Fee Schedule, the literature (Resolve 2016; ASRM 2016, 
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Micromedex Red Book 2016®). I also used Truven Health Analytics MarketScan® 
Commercial Claims and Encounters database for national price estimates for sperm 
isolation with complex prep such as Percoll Gradient and storage for sperm/semen.  The 
average cost of IUI per cycle is estimated to be $865, which includes all procedures and 
physician visits related to the reproductive technology cycle notwithstanding fertility 
drugs (Resolve 2016). Letrozole (2.5–5 milligrams; 5 days: $90.57) was added to each 
IUI cycle in the model with a 23% Medicare reduction, which totaled $69.74 for each 
cycle (Micromedex Red Book 2016®). The average cost of an IVF cycle using fresh 
embryos (including all procedures and physician visits related to the reproductive 
technology cycle notwithstanding fertility drugs) is $8,158 (Resolve 2016). Additional 
medication costs associated with IVF added approximately $3,350.45 to the cost. I added 
a 23% Medicare reduction to the fertility drug costs, which totaled $2,579.83 (See Table 
4.2 below).  
 In addition to the above costs for both IUI and IVF cycles, the model accounted 
for additional costs of sperm isolation using a complex prep strategy such as a Density 
Gradient procedure (ASRM 2016; Zafer et al. 2015). I used Truven Health Analytics 
MarketScan® Commercial Claims and Encounters database for national price estimates 
for this procedure in addition to storage costs for sperm/semen (an average cost of $138 
per cycle and $107 annual storage fee, respectively) (MarketScan® 2013). Moreover, if 
women in the model became infected with HIV (during conception attempts or during 
pregnancy), the model assumed women were treatment-naïve and placed on an integrase-
based regimen (Raltegravir BID + Truvada). The cost of this treatment included the 
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monthly cost of Truvada (TDF + FTC (300mg/200mg; 30 days: AWP pkg price: 
$1,759.73) with a 23% Medicare reduction, which totaled $1,354.99/month (Micromedex 
Red Book 2016®), and Raltegravir BID (400mg; 2 capsules daily; pkg size: 60: AWP pkg 
price: $1,545.07) with a 23% Medicare reduction, which totaled $1,189.70 (Micromedex 
Red Book 2016®).  
 To calculate annual medical costs of non-HIV infected individuals in the model, I 
used data from MEPS, a nationally representative survey of households in the United 
States (MEPS 2013). Using the online query tool, I calculated the mean annual medical 
expenditures from the latest household survey in 2013 stratified by age and sex (female). 
I adjusted the costs to monthly distributions as per the model’s monthly cycle length. To 
calculate annual medical costs of HIV-infected individuals in the model, I used data from 
Schackman et al. 2015 findings on lifetime medical cost savings from preventing HIV in 
the United States. I took their undiscounted lifetime costs saved of preventing an HIV 
infection in the United States ($400,200) and multiplied it by the monthly/age stratified 
costs from the non-HIV infected accumulated medical costs from MEPS.  
 
Quality of Life 
 
For my analyses, I used Quality-Adjusted Life Months (QALMs), which 
incorporated life expectancies and health-related quality of life (HRQL) scales associated 
with different health states into a single index (Sullivan and Ghushchyan 2006).  QALMs 
per health state distinguished between the quality of life of persons who remained HIV-
negative and those who became infected with HIV. After calculating life expectancies for 
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both populations (as explained above and in Table 4.1 below), I used a quality-of-life 
score from the literature (0 to 1 scale) stratified by year. For the non-HIV population in 
the United States, I used preference-based EQ-5D index scores for chronic conditions 
based on ICD-9 codes (Sullivan and Ghushchyan 2006). For HIV-positive individuals in 
the United States, I calculated the average utilities used in previous literature (0.72 to 
0.87) and multiplicatively applied these to the non-HIV HRQL scores (Aden et al. 2015, 
Schackman et al. 2002, Tengs et al. 2002, Fryback et al. 2007). Furthermore, while my 
model distinguished between HIV “aware” and HIV “unaware” to reflect important risks 
of transmission, the utilities did not reflect this distinction. Since the model assumed that 
individuals became “aware” of their HIV status relatively early in their diagnosis, I did 
not expect a utility change between these health states.  
 
 
Table 4.1: Chapter IV, Input parameters – Biologic 
Parameter Baseline values Ranges Sources 
Life expectancy 
Start age of woman in HIV-
serodiscordant couple desiring 
child 
33 -- 
Semprini et al. 2013; 
Vitorino et al. 2011 
Life expectancy of women aged 
33 years in US population, 
weighted using black female 
SMR in US population 
46  
(77 years starting 
at age 0) 
-- 
National Vital 
Statistics 2015; 
Geronimus et al. 2011 
 
Life expectancy at birth (49.6% 
male & 50.4% female - World 
Bank 2016) 
75.75 
72.5 – 77  
(Boy - Girl) 
National Vital 
Statistics 2015; 
Geronimus et al. 2011 
Life expectancy for HIV+ 
patients from 24 weeks after the 
start of HAART 
62.5 
61–64 
(Man - Woman) 
van Sighem et al. 
2005; National Vital 
Statistics 2015 
Geronimus et al. 2011 
HIV transmission risks per risk reductive strategy 
Strategy: cART suppression 
alone; (a) Intercourse NOT 
limited to ovulation 
Transmission risk from male to 
0.0000525 (0.00001 – 0.0003332) 
Cohen et al. 2011. 
Early therapy - 
1/1585.3 person years 
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female partner (early therapy); 
cART only 
Strategy: cART suppression 
alone; (b) Intercourse limited 
to ovulation 
Targeting fertile days with urine 
ovulation test, cART only 
0.0000218 for 3 
sex acts during 
ovulation 
-- Cohen et al. 2011 
cART suppression + 
Truvada® for PrEP; (a) 
Intercourse NOT limited to 
ovulation  
Transmission risk with PrEP, 
using Hazard ratio of 0.34 to 
determine additive effect of 
PrEP when on cART 
0.0000178 -- 
Baeten et al. 2012 
Hazard ratio CI: 0.34 
(0.16 – 0.72) & 
Cohen et al. 2011 
cART suppression + 
Truvada® for PrEP; (b) 
Intercourse LIMITED to 
ovulation 
Transmission risk with PrEP, 
using Hazard ratio of 0.34 to 
determine additive effect of 
PrEP when on cART * 
probability of targeting fertile 
days without PrEP (0.0000218) 
0.0000074 -- 
Baeten et al. 2012 
Hazard ratio CI: 0.34 
(0.16 – 0.72) & 
Cohen et al. 2011 
Strategy: cART + IUI 
• Transmission risk, sperm 
wash + IUI 
• Max # of cycles: 3 
0.0000009 per 
cycle (*Assuming 
40 million 
spermatozoa per 
IUI cycle, Wu 
2015) 
0.000001 (Mabileau) - 
0.0004498 (Barnes 
2014) (Zafer 2015 meta-
analysis CI of .0001 is 
within this CI) 
Mabileau et al. 2015; 
Barnes et al. 2014; 
Zafer et al. 2015; Wu 
et al. 2015 
Strategy: cART + IVF 
• Transmission risk, sperm 
wash + IVF 
• Max # of cycles: 6 
0.000000009 per 
cycle *Weighted 
assuming .4 
million (400,000) 
spermatozoa per 
IVF cycle (Wu 
2015) 
0.00000001 (Mabileau; 
weighted) - 
0.000099995000166663
9 (Zafer 2015 meta-
analysis) 
Mabileau et al. 2015; 
Zafer et al. 2015; Wu 
et al. 2015 
Mother-to-child HIV transmission risks 
Mother-to-child transmission; In 
utero_NOT AWARE 
19 in utero 
transmissions / 
(385 * 9 months) 
between 1990-
1992; 1M 
probability for 
1M rate = 
0.0054683 
0.0054683 – 0.01 
 
Magder (2005): 
19/385 between 
1990–1992 
 
Mother-to-child transmission; In 
utero_AWARE 
4 in utero 
transmissions / 
(312 children 
0.0014234 – .003 
 
Magder (2005): 4/312 
between 1999–2001 
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*9months); 1M 
probability 1M 
rate = 0.0014234 
Pregnancy outcomes 
Pregnancy rate, natural 
conception (ages 30–34) - 
CYCLE 1 
0.2517364 
0.1462299 (Mabileau et 
al. 2015) - 0.2517364 
(Dunson et al. 2004 & 
Gnoth et al. 2003) 
Dunson et al. (2004): 
Rate of conception @ 
first attempt of 
pregnancy: 0.29 
Pregnancy rate, natural 
conception (ages 35–39) - 
CYCLE 1 
0.1974812 
 
0.181269246922018 
(Gnoth et al. 2003) - 
0.197481202037522 
(Dunson et al. 2004) 
Dunson et al. (2004): 
Rate of conception @ 
first attempt of 
pregnancy: 0.22 
Average pregnancy monthly probability, natural conception: 0.2246088 between the ages of 30–39 
Pregnancy rate per cycle, IUI 
(ages 29–40) 
0.1563351 
(Barnes et al. 
2014; 17% 
pregnancy rate 
per cycle for 
HIV-positive 
men) 
0.1392920 (Barnes et al. 
2014; 15%) - 0.1812692 
(Barnes et al. 2014; 
20%) - wider range than 
Zafer's ; OR up to 
Mabileau's 2015: 
0.2710766 
Barnes et al. 2014; 
Zafer et al. 2015; 
Mabileau et al. 2015 
Pregnancy rate, IVF (ages 29–
40) 
0.2591817 
(Barnes et al. 
2014; 30% 
pregnancy rate 
per cycle for 
HIV-positive 
men) 
 
0.2211992 (Barnes et al. 
2014; 25%) - 0.2953119 
(Barnes et al. 2014; 
35%) - wider range than 
Zafer's 
 
Barnes et al. 2014; 
Zafer et al. 2015 
SAB, natural conception (ages 
30–34) 
0.02955446645 
 
-- 
Andersen et al. 
(2000): Under the 
assumption that only 
80% of women with 
abortions in 
recognized 
pregnancies were 
hospitalized, the risk 
of spontaneous 
abortion would be: 
15% for 30–34 yr-
olds. 
Average SAB monthly probability, natural conception: 0.038781833 between the ages of 30–39 
SAB, natural conception (ages 
35–39) 
0.0480092 
 
-- 
Andersen et al. 
(2000): 24.6% for 35–
39 yr-olds 
SAB, IUI (ages 29–38) 
0.0305244 
0.0264440 (Zafer et al. 
2015; 13.4%) - 
0.0347807 (Zafer et al. 
2015; 17.7%) 
Zafer et al. meta-
analysis (2015): Rates 
of spontaneous 
abortions after 
IUI=15.5%  
SAB, IVF (ages 30–40) 0.03478074867 0.0274171 (Zafer et al. Zafer et al. meta-
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2015; 13.9%) - 
0.0430460 (Zafer et al. 
2015; 22.0%) 
analysis (2015): Rates 
of spontaneous 
abortions after IVF = 
17.7% (not 
statistically different 
from IUI rate) 
IUI cancellations per cycle 0.0951625 
(Barnes et al. 
2014: 10% per 
cycle) 
-- 
Barnes et al. (2014): 
The cancellation rate 
was 10% among HIV-
seropositive men 
IVF cancellations per cycle 
0.1512579 
(Barnes et al. 
2014: 16.4% per 
cycle) 
-- 
Barnes et al. (2014): 
The average per cycle 
cancellation rate for 
HIV-seropositive men 
= 16.4% (8.9% 
overall for the U.S.) 
Natural conception, post 12M 
(probability of "keeps trying") 
.44 -- 
Infertility as a 
covered benefit, 
William M. Mercer, 
1997: Approximately 
44% of women with 
infertility have sought 
medical assistance - 
resolve.org (Cornell 
medical school 
website) 
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Table 4.2:  Chapter IV, Input parameters – Costs 
Parameter Baseline 
values 
Ranges Sources 
Costs considered in each strategy 
New office/outpatient visit $154.67 -- MPFS (2016) 
Established office/outpatient visit $101.18 -- MPFS (2016) 
84703 (Gonadotropin, chorionic (hCG) 
qualitative test, urine) $10.24 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
84702 (HCG quantitative), blood 
$20.51 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
Costs related to cART alone and cART + PrEP 
TDF + FTC (300mg/200mg; 30 days) (pkg 
size: 30)  
$1,354.9921 -- 
Micromedex Red Book 
2016® 
Urinary LH testing 
$20 
$15–$24 
 /month 
(Liao et al. 2015) 
87389 (HIV Antigen & Antibody, 4th 
generation screen) $32.8 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
86701 (HIV-1/2 Antibody Differentiation - 
HIV-1) $12.11 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
86702 (HIV-1/2 Antibody Differentiation - 
HIV-2) $18.41 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
87535 (DNA/RNA; HIV 1; amplified 
probe) $47.8 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
86360 (CD4/T-Helper Cell Profile 
(Lymphocyte Subset Panel 4); test 
includes: WBC/T Lymphs, CD4, CD8, 
CD4/CD8 Ratio 
$64.01 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
87536 (HIV-1 RNA, Quantitative PCR) 
115.92 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
86780 (Syphilis Antibody Cascading 
Reflex) $18.03 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
87491 (Chlamydia trachomatis, amplified 
probe technique) $47.8 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
87591 (Neisseria Gonorrhoeae, amplified 
probe technique) $47.8 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
82575 (Creatinine clearance) - for PrEP; 
M3 & M9 
$12.88 -- 
AMA 2016 Clinical 
Diagnostic Laboratory 
Fee Schedule 
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Costs related to insemination strategies 
89261 Sperm isolation; simple prep (e.g., 
sperm wash and swim-up) for insemination 
or diagnosis with semen analysis  
$138 
(+/- 117.79) 
$138–$255 MarketScan® 2013 
89343 Storage costs (per year) for 
sperm/semen 
$107 (+/- 
100.37) 
$107–$207 MarketScan® 2013 
Average cost of an IUI cycle $865 -- 
As per ASRM’s 
estimates; resolve.org 
• IUI: Letrozole (2.5–5 milligrams; 
5 days) (pkg size: 30; priced for 5 
days) 
$69.74 -- 
Micromedex Red Book 
2016® 
Average cost of an IVF cycle using fresh 
embryos 
$8,158 -- 
As per ASRM’s 
estimates; resolve.org 
• Leuprolide 5 mg/1 ml) 2 week 
administration subcutaneous KIT 
$110.88 -- 
Micromedex Red Book 
2016® 
• Insulin Syringe for Lupron ... 
None - N/A Qty: 24 
$20.54 -- 
Micromedex Red Book 
2016® 
• Gonal F RFF 900 iu/1.5ml 
Subcutaneous (Form: SOL); (Pkg 
size: 1.5ml) 
$1,395.97 -- 
Micromedex Red Book 
2016® 
• Needle 30g 0.5 in N/A - N/A Qty: 
2 
$0.20 -- 
Micromedex Red Book 
2016® 
• Pregnyl 10000 iu - Qty: 1; (Form: 
PDS) 
$77.64 -- 
Micromedex Red Book 
2016® 
• Syringe 3cc 22g 1.5 in. Qty: 2 
$0.54 -- 
Micromedex Red Book 
2016® 
• Crinone 8 % - Applicator (Gel) 
Qty: 30 
$661.52 -- 
Micromedex Red Book 
2016® 
• Estradiol Patch 0.1 mg - Dots 
Qty:16 
285.9164 -- 
Micromedex Red Book 
2016® 
• Oral contraceptive (21 days) - 
Sprintec 
26.58975 -- 
Micromedex Red Book 
2016® 
Costs related to HIV positive status of woman; pregnant and non-pregnant 
TDF + FTC (300mg/200mg; 30 days) (pkg 
size: 30) 
$1,354.9921 -- 
Micromedex Red Book 
2016® 
Raltegravir BID (400mg; 2 capsules daily; 
pkg size: 60) 
$1,189.7039 -- 
Micromedex Red Book 
2016® 
Costs related to HIV transmission 
Lifetime (undiscounted) costs for non-HIV 
care if a woman stays HIV-negative 
$470,225 -- MEPS 2013 
Lifetime (undiscounted) costs for HIV care 
if woman became infected during 
conception attempts or during pregnancy 
$725,139  -- 
MEPS 2013 & 
Schackman et al. 2015 
Lifetime (undiscounted) costs for HIV care 
if baby born infected  
$988,561 -- 
MEPS 2013 & 
Schackman et al. 2015 
Discount rate: .03 annual; .0025 monthly 
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Analyses  
 
 To validate the robustness of model parameters, I first validated key parameters 
against the literature such as average life expectancies for non-HIV and HIV cohorts with 
SMR weights, pregnancies for couples that underwent natural conception methods, and 
lifetime undiscounted and discounted costs (See Appendix Document 5). I ran the model 
to simulate the full lifetime of the cohort and babies. I recorded outcomes and calculated 
ICERs as the ratio of marginal cost and marginal quality adjusted life expectancy 
(QALE) gain. I considered as dominated any strategy that has higher cost and lower 
QALE than another strategy, as well as strategies that had lower QALE at a higher 
cost/QALY gained than some other strategy (extended dominance). I interpreted cost-
effectiveness conclusions using commonly cited WTP =$100,000/QALY (Neumann et al. 
2014). I further conducted one-and two-way deterministic sensitivity analyses to test the 
effect of multi-variable uncertainty on conclusions. 
 
RESULTS 
 
Preliminary base case results 
 
 Preliminary base case results regarding the effectiveness, cost, and cost 
effectiveness of different reproductive strategies for HIV serodiscordant couples 
comprised of an HIV-negative female and HIV-positive male is presented in Table 
4.3/Figure 4.3 below. For every 10,000 HIV serodiscordant couples attempting 
conception with the male partner on cART, the probability of HIV transmission to the 
woman was highest in the first strategy, cART (a) intercourse not targeted to ovulation, 
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followed by cART (b) intercourse limited to ovulation, cART + PrEP (a) intercourse not 
targeted to ovulation, cART + PrEP (b) intercourse limited to ovulation, cART + IUI, and 
cART + IVF.  
cART (a) intercourse not targeted to ovulation was associated with a lifetime 
discounted cost of $139,280/couple, which was the second lowest cost strategy after 
cART (b) intercourse limited to ovulation. This approach led to 4.84 heterosexual 
transmissions per 10,000 couples attempting conception by this method and 
correspondingly, 0.073 mother-to-child in-utero transmissions per 10,000 pregnancies. 
The discounted QALE was 239.51 and considered absolutely dominated (i.e. less 
effective and more costly compared to cART (b) intercourse limited to ovulation).  
On the other hand, cART (b) intercourse limited to ovulation was the lowest 
cost strategy in the model (lifetime discounted cost of $139,233/couple). This approach 
led to 3.3 heterosexual transmissions per 10,000 couples attempting conception by this 
method and correspondingly, 0.050 mother-to-child in-utero transmissions per 10,000 
pregnancies. The discounted QALE was 239.52 and considered the cost saving, 
undominated strategy in the model.  
cART + PrEP (a) intercourse not targeted to ovulation resulted in a lifetime 
discounted cost of $146,536/couple. This approach led to 3.06 heterosexual transmissions 
per 10,000 couples attempting conception by this method and correspondingly, 0.047 
mother-to-child in-utero transmissions per 10,000 pregnancies. cART + PrEP. The 
discounted QALE was 239.52 and shared absolute dominance with cART (a) intercourse 
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not targeted to ovulation (i.e. less effective and more costly compared to cART (b) 
intercourse limited to ovulation).  
cART + PrEP (b) intercourse limited to ovulation resulted in a lifetime 
discounted cost of $146,521/couple. This approach led to 2.53 heterosexual transmissions 
per 10,000 couples attempting conception by this method and correspondingly, 0.039 
mother-to-child in-utero transmissions per 10,000 pregnancies. The discounted QALE 
was 239.53 and considered extendedly dominated (i.e. more effective but more costly and 
less efficient) compared to cART (b) intercourse limited to ovulation.  
cART + IUI resulted in a discounted lifetime cost of $156,327/couple. This 
approach led to 0.54 heterosexual transmissions per 10,000 couples attempting 
conception by this method and correspondingly, 0.006 mother-to-child in-utero 
transmissions per 10,000 pregnancies. The discounted QALE was 239.54 and considered 
more effective than the cART alone and PrEP strategies, but also more costly. This 
method was associated with a cost effectiveness ratio of $11,109,002/QALY, which is 
significantly above the recent $100,000/QALY threshold in the United States (Neumann 
et al. 2014). Lastly,  
cART + IVF resulted in a discounted lifetime cost of $170,661/couple. This 
approach led to 0.52 heterosexual transmissions per 10,000 couples attempting 
conception by this method and correspondingly, 0.003 mother-to-child in-utero 
transmissions per 10,000 pregnancies. The discounted QALE was 239.54 and considered 
the most effective strategy but also the most costly with an ICER of 
$1,384,057,662/QALY, which would not be considered cost effective. 
 
 
 
 
1
1
4
 
 
Table 4.3: Effectiveness, cost, and cost-effectiveness of reproductive strategies for HIV serodiscordant couples 
Risk reductive 
strategy 
Pregnancy 
(with SAB) 
HIV+ 
women 
HIV+ 
babies 
Life 
expectancy 
(Undisc.) 
QALM 
Lifetime costs 
(Discounted) 
ICER 
cART (a) non-
targeted ovulation 
1.167 0.000484 0.0000073 42.6844 239.51 $139,280 abs. dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.000327 0.0000050 42.6851 239.52 $139,233 
-- 
*undominated 
cART + PrEP (a) 
non-targeted 
ovulation 
1.167 0.000306 0.0000047 42.6852 239.52 $146,536 abs. dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 .000253 0.0000039 42.6854 239.53 $146,521 
ext. dominated 
=$17,393,694/QALY 
cART + IUI 0.758 .000054 0.0000006 42.6862 239.54 $156,327 
*undominated  
=$11,109,002/QALY 
cART + IVF 0.787 .000052 0.0000003 42.6863 239.54 $170,661 
*undominated 
=$1,384,057,662/QALY 
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Figure 4.3: Cost Effectiveness Analysis of risk reductive options for conception 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity analysis  
 
 Table 4.4 to 4.5 presents one and two-way sensitivity analyses including 
preliminary base case results for comparability. In each uncertain scenario depicted, 
cART (b) intercourse limited to ovulation remains the cost effective option compared to 
the other strategies. A priori sensitivity analyses include the following:  
 
• Cost of PrEP 
 Since TDF will become generically available in 2017, I conducted a sensitivity 
analysis at a conservative 25% lower than brand-name TDF/FTC with comparable 
efficiency (Walensky et al. 2016). As Figure 4.4/Table 4.4 depict, PrEP would still not be 
cost effective at the conservative generic price of the medication and only became cost 
effective when it was coupled with intercourse limited to ovulation and priced at 
$10/month ($98,688/QALY).  
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• Transmission risk  
 
When the transmission probability changed from 89% of participants with a 
plasma viral load of less than 400 copies per milliliter to 9%, PrEP with intercourse 
limited to ovulation remained extendedly dominated compared to cART alone with 
intercourse limited to ovulation. The QALY, however, changed from $17,393,694/QALY 
when 89% of participants contained a plasma viral load less than 400 copies per milliliter 
to $597,374/QALY when less than 9% of participants had viral loads below 400 copies 
per milliliter. PrEP became “undominated” at $850/month at $358,352/QALY. At 
$500/month, PrEP was $189,367/QALY. All PrEP options, however, were undominated 
only when intercourse was limited to ovulation.   
 
• Pregnancy probability  
 
Moreover, lowering the natural monthly pregnancy probability to 0.146 
(Mabileau et al. 2015) from the base case of 0.224, also did not impact results. Therefore, 
while the potential impacts of HIV and/or antiretroviral therapy on male sperm 
parameters could potentially lower the probability of natural conception, lowering the 
probability in the model did not alter the results (Frapsauce et al. 2015, van Leeuwen et 
al. 2008, Bujan et al. 2007, Nicopoullos et al. 2004, and Mascnhas et al. 2012).  
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Figure 4.4: CEA analysis when Truvada becomes generic in 2017  
(Truvada cost: 1,016.244) 
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Table 4.4: One-way sensitivity analyses  
Base case 
Risk reductive strategy 
Pregnancy 
(with 
SAB) 
HIV+ 
women 
HIV+ babies 
Life 
expectancy 
(Undisc.) 
QALM 
Lifetime costs 
(Discounted) 
ICER 
cART (a) non-targeted 
ovulation 
1.167 0.000484 0.0000073 42.6844 239.51 $139,280 abs. dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.000327 0.0000050 42.6851 239.52 $139,233 
-- 
*undominated 
cART + PrEP (a) non-
targeted ovulation 
1.167 0.000306 0.0000047 42.6852 239.52 $146,536 abs. dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 .000253 0.0000039 42.6854 239.53 $146,521 
ext. dominated 
=$17,393,694/QALY 
cART + IUI 0.758 .000054 0.0000006 42.6862 239.54 $156,327 
*undominated  
=$11,109,002/QALY 
cART + IVF 0.787 .000052 0.0000003 42.6863 239.54 $170,661 
*undominated 
=$1,384,057,662/QALY 
Cost of PrEP @ 25% monthly reduction ($1,016.244/month) (base case: $1,354.9921/month) 
cART (a) non-targeted 
ovulation 
1.167 0.000484 0.0000073 42.6844 239.51 $139,279 Dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.000327 0.0000050 42.6851 239.52 $139,232 -- 
cART + PrEP (a) non-
targeted ovulation 
1.167 0.000306 0.0000047 42.6852 239.52 $144,711 Dominated  
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 .000253 0.0000039 42.6854 239.53 $144,695 
ext. dominated 
= $13,037,797/QALY 
cART + IUI 0.758 .000054 0.0000006 42.6862 239.54 $156,327 
*undominated 
= $11,109,348/QALY 
cART + IVF 0.787 .000052 0.0000003 42.6863 239.54 $170,661 
*undominated 
=$1,384,061,204/QALY 
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Cost of PrEP @ $30/month (base case: $1,354.9921/month) 
cART (a) non-targeted 
ovulation 
1.167 0.000484 0.0000073 42.6844 239.51 $139,275 abs. dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.000327 0.0000050 42.6851 239.52 $139,231 *undominated 
cART + PrEP (a) non-
targeted ovulation 
1.167 0.000306 0.0000047 42.6852 239.52 $139,395 abs. dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 .000253 0.0000039 42.6854 239.53 $139,380 
*undominated 
=$355,871/QALY 
cART + IUI 0.758 .000054 0.0000006 42.6862 239.54 $156,326 
*undominated 
=$15,134,623/QALY 
cART + IVF 0.787 .000052 0.0000003 42.6863 239.54 $170,661 
*undominated 
=$1,384,071,516/QALY 
Cost of PrEP @ $10/month (base case: $1,354.9921/month) 
cART (a) non-targeted 
ovulation 
1.167 0.000484 0.0000073 42.6844 239.51 $139,275 abs. dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.000327 0.0000050 42.6851 239.52 $139,231 *undominated 
cART + PrEP (a) non-
targeted ovulation 
1.167 0.000306 0.0000047 42.6852 239.52 $139,287 abs. dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 .000253 0.0000039 42.6854 239.53 $139,272 
*undominated 
=$98,688/QALY 
cART + IUI 0.758 .000054 0.0000006 42.6862 239.54 $156,326 
*undominated 
=$15,230,885/QALY 
cART + IVF 0.787 .000052 0.0000003 42.6863 239.54 $170,0661 
*undominated 
=$1,384,071,725/QALY 
Monthly probability of pregnancy, natural conception down to 0.146 (Mabileau et al. 2015) (base case: 0.224) 
cART (a) non-targeted 
ovulation 
1.061 0.00055 0.0000076 42.6841 239.51 $140,789 Dominated 
cART (b) intercourse 
limited to ovulation 
1.061 0.00034 0.0000048 42.6850 239.52 $140,726 -- 
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cART + PrEP (a) non-
targeted ovulation 
1.061 0.00031 0.0000045 42.6851 239.52 $150,608 Dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.061 0.00024 0.0000035 42.6855 239.53 $150,587 
ext. dominated 
= $17,659,464/QALY 
cART + IUI 0.758 0.00005 0.00000060 42.6862 239.54 $156,327 
*undominated 
= $9,697,126/QALY 
cART + IVF 0.787 0.00005 0.00000033 42.6863 239.54 $170,661 
*undominated 
=$1,384,057,662/QALY 
Monthly transmission probability modeled from HPTN 052’s “delayed therapy” group (0.001434559902) as opposed to the base 
case “early therapy” group (0.0000525649045).  
• Sexual encounters not limited: 0.001434559902 (compared to 0.0000525649045 in “early therapy” group) 
• Limited ovulation: 0.000591414276881 (compared to 0.0000218568406074038 in “early therapy” group) 
• Additive effect of PrEP, not limited: 0.0004877503666 (compared to 0.000017872067531286 in “early therapy” group) 
• Additive effect of PrEP, limited: 0.0002010808541 (compared to 0.000007431325807 in “early therapy” group) 
By 3 months after randomization, 89% of the participants in the early-therapy group had a plasma viral load of less than 400 
copies per milliliter, as compared with 9% in the delayed-therapy group (Cohen et al. 2011).  
cART (a) non-targeted 
ovulation 
1.167 0.01311 0.00019811 42.6282 238.66 $142,918 abs. dominated 
cART (b) intercourse 
limited to ovulation 
1.167 0.00885 0.00013456 42.6473 238.95 $141,653 *undominated 
cART + PrEP (a) non-
targeted ovulation 
1.167 0.00833 0.00012672 42.6497 238.98 $148,791 abs. dominated 
cART + PrEP (b) 
intercourse limited to 
ovulation 
1.167 0.00688 0.00010501 42.6562 239.08 $148,366 
ext. dominated 
=$597,374/QALY 
cART + IUI 0.758 0.00138 0.00001519 42.6805 239.45 $156,693 
*undominated 
=$357,313/QALY 
cART + IVF 0.787 0.00142 0.00000910 42.6803 239.45 $171,029 abs. dominated 
 
 
 
 
 
 
 
 
1
2
1
 
Table 4.5: Two-way sensitivity analyses 
Monthly transmission probability modeled from HPTN 052’s ‘delayed therapy’ group + cost of PrEP @  
Cost of PrEP @ 25% monthly reduction ($1,016.244/month) (base case: $1,354.9921/month) 
cART (a) non-targeted ovulation 1.167 0.01311 0.00019811 42.6282 238.66 $142,888 abs. dominated 
cART (b) intercourse limited to 
ovulation 
1.167 0.00885 0.00013456 42.6473 238.95 $141,637 *undominated 
cART + PrEP (a) non-targeted 
ovulation 
1.167 0.00833 0.00012672 42.6497 238.98 $146,955 abs. dominated 
cART + PrEP (b) intercourse 
limited to ovulation 
1.167 0.00688 0.00010501 42.6562 239.08 $146,536 
ext. dominated 
=$435,721/QALY 
cART + IUI 0.758 0.00138 0.00001519 42.6805 239.45 $156,692 
*undominated 
=$357,658/QALY 
cART + IVF 0.787 0.00142 0.00000910 42.6803 239.45 $171,029 abs. dominated 
Monthly transmission probability modeled from HPTN 052’s “delayed therapy” group + cost of PrEP @ $850/month (base case: 
$1,354.9921/month) PrEP became undominated* 
cART (a) non-targeted ovulation 1.167 0.01311 0.00019811 42.6282 238.66 $142,873 abs. dominated 
cART (b) intercourse limited to 
ovulation 
1.167 0.00885 0.00013456 42.6473 238.95 $141,629 *undominated 
cART + PrEP (a) non-targeted 
ovulation 
1.167 0.00833 0.00012672 42.6497 238.98 $146,055 abs. dominated 
cART + PrEP (b) intercourse 
limited to ovulation 
1.167 0.00688 0.00010501 42.6562 239.08 $145,634 
*undominated 
=$356,389/QALY 
cART + IUI 0.758 0.00138 0.00001519 42.6805 239.45 $156,691 
*undominated 
=$358,352/QALY 
cART + IVF 0.787 0.00142 0.00000910 42.6803 239.45 $171,028.49 abs. dominated 
Monthly transmission probability modeled from HPTN 052’s “delayed therapy” group + cost of PrEP @ $500/month (base case: 
$1,354.9921/month) *PrEP ICER = $189,367.08/QALY 
cART (a) non-targeted ovulation 1.167 0.01311 0.00019811 42.6282 238.66 $142,842 abs. dominated 
cART (b) intercourse limited to 
ovulation 
1.167 0.00885 0.00013456 42.6473 238.95 $141,613 *undominated  
cART + PrEP (a) non-targeted 
ovulation 
1.167 0.00833 0.00012672 42.6497 238.98 $144,158 abs. dominated 
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cART + PrEP (b) intercourse 
limited to ovulation 
1.167 0.00688 0.00010501 42.6562 239.08 $143,741 
*undominated 
=$189,367/QALY 
cART + IUI 0.758 0.00138 0.00001519 42.6805 239.45 $156,690 
*undominated 
=$419,671/QALY 
cART + IVF 0.787 0.00142 0.00000910 42.6803 239.45 $171,028 abs. dominated 
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DISCUSSION  
 
This analysis suggests that although PrEP for conception reduced HIV 
transmission to mothers and children, it provided little benefit compared to cART with 
intercourse timed to ovulation and did not provide adequate value to justify the cost. The 
analysis assumed that having suppressed HIV RNA in the male partner was prerequisite 
to any clinical decision-making about PrEP for conception (CDC/HHS 2014). Evidence 
suggests, however, that suppressed plasma viral loads could still intermittently shed virus 
in genital secretions; therefore, PrEP or assisted reproductive options could be valuable 
options for these couples. This study, however, uses transmission data from the HPTN 
052 study, which reflects a variation in adherence levels and would reflect any shedding 
that occurred during the follow-up time for a similar serodiscordant population. This 
analysis found that PrEP adds little benefit in a situation in which the male partner was on 
cART. This method was slightly more effective but more costly and less efficient 
compared to cART alternative with timed ovulation. In each scenario depicted in Tables 
4.3–4.5, timed intercourse was the more effective strategy among all natural conception 
options.    
These findings concur with others in that cART alone with intercourse limited to 
ovulation was the cost effective, risk reductive option for conception compared to 
comparative strategies (Mabileau et al. 2015 and Letchumanan et al. 2015). Similar to 
Hoffman et al.’s simulation results suggesting minimal additional benefit of PrEP with an 
already suppressed viral load, this study also revealed the lack of efficiency of PrEP 
compared to other strategies (Hoffman et al. 2015). Unlike other cost effectiveness 
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studies on PrEP for conception, this study incorporated a QoL component for the mother 
and child and differentiated between HIV infection and non-infection. This model 
additionally isolated the protective effect of each method by subtracting off QALM’s and 
adding the costs for HIV-positive babies, only. I incorporated a similar method for costs 
by adding a transitional discounted cost for babies who became infected with HIV, only.  
Additionally and in contrast to other cost effectiveness and simulation studies for 
HIV serodiscordant couples seeking conception, this study examined the cost 
effectiveness of PrEP compared to the full range of reproductive strategies for HIV 
serodiscordant couples in the US. It also simulated the probability of couples continuing 
conception attempts after 12 months of trying naturally, including average dropout rates 
for IUI and IVF. The model further considered the timing of HIV testing and its impacts 
on HIV transmission within this context, which could influence the outcomes being 
examined. By integrating the probability and cost of females becoming infected with HIV 
but “unaware” of their status and those becoming “aware” after a true positive test, we 
can closely examine the protocols for different strategies and how important HIV testing 
might be. The model also considered the impact of male fertility parameters in HIV-
positive men in the assisted reproductive options (Bujan et al. 2014, Zafer et al. 2015).  
When TDF becomes generic at an estimated 25% reduction, PrEP would still not 
be cost effective for this purpose. PrEP, however, became cost effective when limiting 
intercourse to ovulation and priced at $10/month ($98,688/QALY). The sensitivity 
analyses illustrate, however, that when a partner’s viral load was above 400 copies per 
milliliter, PrEP became “undominated” at $850/month at $358,351.68/QALY. At 
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$500/month, PrEP became $189,367.08/QALY, which is closer to the widely accepted 
cost effectiveness threshold. All PrEP options, however, were undominated only when 
sexual intercourse was limited to ovulation, when the current price of PrEP was reduced, 
and/or when the male partners viral load was greater than 400 copies per milliliter. Other 
PrEP CEA intervention studies show PrEP at $170,000 to $250,000 per QALY gained, 
which suggests that perhaps the CEA threshold for PrEP should be higher (Juusola et al. 
2012, Bernard et al. 2016).  
This analysis has limitations. I approached the analysis from a healthcare payer’s 
perspective and therefore did not consider the current realities of insurance coverage for 
PrEP or for assisted reproductive technology services. To date, many private insurance 
companies cover the cost of PrEP (Project Inform 2016). For individuals without private 
insurance, Gilead has a financial assistance program for patients in the United States who 
cannot afford Truvada (Gilead U.S. Advancing Access® Program 2016).  
There are more financial barriers to ART coverage in the United States. Currently, 
the cost of care has been cited as the greatest barrier in accessing fertility services for the 
general population, notwithstanding the added barriers to care for HIV serodiscordant 
couples (Chambers et al. 2009, ASRM 2015, Quinn and Fujimoto 2016). A single IVF 
cycle is estimated to exceed 50% of an average individual’s disposable yearly income 
(Chambers et al. 2009). States such as Connecticut, Illinois, Maryland, Massachusetts, 
New Jersey, and Rhode Island have implemented state mandates for infertility coverage 
through private insurance. Such mandates, however, differ in degrees of services covered, 
and government programs such as Medicaid, do not currently cover such services 
 
 
 
 
126
(ASRM 2015, Quinn and Fujimoto 2016).  Results from this study show that while cART 
+ IUI and IVF are more effective than the other strategies, these options are not 
considered cost effective.    
Additionally, this study did not consider the “value” of PrEP or the value of other 
risk reductive options for couples. Mushlin et al. 2005 argued that “value” is often 
missing from decision and cost-effectiveness analyses, particularly preferences for 
“cognitive states” in the absence of disease. They noted that measuring the value of 
reassurance and other psychological effects of testing has implications when conducting a 
cost effectiveness analysis, for instance. For this analysis, we did not consider the value 
placed on PrEP neither in terms of psychological reassurance nor regarding the agency of 
the woman. PrEP is the first HIV prevention strategy that offers individual agency and 
empowerment over ones sexuality (Heffron et al. 2016). Rather than relying on her 
partner’s viral load, a woman can have the agency over her sexuality and HIV protection.  
It is also important to account for the value of opting for an in vitro procedure as 
opposed to engaging in risk to conceive naturally. Patient information and choice are 
critical components to quality of care and therefore, patients should have a wide spectrum 
of options to improve their health outcomes and that of their children. Patient choice is 
also critical when the woman is unsure of her partner’s cART adherence. While our 
model assumes the male partner is on cART, this assumption represents only a fraction of 
people with HIV; those not virally suppressed could also be interested in having children.   
In summary, this analysis suggests that although PrEP for conception reduced 
HIV transmission to mothers and children, it provided little benefit compared to cART 
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with timed intercourse and did not provide adequate value to justify the cost. While this 
study suggests unfavorable cost effectiveness results for PrEP in the setting of 
conception, it suggests that PrEP could be a viable option if the cost of PrEP reduces 
(AWP $850/month) and the male partner’s viral load is > 400 copies per milliliter 
(undominated at $356,389/QALY). While this QALY is higher than the typically used 
WTP threshold, it is not much higher than the ICER for PrEP for MSM or intravenous 
drug users (Juusola et al. 2012, Bernard et al. 2016). With the continued rollout of PrEP 
in the U.S. and given the results from cost effectiveness analyses across different at-risk 
populations, the CEA threshold for PrEP should be revisited. 
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CHAPTER V: Conclusive Remarks 
 
 
 With an estimated 1.2 million people living with HIV in the United States and 
over half with HIV-negative partners, PrEP has transformed the prevention landscape for 
adults at heightened risk for HIV infection (CDC 2014, Lampe et al. 2011). Many 
persons in HIV serodiscordant relationships desire to have children. Historically, 
serodiscordant couples comprised of an HIV-positive male and HIV-negative female 
have faced challenges to accessible, affordable options for safe conception. Assisted 
reproductive technologies are prohibitively expensive and have been more inaccessible to 
this population (Sauer 2006). Truvada® for PrEP, however, is also costly and may 
provide only modest prevention benefits to serodiscordant couples in which the HIV-
infected partner is already on continuous anti-retroviral therapy with suppressed HIV 
viremia (Hoffman et al. 2016). My thesis therefore sought to better understand barriers to 
access to risk reduction strategies for serodiscordant couples seeking conception and the 
cost effectiveness of strategies that can help couples have a child. 
The overall research question that I addressed in this thesis was: What are the 
access and cost implications for HIV serodiscordant couples who seek conception 
services in the United States? To attempt to answer this question, I took an integrative 
perspective in examining patient access to conception options, provider behaviors and 
perceptions of such options, and cost implications for serodiscordant couples seeking 
conception services. The first paper examined the perceptions and experiences of 
providers in the U.S. in regard to prescribing PrEP in general, and their attitudes towards 
PrEP and other reproductive options for serodiscordant couples. The second paper aimed 
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to better understand access to the range of assisted reproductive services for 
serodiscordant couples where the male is HIV-positive and the woman is HIV-negative. 
Finally, the third paper projected the long-term outcomes and cost effectiveness of 
Truvada® for conception compared to alternative reproductive methods.  
In the first study examining provider perceptions of PrEP and other risk reduction 
options for couples seeking conception, 519 independent prescribers responded to a 
survey at an advanced CME course on HIV. The survey assessed practices, attitudes, and 
openness regarding the provision of PrEP and other reproductive options for 
serodiscordant couples seeking conception. A key finding from this study was that over 
half of the prescribers in the sample had experience prescribing PrEP to at least some 
populations with the majority practicing in internal medicine. This finding represents the 
highest proportion in the literature to date in regard to independent prescribers’ 
experience prescribing PrEP. Since the FDA approval of PrEP in 2012, trends in the 
literature suggest that providers have continually increased their engagement with PrEP 
over time (White et al. 2012; Levin 2014; Karris et al. 2014; Scherer et al. 2014; 
Krakower et al. 2016).  
The findings from this study also suggest, however, that provider willingness to 
prescribe PrEP as the “first best step” varied between indications of the medication. For 
instance, prescribers that were willing to prescribe PrEP for the MSM population were 
more likely to also consider prescribing for IDUs and less likely for conception purposes. 
Specialty area was not a significant predictor in the model. These findings imply the need 
to better understand practice behaviors and perceptions of PrEP for different populations. 
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An increased understanding of provider perceptions and behaviors related to 
prescribing PrEP is important to realize its benefits among couples seeking conception 
and other at-risk populations. Serodiscordant couples, however, should also have a choice 
among a spectrum of risk reductive strategies. Findings from the first study indicate that 
if cost and access were not barriers, 70% of respondents in the sample would refer 
couples to assisted reproductive technologies. These responses were not random (Table 
2.20) and significantly deviated from previous literature (Scherer et al. 2014).  
The cost of care has been cited as the greatest barrier in accessing fertility services 
for the general population; albeit, there are added barriers to care for HIV couples with 
requirements of separate laboratory space, equipment, and other specialized services 
(Chambers et al. 2009, ASRM 2015, Quinn and Fujimoto 2016). A single IVF cycle is 
estimated to exceed 50% of an average individual’s disposable income (Chambers et al. 
2009). States such as Connecticut, Illinois, Maryland, Massachusetts, New Jersey, and 
Rhode Island have implemented state mandates for infertility coverage through private 
insurance. Such mandates, however, differ in degrees of access, and government 
programs such as Medicaid, do not currently cover such services (ASRM 2015, Quinn 
and Fujimoto 2016). Meanwhile, couples that seek risk reductive services as opposed to 
an indication for ‘infertility’ could also pose a challenge for these couples.  
Notwithstanding clear cost barriers for couples seeking ART services, Truvada® 
for PrEP is also costly and might provide minimal additional benefit of PrEP with an 
already suppressed viral load (Hoffman et al. 2015, Mabileau et al. 2015, Ciaranello and 
Matthews 2015, Letchumanan et al. 2015). Findings from the third study similarly 
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suggest unfavorable cost effectiveness of PrEP compared to the alternative method of 
cART suppression with intercourse limited to peak ovulation. Although PrEP for 
conception reduced HIV transmission to mothers and children, it provided little benefit 
compared to cART with timed intercourse and did not provide adequate value to justify 
the cost. Additionally, when TDF becomes generic at an estimated 25% price reduction, 
PrEP is still not cost effective for this purpose. PrEP only became cost effective when 
limiting intercourse to ovulation and priced at $10/month ($98,688/QALY).  
The sensitivity analyses illustrate, however, that when a partner’s viral load was 
above 400 copies per milliliter, PrEP became ‘undominated’ at $850/month at 
$358,352/QALY. At $500/month, PrEP is $189,367/QALY, which is closer to the widely 
accepted cost effectiveness threshold (Neumann et al. 2014, Walensky et al. 2016). All 
PrEP options, however, were undominated only when intercourse was limited to 
ovulation and when the current price of PrEP was reduced. Other cost effectiveness and 
simulation studies on PrEP suggest that PrEP could be cost effective for the highest-risk 
subgroups, or if Truvada® was lower in price or higher in efficacy (Juusola et al. 2012). 
Such studies further reveal the cost effectiveness of PrEP above the widely accepted CEA 
threshold of $100,000 per QALY gained (Juusola et al. 2012, Bernard et al. 2016). Due to 
the implications of HIV seroconversion, perhaps the CEA threshold for PrEP should be 
revisited.  
With private insurance coverage and Gilead’s financial assistance program for 
Truvada®, PrEP could be considered a more accessible option for couples seeking risk 
reductive services for conception. While cART suppression alone with intercourse 
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limited to peak ovulation was the most optimal strategy in my analysis, it did not consider 
the value of PrEP in offering empowerment over ones sexuality. Future research should 
assess a couple’s decision-making process to take PrEP or other risk reductive options, 
including their added utility for this population; both of which are currently missing in 
cost effectiveness literature.  
While my study revealed an unfavorable cost effectiveness ratio of IUI for these 
couples seeking safe conception, efforts to expand options and ensure a more uniform 
experience when seeking care could improve HIV and pregnancy outcomes for women 
and their children. Barriers remain in accessing this service among HIV serodiscordant 
couples. While the cost of services and insufficient insurance coverage present barriers in 
accessing ART services, HIV-positive individuals face other challenges in accessing such 
services. Evidence reveals an acceptance and demand of ART services among this 
population including support from both ASRM and ACOG (Cohan 2013). However, 
recent literature cites that only 3% of fertility clinics registered with SART report 
offering services to such couples (ASRM 2002, 2010, 2015; ACOG 2001). Reasons 
given for low access to such services include transmission and cross-contamination 
concerns, lack of expertise, and high costs for maintain a separate laboratory space, as 
recommended by ASRM. There have been no reported cases to date, however, of 
occupational transmission to personnel or contamination in the clinic setting (ASRM 
2008, 2010, 2015).  
The second study above, however, presented a more optimistic picture of access 
compared to recently cited literature (ASRM 2015). Yet, there was heterogeneity in 
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responses with access dependent on the person calling the clinic. In this study, I 
employed a “secret shopper” methodology whereby investigators posed as patient and 
physicians in standardized, scripted phone calls to a sample of SART registered fertility 
clinics. Of the clinics sampled, 63% of physician callers were told that the clinic could 
offer services, as compared to only 40% of patient callers (p<.0001). There was also lack 
compliance with ASRM’s 2015 guidelines of referring patients to other facilities. Of the 
clinics that denied services to the patient caller, 51% referred to other clinics with 
conviction of them offering services, 18% referred but were uncertain whether the clinics 
offered services, and 31% could not refer to another facility. Of the clinics that offered 
services to the physician caller, 74% offered sperm washing with banking, 81% offered 
IUI, 96% offered IVF, and 94% offered ICSI. Based on physician inquiries, 67% of 
clinics would provide services to couples for both prevention and infertility purposes.  
Serodiscordant couples should have access to ART either for the purpose of risk 
aversion or for supported fertility. While this study sampled clinics within 15 states with 
the highest HIV prevalence rates per 100,000 people excluding MSM contact, these 
results likely reflect higher proportional estimates in terms of access. Therefore, these 
results could pose as an upper confidence interval in later studies. There is an opportunity 
for future research to more thoroughly study barriers to accessing ART services across 
the United States. During the scripted phone calls, clinics discussed elements of access 
that could be further researched. For instance, clinics often mentioned their ability to use 
an off-site lab to process HIV-positive semen and factors that prevented clinics from 
offering services to this patient population.  
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PrEP use in periconception has not been shown to increase the risk of pregnancy 
loss, birth defects, per-term birth, or other congenital abnormalities (Mugo et al. 2014, 
Heffron et al. 2016). PrEP is also the first prevention tool that empowers individuals, 
including women, to make independent decisions concerning their sexuality. The studies 
above provide further insight into provider prescribing behaviors and perceptions of PrEP 
across different populations, the cost effectiveness of PrEP compared to alternative risk 
reductive methods for conception, and the reality of accessing ART services for 
serodiscordant couples. Future studies should further examine provider acceptabiliy of 
PrEP across populations and factors that might lead providers to feel more comfortable or 
more willing to prescribe to certain populations compared to others. Current gaps also 
exist in examining attitudes and behaviors of PrEP among OBGYN providers. OBGYN 
is a critical interface for serodiscordant couples seeking conception and thus it is 
important to recognize any barriers that might exist in implementing PrEP within this 
setting. It is equally necessary to discern attitudes or barriers in counseling and referring 
couples to ART services. Couples should be offered the same spectrum of reproductive 
options as non-HIV couples and future research should examine patient preference of 
safe conception options. Overall, reducing barriers in accessing safer conception options 
for HIV serodiscordant couples could improve HIV and pregnancy outcomes for women 
and their children.  
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APPENDICES 
 
 
• Appendix Document 1: [For study #1] Provider Survey 
 
Research Survey conducted at IAS-USA Continuing Medical Education (CME)  
practitioner course 
This survey is part of a research study being conducted by a doctoral candidate from Boston University’s 
School of Public Health. The purpose of the study is to evaluate whether providers differ in their 
experience and perceptions around prescribing indications and the efficacy of utilization of PrEP for 
conception. This survey examines practitioner perceptions of prescribing Truvada® for different 
indications of PrEP compared to other methods in addition to gauging one’s experiences with this 
medication. Participation in the survey is voluntary and will take approximately 5–7 minutes to complete. 
Please feel free to contact Ashley Leech at 917-816-1055 or by email at ashleyl@bu.edu with any questions 
you might have about the research.   
 
1. Age: _________________________ 
 
2. Gender:  Male  Female  Other: ____________________ 
 
3. Which ethnic and racial group(s) do you identify with? 
  Hispanic/Latino     White    
  American Indian or Alaska Native   Black or African American   
  Native Hawaiian or other Pacific Islander  Asian  
         Other, specify: ____________________  
 
4. In what State do you practice? ________________________________________ 
 
5. Please state your qualification/licensure:  
  Doctor of Medicine (MD) /    Physician Assistant (PA) 
  Doctor of Osteopathic Medicine (DO)  PhD 
   Nurse Practitioner (NP)     Other (please specify): _____________________ 
  Registered Nurse (RN)     
 
6. How long have you been practicing independently?  
  In training   11–20 years   5–10 years 
  <5 years   21+ years   
     
7. What is your specialty area? 
  Infectious diseases    Internal medicine 
  Family medicine      Obstetrics/gynecology 
  Pediatrics     Other (please specify): _____________________ 
 
8. Have you prescribed PrEP? 
  Yes  No 
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8a. If yes, what has been the primary population to which you have prescribed?  
  Anticipated men who have sex with men (MSM) exposure 
  Anticipated intravenous drug-user (IDU) exposure 
  Anticipated at-risk heterosexual exposure (not trying to conceive) 
  Anticipated conception exposure  
  Other (please specify): _________________________ 
 
9. How often in the course of routine care do you typically ask your patients their partners’ HIV sero-
status?  
  Never  Rarely  Sometimes  Most of the time  Always  
 
10. How often in the course of routine care do you typically ask your HIV+ male patients their partners’ 
HIV sero-status?  
  Never  Rarely  Sometimes  Most of the times  Always  
 
11. How often in the course of routine care do you typically ask your HIV+ female patients their partners’ 
HIV sero-status?  
 Never  Rarely  Sometimes  Most of the times  Always 
 
 
Please state whether you “strongly agree,” “agree,” are “neutral,” “disagree,” or “strongly disagree” 
with the following: 
 
12. If cost and access were not barriers, I would refer all of my HIV-infected patients in sero-discordant 
relationships who wish to conceive for assisted reproductive technologies.  
  Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree  
 
13. I am comfortable counseling my HIV-infected patients on safe options for conception/pregnancy. 
  Strongly Agree  Agree  Neutral  Disagree  Strongly Disagree  
 
The following case vignettes are followed by specific clinical options, none of which can be considered 
either correct or incorrect. Please choose one option as the best first step in your opinion.  
 
14. A 30-year-old male who is HIV-negative and has sex with men with an unremarkable PMH is sexually 
active with his HIV-positive husband. The (+) partner is on cART but having challenges reaching an 
undetectable HIV viral load. What do you recommend as a first step?   
  Use condoms 
  Recommend initiating PrEP for HIV-negative partner    
  Use both condoms and initiate PrEP for HIV-negative partner 
   Other (please specify): ___________________________________________________________ 
 
15. A 30-year old female who is HIV-negative with an unremarkable PMH is hoping to conceive with her 
HIV-positive partner.  The (+) partner is on cART with an undetectable HIV viral load. What do you 
recommend as a first step?   
  Do not conceive 
  Recommend initiating PrEP for HIV-negative woman    
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  Refer couple for Assisted Reproductive Technology services 
  Other (please specify): ___________________________________________________________ 
 
16. A 30-year old male who is HIV-negative with a history of injection drug use reports sharing needles 
with injection partners of unknown sero-status. What do you recommend as a first step?   
  Refer to harm reduction program only, such as safe needle exchange  
 Refer to substance abuse treatment and harm reduction program such as safe needle exchange  
 if exists  
  Recommend initiating PrEP     
   Other (please specify): ___________________________________________________________ 
 
17. What barriers, if any, do you foresee OR have encountered in implementing PrEP for conception 
purposes? 
 
______________________________________________________________________________________ 
 
______________________________________________________________________________________ 
 
______________________________________________________________________________________ 
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• Appendix Document 2: [For study #1] Analyses when IDU was the outcome 
variable of interest  
 
 
Table 2.18: Chi Square frequencies (Hypothesis #2), MSM and IDU 
N=502 
MSM 
(449/502 = 89%) 
IDU (178/502 = 35%) 
Selected PrEP option Did NOT select PrEP Total 
Selected PrEP option 172 277 449 
Did NOT select PrEP 6 47 53 
Total 178 324 502 
• Of those that selected PrEP for IDU (178/502=35%), 172/178 (97% would also 
consider PrEP for MSM 
• Of those that did not select PrEP for IDU (324/502= 64%), 277/324 (85%) selected 
PrEP for MSM 
Chi Square: DF=1; Value = 15.0854; Prob= 0.0001  
 
 
 
Table 2.19: Logistic Regression [Unadjusted Analysis] (Hypothesis #2) 
Outcome = IDU 
N=502 
Parameter Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq Odds 
ratio 
95% CI 
Intercept -2.6006 0.4631 31.5350 <.0001   
MSM 1.6394 0.4475 13.4225 0.0002 5.152 2.143 – 12.384 
Conception 0.7674 0.2037 14.1900 0.0002 2.154 1.445 – 3.211 
IDU Outcome 
 
 
 
Table 2.20:  Logistic Regression [Unadjusted Analysis] (Hypothesis #2) 
Outcome = IDU; Interaction model 
N=502 
Parameter Estimate Standard Error Wald Chi-Square Pr > ChiSq 
Intercept -2.8898 1.0271 7.9154 0.0049 
MSM 1.9375 1.0408 3.4650 0.0627 
Conception 1.1320 1.1356 0.9937 0.3188 
MSM*Conception -0.3780 1.1544 0.1072 0.7433 
IDU Outcome  
 
  
 
 
 
 
139
 
Table 2.21:  Logistic Regression (ADJUSTED Analysis]  
Outcome = IDU 
N=502 
Global null hypothesis: BETA=0; likelihood ratio Chi-Square= 43.6147; Pr>ChiSq <0.0001 
Parameter Estimate Standard 
Error 
Wald Chi-
Square 
Pr > ChiSq Odds 
ratio 
95% CI 
Intercept -3.0798 0.4969 38.4211 <.0001   
MSM 1.7162 0.4547 14.2453 0.0002 5.563 2.282 – 13.564 
Conception  0.7515 0.2064 13.2573 0.0003 2.120 1.415 – 3.177 
Internal 
Medicine 
0.6642 0.2480 7.1752 0.0074 1.943 1.195 – 3.159 
Family 
Medicine 
0.7187 0.2477 8.4176 0.0037 2.052 1.263 – 3.334 
Other specialty 0.4354 0.3622 1.4445 0.2294 1.546 0.760 – 3.144 
Reference: Infectious Disease 
IDU Outcome 
 
 
In Table 2.18, the chi square frequencies reveal a significant association between 
those considering PrEP as the ‘first best step’ for  MSM and IDUs. Table 2.19 shows that 
those who view PrEP as the ‘first best step’ for MSMs are five times as likely to also 
consider PrEP for intravenous drug users. Additionally, those that view PrEP as the ‘first 
best step’ for conception are two times as likely to also consider PrEP for intravenous 
drug users. As Table 2.20 illustrates, I performed a test for interaction between MSM and 
conception and its effect on the outcome variable, IDU. The interactions were not 
significant and thus I refit the models excluding the interaction terms. When adjusting for 
important covariates (Table 2.21), provider specialty was the only control variable that 
met the required level of significance to stay in the second model, when IDU is the 
outcome variable. When IDU was the outcome variable, those who view PrEP as the 
‘first best step’ for MSM and for conception purposes are still at greater odds to also view 
PrEP as the ‘first best step’ for IDUs. However, when specialty area is added to the 
model, internal medicine providers are 1.9 times as likely (p=0.0074) and family 
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medicine providers two times as likely (p=0.0037) compared to infectious disease 
providers to view PrEP as the ‘first best step’ for IDUs.   
The results indicate that infectious disease providers might prefer other options as 
first treatment steps for this population such as harm reduction programs and/or substance 
abuse treatment. The efficacy of PrEP has been demonstrated among IDUs through the 
Bangkok Tenofovir study (Smith et al. 2013). Despite accounting for less than 1% of the 
total HIV population in the U.S., an estimated 10% of new infections are attributable to 
injection drug use alone or in combination with MSM sexual contact (Bernard et al. 2016, 
Friedman et al. 2004, CDC 2012, Spiller et al. 2012). Furthermore, a recent cost 
effectiveness study on PrEP for people who inject drugs in the U.S. suggest that with the 
current cost of PrEP, it remains an expensive intervention for this population both in 
absolute terms and in cost per QALY gained (Bernard et al. 2016). These results suggest 
the need to better understand practice behavior and perceptions of PrEP across all at risk 
populations.  
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• Appendix Document 3: [For study #2] Sampled fertility clinics 
 
 
Assisted Reproductive Technology clinics in the United States, per prevalence category 
 
Top 15 states with highest number of “persons living with diagnosed HIV”; among males 
of all race/ethnicities/age groups, and transmission categories of (1) heterosexual contact; 
(2) Injection drug use; (3) other.*Persons living with diagnosed HIV data reflect persons 
living with diagnosed HIV infection at the end of each year during 2008–2011. Based on 
this data, I calculated the prevalence per 100,000, excluding MSMs.  
 
CDC NCHHSTP Atlas 2015 
 
 
Total fertility clinics: 140 
State Clinics 
 
District of Columbia (DC) 
 
 463.50 / 100,000 
 2 fertility clinics 
 
 
• Columbia Fertility Associates 
• George Washington University 
 
New York  
 
 164.12 / 100,000 
 32 fertility clinics  
 
 
 
• Genesis Fertility and Reproductive Medicine 
• The Fertility Institute at New York Methodist Hospital 
• Infertility and IVF Medical Associates of Western NY 
• Hudson Valley Fertility 
• Montefiore Institute for Reproductive Medicine and Health 
• Albany IVF, Fertility and Gynecology LLC 
• North Shore University Hospital 
• Long Island IVF 
• Reproductive Specialists of New York LLP 
• Westchester Reproductive Medicine 
• Brooklyn/Westside Fertility Center 
• Center for Human Reproduction 
• Columbia University Center for Women's Reproductive Care 
• Geoffrey Sher, M.D., PC 
• Manhattan Reproductive Medicine 
• Metropolitan Reproductive Medicine PC 
• New Hope Fertility Center 
• New York Fertility Institute 
• New York Fertility Services PC 
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• New York University School of Medicine 
• Neway Medical 
• Offices for Fertility & Reproductive Medicine PC 
• Reproductive Medicine Associates of New York, LLP 
• Weill Medical College of Cornell University 
• WESTMED Reproductive Services 
• Rochester Fertility Care PC 
• Strong Fertility Center, University of Rochester Medical Center 
• Island Reproductive Services 
• CNY Fertility Center 
• Westchester Fertility & Reprod. Endo. 
• Braverman Reproductive Immunology, PC 
• Gold Coast IVF 
• Braverman Reproductive Immunology, PC 
• Gold Coast IVF 
 
Florida 
 
 100.23 / 100,000 
 19 fertility clinics  
 
 
 
 
 
 
 
 
 
 
 
 
• Boca Fertility 
• Palm Beach Fertility Center 
• Specialists in Reproductive Medicine and Surgery, P.A, 
Embryo Donation International 
• UF and Shands Reproductive Medicine at Spring Hill 
• Jacksonville Center for Reproductive Medicine 
• Center for Natural IVF 
• IVF Florida 
• Viera Fertility Center/Fertility and Reproductive Medicine 
Center for Women 
• Conceptions Florida: Center for Fertility and Genetics 
• Fertility and IVF Center of Miami 
• S. Florida Institute for Reproductive Med 
• University of Miami Infertility Center 
• Center for Reproductive Medicine PA 
• New Leaders in Fertility &amp; Endocrinology, LLC 
• Fertility and Genetics 
• The Reproductive Medicine Group 
• University of South Florida IVF 
• Florida Institute for Reproductive Sciences and Technologies 
(FIRST) 
• Fertility Center of Assisted Reproduction and Endocrinology 
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Maryland 
 
 137.66 / 100,000 
 6 fertility clinics  
 
 
 
 
 
 
• A.R.T.Institute of Washington, Inc. 
• Endrika Hinton, M.D. 
• Johns Hopkins Medical Institute 
• Shady Grove Fertility Center 
• Fertility Center of Maryland 
• Shady Grove Fertility Center at GBMC 
 
Georgia  
 
 51.57 / 100,000 
 7 fertility clinics 
 
 
 
 
 
 
• Emory Reproductive Center 
• Georgia Reproductive Specialists 
• Reproductive Biology Associates 
• Atlanta Center for Reproductive Medicine 
• MCG Reproductive Medicine and Infertility Associates 
• Servy Institute for Reproductive Endocrinology 
• Georgia Center for Reproductive Medicine 
 
New Jersey 
 122.53 / 100,000 
 16 fertility clinics  
 
 
 
 
 
 
 
• Reproductive Medicine Associates of New Jersey 
• Reproductive Science Center of New Jersey, PA 
• Ctr for Advanced Reproductive Medicine & Fertility 
• North Hudson IVF 
• University Reproductive Associates 
• Shore Institute for Reproductive Medicine 
• Princeton IVF 
• Institute for Reproductive Medicine & Science 
• Cooper Institute for Reproductive Hormonal Disorders PC 
• Delaware Valley Institute of Fertility and Genetics 
• South Jersey Fertility Center 
• Diamond Institute for Infertility 
• The Valley Hospital Fertility Center 
• Damien Fertility Partners 
• Louis R. Manara, D.O. 
• Fertility Institute of New Jersey 
 
Louisianna  
 67.93 / 100,000 
 5 fertility clinics  
 
 
• A Woman's Center for Reproductive Medicine 
• Fertility and Women's Health Center of Louisiana 
• The Fertility Institute of New Orleans 
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 • Audubon Fertility and Reproductive Medicine 
• Arklatex Fertility and Reproductive Medicine 
 
South Carolina 
 60.03 / 100,000 
 5 fertility clinics 
 
 
 
 
 
 
• Fertility Center of the Carolinas 
• Piedmont Reproductive Endocrinology Group PA 
• The Fertility Center of Charleston 
• Coastal Fertility Specialists 
• Advanced Fertility and Reproductive Endocrinology Institute, 
LLC 
 
Mississippi  
 43.01 / 100,000 
 2 ferility clinics  
 
 
 
• Mississippi Reproductive Medicine, PLLC 
• University of Mississippi Med Center 
 
Massachusetts  
 67.69 / 100,000 
 8 fertility clinics  
 
 
 
 
 
 
 
 
 
 
• Brigham & Women's Hospital Center for Assisted 
Reproduction 
• Massachusetts General Hospital Fertility Center 
• Fertility Solutions, P.C. / Massachusetts Fertility Center, 
L.L.C. 
• IVF New England, a Boston IVF partner 
• Fertility Centers of New England 
• Bay state Reproductive Medicine 
• Cardone Reproductive Medicine &amp; Infertility LLC 
• Boston IVF 
 
North Carolina  
 49.42 / 100,000 
 12 fertility clinics  
 
 
 
 
 
 
 
 
 
• NC Center for Reproductive Medicine 
• Carolinas Medical Center 
• Reproductive Endocrinology Associates of Charlotte 
• Duke Fertility Center 
• ECU Women's Physicians 
• Premier Fertility Center 
• Advanced Reproductive Concepts 
• Atlantic Reproductive Medicine Specialists 
• Carolina Conceptions P A 
• UNC Fertility, LLC 
• Carolinas Fertility Institute 
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• Wake Forest University Center for Reproductive Medicine 
 
Conneticut  
 94.18 / 100,000 
 7 fertility clinics  
 
 
 
 
 
 
 
• Connecticut Fertility Associates 
• The Center for Advanced Reproductive Services 
• Greenwich Fertility and IVF Center, P.C. 
• Yale University IVF Program 
• Reproductive Medicine Associates of Connecticut 
• Stamford Hospital 
• Park Avenue Fertility and Reproductive Medicine 
 
Delaware  
 90.42 / 100,000 
 2 fertility clinics  
 
 
• Delaware Institute for Reproductive Medicine, PA 
• Reproductive Associates of Delaware 
 
Pennsylvania 
 72.67 / 100,000 
 16 fertility clinics 
 
 
 
 
• Toll Center for Reproductive Sciences 
• Reproductive Medicine Associates of Pennsylvania 
• Family Fertility Center 
• Main Line Fertility & Reproductive Medicine 
• Geisinger Medical Center Fertility Center 
• Penn State Univ/Milton S. Hershey Med Ctr 
• Reproductive Medicine Associates of Philadelphia 
• Fertility & Gynecology Associates 
• Society Hill Reproductive Medicine 
• University of Pennsylvania Penn Fertility Care 
• Jones Institute at West Penn Allegheny Health Systems 
• Reproductive Health Specialists, Inc 
• University of Pittsburgh Physicians 
• Crozer Chester Medical Center 
• Shady Grove Fertility RSC of Philadelphia 
• RHPN Women's Clinic and IVF-Fertility 
 
Rhode Island 
 52.70 / 100,000 
 1 fertility clinic 
 
 
• Women & Infants Hospital 
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• Appendix Document 4: [For study #2] Fertility clinic call scripts 
 
 
 
Physician Script: 
The scenario is that you are an ObGyn who is new to the area and trying to get care for one of 
your new clinic patients. She is a 30yo G1P0 HIV negative woman with no medical issues who is 
married to an HIV positive man. They are trying to conceive but want to do so safely and 
minimize their risk of transmission to each other. Neither has a diagnosis of infertility. Your goal 
is to get a provider on the line to answer some questions about access for HIV patients by using 
this patient scenario. 
 
START CALL 
 
Hi this is Doctor Brown, I am a new gynecologist in the area and was hoping to speak with 
someone about referring a couple with HIV to your practice 
 
->Transfer to Physician or Nurse Manager->  
Did you get transferred? 
1) Yes 
2) No 
Who did you speak with? 
1) RN 
2) NP/PA 
3) Physician 
4) Other 
 
Thanks for your time! I wanted to ask a few questions about a couple I wanted to refer. She is 
HIV negative and he is HIV positive and they are trying to get pregnant. 
 
Does your clinic offer services to couples where at least one person is HIV positive? 
1) Yes 
2) No 
3) Not sure 
If yes: 
Has your clinic taken care for these couples before? 
1) Yes 
2) No 
Does your clinic offer the following for HIV positive male / HIV negative female? 
1) Sperm Washings 
2) ICSI 
3) Sperm Banking 
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If yes,  
Do you still see couples if the reason for seeking services is for prevention of an infection in the 
female partner, for infertility only, or both? 
1) To prevent infection 
2) Infertility only 
3) Both 
If yes "To Prevent Infection" or "Both" 
Do you give them PrEP [pre-exposure prophylaxis]? 
1) Yes 
2) No 
3) Not sure 
If do not give patients PrEP, 
Is there a reason why? 
 
If services NOT offered to these couples,  
Can you refer me to someone who does? 
1) Yes, referred to other clinic(s) that DO offer such services 
2) Yes, referred to other clinic(s), but unsure if they offer such services 
3) No 
Any other comments or observations from your call? 
 
 
HIV Positive Female Caller: 
The scenario is that you [Amanda Lewis] are an HIV-negative 30-year-old woman who just 
moved to the area and trying to get pregnant with your HIV-positive husband. You want to have a 
child but want to do so safely and minimize your risk of HIV. You nor your husband has a 
diagnosis of infertility. Your goal is to inquire about access to assisted reproductive fertility 
services based on the following patient scenario. 
 
START CALL 
 
Hi, I have a question about services you offer. I just moved to the area with my husband and we 
are looking for ways to have a child. My husband is HIV positive, but I am negative and we 
wanted to know whether you offer services for this situation. 
 
Did you get transferred? 
1) Yes 
2) No 
Who did you speak with? 
1) Receptionist/person that answered phone 
2) NP/PA 
3) Physician 
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Offers fertility services for this situation? 
1) Yes 
2) No 
3) Not sure 
If YES to services, 
Would we be able to use my husband's sperm? 
1) Yes 
2) No 
3) Not sure 
 
If YES to services, 
What kinds of services could you offer us? 
 
If YES to services, 
I have to check my insurance with my new employer, but do you accept insurance? 
 
If they ask about if the services are for prevention or infertility, state “prevention” purposes & 
note that this question was asked and if it changed whether they provided services or not. 
1) Asked 
2) Not asked 
3) Changed if services provided  
4) Did not change if services provided 
If yes to services,  
Okay thank you! can I make an appointment with a doctor? [Get answer and then say, 'Actually, I 
am going to check my insurance and then I will call back to make the appointment]. 
 
If NO to services, 
Do you know of any other clinics in the area that you could refer me to? 
1) Yes, referred to other clinic(s) that DO offer such services 
2) Yes, referred to other clinic(s) but unsure if they offer such services 
3) No 
Any other comments or observations from your call? 
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• Appendix Document 5: [For study #3] CEA validations 
 
 
Table 4.6: Cumulative probability check of natural conception parameters 
Cycle Model Prob. Dunson et al. Calibration 
1 0.2246088 0.23 0.21337836 
2 0.4  0.38 
3 0.535  0.50825 
4 0.64  0.608 
5 0.721 0.66 0.68495 
6 0.784  0.7448 
7 0.833 0.725 0.79135 
8 0.87  0.8265 
9 0.9  0.855 
10 0.922 0.805 0.8759 
11 0.94  0.893 
12 0.953 0.835 0.90535 
 
 
 
Figure 4.5: Life Expectancies with SMR adjustments 
• Non-HIV women  
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Figure 4.6: Life Expectancies with SMR adjustments 
• HIV+ women  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Cumulative probability of conception validation (Dunson et al. 2004)  
• Assuming intercourse occurs at a frequency of 2 times a week 
• Callibrated by .095  
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Manual Operating Procedures (MOPs) and SOPs, data analysis plan, 
and in liaisons with subcontractors and the funding agency.  
• Designed the database for which all data from the study will be 
inputted and transported into SAS® for analysis, while supervising 
and training research staff including external partners and clinical 
personnel in protocol implementation, data collection, and participant 
tracking and compliance.  
• Currently leading data collection and both quantitative and qualitative 
analyses, overseeing day-to-day operations of the study, and leading in 
all correspondence and document preparation with the BU IRB and 
federal agency (OMB).  
• Currently undergoing writing and data reviews for conferences. 
 
2012-2015  Boston University; Boston, Massachusetts 
Project Director / Study Coordinator for NIDA-funded randomized 
clinical trial with intention-to-treat (ITT) analysis on patient 
navigation and contingency management  
• Leading Boston University/Boston Medical Center in a multi-site (10 
sites) federally funded study with major subcontracts examining 
patient navigation and contingency management to achieve virologic 
suppression in HIV-positive drug users.  
• Collected costing data for the project’s cost-effectiveness analysis to 
map key model parameters in estimating the costs and projecting the 
cost-effectiveness of integrating the patient navigation and 
contingency management model into standard of care.  
• Oversaw participant recruitment and data collection for baseline and 
follow-up visits, while also supervised and trained research staff 
including external partners in data collection activities.  
• Developed Site Operating Procedures (SOPs) and led document 
preparation for BU’s IRB and federal agency (OMB), while also 
facilitating team calls with partners and federal agencies.  
• Currently undergoing writing and data analysis reviews for 
publication.  
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2012  University of California, San Francisco; Ndola, Zambia 
Study Program Manager for NIH/NICHD-funded randomized clinical 
trial on the non-pneumatic anti-shock garment (NASG) for women at 
risk for severe obstetric hemorrhage  
• Oversaw clinical activities across 14 clinics and two referral hospitals 
in Ndola and Kitwe sites, managing research staff and working closely 
with local physicians and midwives to ensure quality data collection 
for the Non-pneumatic Anti Shock Garment (NASG) clinical trial 
supported by NIH/NICHD and the Bill and Melinda Gates Foundation.  
• Conducted trainings for research coordinators and local clinicians at 
clinics and referral hospitals on the study protocol, completion of 
protocol violation and adverse event documentation, as well as 
mentoring and supervising student interns. 
• Led data collection at all sites, while also resolving data queries, 
conducted quality data checks ensuring completeness and accuracy of 
forms, and verified adverse events such as maternal deaths with death 
records and clinician inquiry.  
• Provided research and case tracking support to study coordinators in 
addition to overseeing the research budget and closely tracking all 
financial transactions.   
• Led all site closeout activities including NASG handover to provincial 
and district health management departments, data consolidation and 
analysis, and financial reporting.    
 
2010-2012 Christian Aid NGO; London, United Kingdom; Nairobi, Kenya  
  Health Development Consultant  
• Led an evaluation program with Boston University on measuring the 
cost effectiveness of Christian Aid’s development approach. The 
process resulted in a retrospective cohort study on the quantitative 
impacts of a USAID-funded community development program, and 
key recommendations to the U.S. Government for future development 
programs.    
• Designed an evaluation methodology and baseline study for the UK’s 
Department for International Development (DFID) program focused 
on maternal health and infectious diseases in Kenya, Burundi, 
Ethiopia, Uganda, Malawi, and Nigeria.  
• Trained and technically supported Christian Aid program staff in over 
12 countries in Africa, Latin America, and Asia to conduct baseline 
studies—ensuring tools were consistent and reflective of country 
context, study protocols adhered to, participatory approaches and 
methodology were scientifically rigorous, and data collection 
appropriately consolidated.  
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• Developed the organization’s annual HIV report and published guide 
for program managers to integrate HIV preventive methodologies into 
wider public health frameworks.  
 
2008-2010 Africare NGO; Abuja, Nigeria; Kampala, Uganda 
 Health Development Consultant 
• Provided technical input to the Federal Ministry of Women Affairs and 
Social Development in Nigeria on the Situational Assessment of the 
National Response to Almajiri and Guidelines for Mainstreaming 
Economic Empowerment of Vulnerable Women into the country’s 
priority areas.  
• Oversaw the final evaluation of a World Bank project on Women’s 
Initiative for Sex Education and Economic Empowerment program in 
Nigeria, ensuring the analysis captured relevant covariates and degrees 
of association across subgroups of interest.  
• Advised on the design of program strategies and identified new areas 
of interface for projects in Nigeria and in neighboring West African 
countries for exchange of learning and technical expertise.  
• Managed a nation-wide needs assessment of the community and 
government response to orphans and vulnerable children in Uganda, 
conducting over 200 focus group and semi-structured interviews with 
local government officials, organizational heads, and referral clinics to 
obtain strategic information for rights-based health programming.  
 
TEACHING EXPERIENCE  
2015 Boston University; Teaching Assistant for PM755: Health Care Delivery 
Systems: Issues and Innovations 
2014 Boston University; Teaching Assistant for PM740: Comparative Health 
Systems and Policy in Industrialize    and BRIC Countries 
2013  Boston University; Teaching Assistant for PM810: American 
Government for Public Health Students 
 
*Received a certificate of teaching for completing the course, ‘Preparing Doctoral 
Students to Teach’ 
 
SOFTWARE PROFICIENCIES 
Proficient in SAS®, R®, TreeAge®, REDCap®, and all Microsoft Office packages.   
*Received funding to undertake a TreeAge Advanced Markov/DES Modeling at Tufts 
University; course completed in 2014. 
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